id	sid	tid	token	lemma	pos
ajlm-2681	1	1	abstract	abstract	ADJ
ajlm-2681	1	2	introduction	introduction	NOUN
ajlm-2681	1	3	methods	method	NOUN
ajlm-2681	1	4	results	result	VERB
ajlm-2681	1	5	discussion	discussion	NOUN
ajlm-2681	1	6	acknowledgements	acknowledgement	NOUN
ajlm-2681	1	7	references	reference	NOUN
ajlm-2681	1	8	about	about	ADP
ajlm-2681	1	9	the	the	DET
ajlm-2681	1	10	author(s	author(s	NOUN
ajlm-2681	1	11	)	)	PUNCT
ajlm-2681	1	12	bavinash	bavinash	PROPN
ajlm-2681	1	13	pillay	pillay	PROPN
ajlm-2681	1	14	department	department	PROPN
ajlm-2681	1	15	of	of	ADP
ajlm-2681	1	16	internal	internal	ADJ
ajlm-2681	1	17	medicine	medicine	NOUN
ajlm-2681	1	18	,	,	PUNCT
ajlm-2681	1	19	faculty	faculty	NOUN
ajlm-2681	1	20	of	of	ADP
ajlm-2681	1	21	health	health	NOUN
ajlm-2681	1	22	sciences	sciences	PROPN
ajlm-2681	1	23	,	,	PUNCT
ajlm-2681	1	24	university	university	NOUN
ajlm-2681	1	25	of	of	ADP
ajlm-2681	1	26	the	the	DET
ajlm-2681	1	27	witwatersrand	witwatersrand	NOUN
ajlm-2681	1	28	,	,	PUNCT
ajlm-2681	1	29	johannesburg	johannesburg	PROPN
ajlm-2681	1	30	,	,	PUNCT
ajlm-2681	1	31	south	south	PROPN
ajlm-2681	1	32	africa	africa	PROPN
ajlm-2681	1	33	sarah	sarah	PROPN
ajlm-2681	1	34	a.	a.	PROPN
ajlm-2681	1	35	van	van	PROPN
ajlm-2681	1	36	blydenstein	blydenstein	PROPN
ajlm-2681	1	37	department	department	PROPN
ajlm-2681	1	38	of	of	ADP
ajlm-2681	1	39	internal	internal	ADJ
ajlm-2681	1	40	medicine	medicine	NOUN
ajlm-2681	1	41	,	,	PUNCT
ajlm-2681	1	42	faculty	faculty	NOUN
ajlm-2681	1	43	of	of	ADP
ajlm-2681	1	44	health	health	NOUN
ajlm-2681	1	45	sciences	sciences	PROPN
ajlm-2681	1	46	,	,	PUNCT
ajlm-2681	1	47	university	university	NOUN
ajlm-2681	1	48	of	of	ADP
ajlm-2681	1	49	the	the	DET
ajlm-2681	1	50	witwatersrand	witwatersrand	NOUN
ajlm-2681	1	51	,	,	PUNCT
ajlm-2681	1	52	johannesburg	johannesburg	PROPN
ajlm-2681	1	53	,	,	PUNCT
ajlm-2681	1	54	south	south	PROPN
ajlm-2681	1	55	africa	africa	PROPN
ajlm-2681	1	56	department	department	PROPN
ajlm-2681	1	57	of	of	ADP
ajlm-2681	1	58	internal	internal	ADJ
ajlm-2681	1	59	medicine	medicine	NOUN
ajlm-2681	1	60	,	,	PUNCT
ajlm-2681	1	61	faculty	faculty	NOUN
ajlm-2681	1	62	of	of	ADP
ajlm-2681	1	63	health	health	NOUN
ajlm-2681	1	64	sciences	sciences	PROPN
ajlm-2681	1	65	,	,	PUNCT
ajlm-2681	1	66	chris	chris	PROPN
ajlm-2681	1	67	hani	hani	PROPN
ajlm-2681	1	68	baragwanath	baragwanath	PROPN
ajlm-2681	1	69	hospital	hospital	PROPN
ajlm-2681	1	70	,	,	PUNCT
ajlm-2681	1	71	johannesburg	johannesburg	PROPN
ajlm-2681	1	72	,	,	PUNCT
ajlm-2681	1	73	south	south	PROPN
ajlm-2681	1	74	africa	africa	PROPN
ajlm-2681	1	75	shahed	shahe	VERB
ajlm-2681	1	76	omar	omar	PROPN
ajlm-2681	1	77	school	school	NOUN
ajlm-2681	1	78	of	of	ADP
ajlm-2681	1	79	clinical	clinical	ADJ
ajlm-2681	1	80	medicine	medicine	NOUN
ajlm-2681	1	81	,	,	PUNCT
ajlm-2681	1	82	department	department	NOUN
ajlm-2681	1	83	of	of	ADP
ajlm-2681	1	84	critical	critical	ADJ
ajlm-2681	1	85	care	care	NOUN
ajlm-2681	1	86	,	,	PUNCT
ajlm-2681	1	87	faculty	faculty	NOUN
ajlm-2681	1	88	of	of	ADP
ajlm-2681	1	89	health	health	NOUN
ajlm-2681	1	90	sciences	sciences	PROPN
ajlm-2681	1	91	,	,	PUNCT
ajlm-2681	1	92	university	university	NOUN
ajlm-2681	1	93	of	of	ADP
ajlm-2681	1	94	the	the	DET
ajlm-2681	1	95	witwatersrand	witwatersrand	NOUN
ajlm-2681	1	96	,	,	PUNCT
ajlm-2681	1	97	johannesburg	johannesburg	PROPN
ajlm-2681	1	98	,	,	PUNCT
ajlm-2681	1	99	south	south	PROPN
ajlm-2681	1	100	africa	africa	PROPN
ajlm-2681	1	101	department	department	PROPN
ajlm-2681	1	102	of	of	ADP
ajlm-2681	1	103	critical	critical	ADJ
ajlm-2681	1	104	care	care	NOUN
ajlm-2681	1	105	,	,	PUNCT
ajlm-2681	1	106	faculty	faculty	NOUN
ajlm-2681	1	107	of	of	ADP
ajlm-2681	1	108	health	health	NOUN
ajlm-2681	1	109	sciences	sciences	PROPN
ajlm-2681	1	110	,	,	PUNCT
ajlm-2681	1	111	chris	chris	PROPN
ajlm-2681	1	112	hani	hani	PROPN
ajlm-2681	1	113	baragwanath	baragwanath	PROPN
ajlm-2681	1	114	hospital	hospital	PROPN
ajlm-2681	1	115	,	,	PUNCT
ajlm-2681	1	116	johannesburg	johannesburg	PROPN
ajlm-2681	1	117	,	,	PUNCT
ajlm-2681	1	118	south	south	PROPN
ajlm-2681	1	119	africa	africa	PROPN
ajlm-2681	1	120	citation	citation	PROPN
ajlm-2681	1	121	pillay	pillay	PROPN
ajlm-2681	1	122	b	b	PROPN
ajlm-2681	1	123	,	,	PUNCT
ajlm-2681	1	124	van	van	PROPN
ajlm-2681	1	125	blydenstein	blydenstein	PROPN
ajlm-2681	1	126	sa	sa	PROPN
ajlm-2681	1	127	,	,	PUNCT
ajlm-2681	1	128	omar	omar	PROPN
ajlm-2681	1	129	s.	s.	PROPN
ajlm-2681	1	130	thromboelastography	thromboelastography	VERB
ajlm-2681	1	131	in	in	ADP
ajlm-2681	1	132	covid-19	covid-19	PROPN
ajlm-2681	1	133	patients	patient	NOUN
ajlm-2681	1	134	:	:	PUNCT
ajlm-2681	1	135	an	an	DET
ajlm-2681	1	136	observational	observational	ADJ
ajlm-2681	1	137	study	study	NOUN
ajlm-2681	1	138	in	in	ADP
ajlm-2681	1	139	the	the	DET
ajlm-2681	1	140	south	south	ADJ
ajlm-2681	1	141	african	african	ADJ
ajlm-2681	1	142	context	context	NOUN
ajlm-2681	1	143	.	.	PUNCT
ajlm-2681	2	1	afr	afr	PROPN
ajlm-2681	2	2	j	j	PROPN
ajlm-2681	2	3	lab	lab	PROPN
ajlm-2681	2	4	med	med	PROPN
ajlm-2681	2	5	.	.	PUNCT
ajlm-2681	3	1	2025;14(1	2025;14(1	NUM
ajlm-2681	3	2	)	)	PUNCT
ajlm-2681	3	3	,	,	PUNCT
ajlm-2681	3	4	a2681	a2681	PROPN
ajlm-2681	3	5	.	.	PUNCT
ajlm-2681	3	6	https://doi.org/10.4102/ajlm.v14i1.2681	https://doi.org/10.4102/ajlm.v14i1.2681	PRON
ajlm-2681	3	7	note	note	VERB
ajlm-2681	3	8	:	:	PUNCT
ajlm-2681	3	9	additional	additional	ADJ
ajlm-2681	3	10	supporting	support	VERB
ajlm-2681	3	11	information	information	NOUN
ajlm-2681	3	12	is	be	AUX
ajlm-2681	3	13	available	available	ADJ
ajlm-2681	3	14	for	for	ADP
ajlm-2681	3	15	download	download	NOUN
ajlm-2681	3	16	alongside	alongside	ADP
ajlm-2681	3	17	the	the	DET
ajlm-2681	3	18	online	online	ADJ
ajlm-2681	3	19	version	version	NOUN
ajlm-2681	3	20	of	of	ADP
ajlm-2681	3	21	this	this	DET
ajlm-2681	3	22	article	article	NOUN
ajlm-2681	3	23	as	as	ADP
ajlm-2681	3	24	online	online	ADJ
ajlm-2681	3	25	supplementary	supplementary	ADJ
ajlm-2681	3	26	document	document	NOUN
ajlm-2681	3	27	1	1	NUM
ajlm-2681	3	28	.	.	PUNCT
ajlm-2681	3	29	original	original	ADJ
ajlm-2681	3	30	research	research	NOUN
ajlm-2681	3	31	thromboelastography	thromboelastography	NOUN
ajlm-2681	3	32	in	in	ADP
ajlm-2681	3	33	covid-19	covid-19	PROPN
ajlm-2681	3	34	patients	patient	NOUN
ajlm-2681	3	35	:	:	PUNCT
ajlm-2681	3	36	an	an	DET
ajlm-2681	3	37	observational	observational	ADJ
ajlm-2681	3	38	study	study	NOUN
ajlm-2681	3	39	in	in	ADP
ajlm-2681	3	40	the	the	DET
ajlm-2681	3	41	south	south	ADJ
ajlm-2681	3	42	african	african	ADJ
ajlm-2681	3	43	context	context	PROPN
ajlm-2681	3	44	bavinash	bavinash	PROPN
ajlm-2681	3	45	pillay	pillay	PROPN
ajlm-2681	3	46	,	,	PUNCT
ajlm-2681	3	47	sarah	sarah	PROPN
ajlm-2681	3	48	a.	a.	PROPN
ajlm-2681	3	49	van	van	PROPN
ajlm-2681	3	50	blydenstein	blydenstein	PROPN
ajlm-2681	3	51	,	,	PUNCT
ajlm-2681	3	52	shahed	shahed	ADJ
ajlm-2681	3	53	omar	omar	PROPN
ajlm-2681	3	54	received	receive	VERB
ajlm-2681	3	55	:	:	PUNCT
ajlm-2681	3	56	05	05	NUM
ajlm-2681	3	57	nov	nov	PROPN
ajlm-2681	3	58	.	.	PROPN
ajlm-2681	3	59	2024	2024	NUM
ajlm-2681	3	60	;	;	PUNCT
ajlm-2681	3	61	accepted	accept	VERB
ajlm-2681	3	62	:	:	PUNCT
ajlm-2681	3	63	28	28	NUM
ajlm-2681	3	64	jan	jan	PROPN
ajlm-2681	3	65	.	.	PROPN
ajlm-2681	3	66	2025	2025	NUM
ajlm-2681	3	67	;	;	PUNCT
ajlm-2681	3	68	published	publish	VERB
ajlm-2681	3	69	:	:	PUNCT
ajlm-2681	3	70	26	26	NUM
ajlm-2681	3	71	june	june	PROPN
ajlm-2681	3	72	2025	2025	NUM
ajlm-2681	3	73	copyright	copyright	NOUN
ajlm-2681	3	74	:	:	PUNCT
ajlm-2681	3	75	©	©	PROPN
ajlm-2681	3	76	2025	2025	NUM
ajlm-2681	3	77	.	.	PUNCT
ajlm-2681	4	1	the	the	DET
ajlm-2681	4	2	author(s	author(s	PROPN
ajlm-2681	4	3	)	)	PUNCT
ajlm-2681	4	4	.	.	PUNCT
ajlm-2681	5	1	licensee	licensee	NOUN
ajlm-2681	5	2	:	:	PUNCT
ajlm-2681	5	3	aosis	aosis	NOUN
ajlm-2681	5	4	.	.	PUNCT
ajlm-2681	6	1	this	this	PRON
ajlm-2681	6	2	is	be	AUX
ajlm-2681	6	3	an	an	DET
ajlm-2681	6	4	open	open	ADJ
ajlm-2681	6	5	access	access	NOUN
ajlm-2681	6	6	article	article	NOUN
ajlm-2681	6	7	distributed	distribute	VERB
ajlm-2681	6	8	under	under	ADP
ajlm-2681	6	9	the	the	DET
ajlm-2681	6	10	terms	term	NOUN
ajlm-2681	6	11	of	of	ADP
ajlm-2681	6	12	the	the	DET
ajlm-2681	6	13	creative	creative	ADJ
ajlm-2681	6	14	commons	common	NOUN
ajlm-2681	6	15	attribution	attribution	NOUN
ajlm-2681	6	16	license	license	NOUN
ajlm-2681	6	17	,	,	PUNCT
ajlm-2681	6	18	which	which	PRON
ajlm-2681	6	19	permits	permit	VERB
ajlm-2681	6	20	unrestricted	unrestricted	ADJ
ajlm-2681	6	21	use	use	NOUN
ajlm-2681	6	22	,	,	PUNCT
ajlm-2681	6	23	distribution	distribution	NOUN
ajlm-2681	6	24	,	,	PUNCT
ajlm-2681	6	25	and	and	CCONJ
ajlm-2681	6	26	reproduction	reproduction	NOUN
ajlm-2681	6	27	in	in	ADP
ajlm-2681	6	28	any	any	DET
ajlm-2681	6	29	medium	medium	NOUN
ajlm-2681	6	30	,	,	PUNCT
ajlm-2681	6	31	provided	provide	VERB
ajlm-2681	6	32	the	the	DET
ajlm-2681	6	33	original	original	ADJ
ajlm-2681	6	34	work	work	NOUN
ajlm-2681	6	35	is	be	AUX
ajlm-2681	6	36	properly	properly	ADV
ajlm-2681	6	37	cited	cite	VERB
ajlm-2681	6	38	.	.	PUNCT
ajlm-2681	7	1	abstract	abstract	ADJ
ajlm-2681	7	2	background	background	NOUN
ajlm-2681	7	3	:	:	PUNCT
ajlm-2681	7	4	coronavirus	coronavirus	NOUN
ajlm-2681	7	5	disease	disease	NOUN
ajlm-2681	7	6	2019	2019	NUM
ajlm-2681	7	7	(	(	PUNCT
ajlm-2681	7	8	covid-19	covid-19	PROPN
ajlm-2681	7	9	)	)	PUNCT
ajlm-2681	7	10	increases	increase	VERB
ajlm-2681	7	11	the	the	DET
ajlm-2681	7	12	risk	risk	NOUN
ajlm-2681	7	13	of	of	ADP
ajlm-2681	7	14	venous	venous	ADJ
ajlm-2681	7	15	thromboembolism	thromboembolism	NOUN
ajlm-2681	7	16	,	,	PUNCT
ajlm-2681	7	17	requiring	require	VERB
ajlm-2681	7	18	monitoring	monitoring	NOUN
ajlm-2681	7	19	of	of	ADP
ajlm-2681	7	20	low	low	ADJ
ajlm-2681	7	21	molecular	molecular	ADJ
ajlm-2681	7	22	weight	weight	NOUN
ajlm-2681	7	23	heparin	heparin	NOUN
ajlm-2681	7	24	(	(	PUNCT
ajlm-2681	7	25	lmwh	lmwh	PROPN
ajlm-2681	7	26	)	)	PUNCT
ajlm-2681	7	27	via	via	ADP
ajlm-2681	7	28	a	a	DET
ajlm-2681	7	29	time	time	NOUN
ajlm-2681	7	30	-	-	PUNCT
ajlm-2681	7	31	consuming	consume	VERB
ajlm-2681	7	32	,	,	PUNCT
ajlm-2681	7	33	costly	costly	ADJ
ajlm-2681	7	34	and	and	CCONJ
ajlm-2681	7	35	often	often	ADV
ajlm-2681	7	36	unavailable	unavailable	ADJ
ajlm-2681	7	37	test	test	NOUN
ajlm-2681	7	38	–	–	PUNCT
ajlm-2681	7	39	anti	anti	ADJ
ajlm-2681	7	40	-	-	ADJ
ajlm-2681	7	41	factor	factor	ADJ
ajlm-2681	7	42	xa	xa	PROPN
ajlm-2681	7	43	(	(	PUNCT
ajlm-2681	7	44	anti	anti	NOUN
ajlm-2681	7	45	-	-	PROPN
ajlm-2681	7	46	xa	xa	NUM
ajlm-2681	7	47	)	)	PUNCT
ajlm-2681	7	48	.	.	PUNCT
ajlm-2681	8	1	an	an	DET
ajlm-2681	8	2	affordable	affordable	ADJ
ajlm-2681	8	3	,	,	PUNCT
ajlm-2681	8	4	rapid	rapid	ADJ
ajlm-2681	8	5	point	point	NOUN
ajlm-2681	8	6	-	-	PUNCT
ajlm-2681	8	7	of	of	ADP
ajlm-2681	8	8	-	-	PUNCT
ajlm-2681	8	9	care	care	NOUN
ajlm-2681	8	10	alternative	alternative	NOUN
ajlm-2681	8	11	,	,	PUNCT
ajlm-2681	8	12	the	the	DET
ajlm-2681	8	13	thromboelastogram	thromboelastogram	NOUN
ajlm-2681	8	14	,	,	PUNCT
ajlm-2681	8	15	is	be	AUX
ajlm-2681	8	16	available	available	ADJ
ajlm-2681	8	17	,	,	PUNCT
ajlm-2681	8	18	but	but	CCONJ
ajlm-2681	8	19	performance	performance	NOUN
ajlm-2681	8	20	comparisons	comparison	NOUN
ajlm-2681	8	21	to	to	ADP
ajlm-2681	8	22	anti	anti	ADJ
ajlm-2681	8	23	-	-	ADJ
ajlm-2681	8	24	xa	xa	PROPN
ajlm-2681	8	25	are	be	AUX
ajlm-2681	8	26	lacking	lack	VERB
ajlm-2681	8	27	.	.	PUNCT
ajlm-2681	9	1	objective	objective	NOUN
ajlm-2681	9	2	:	:	PUNCT
ajlm-2681	9	3	this	this	DET
ajlm-2681	9	4	study	study	NOUN
ajlm-2681	9	5	evaluated	evaluate	VERB
ajlm-2681	9	6	the	the	DET
ajlm-2681	9	7	relationship	relationship	NOUN
ajlm-2681	9	8	between	between	ADP
ajlm-2681	9	9	anti	anti	NOUN
ajlm-2681	9	10	-	-	PROPN
ajlm-2681	9	11	xa	xa	PROPN
ajlm-2681	9	12	and	and	CCONJ
ajlm-2681	9	13	thromboelastogram	thromboelastogram	NOUN
ajlm-2681	9	14	in	in	ADP
ajlm-2681	9	15	patients	patient	NOUN
ajlm-2681	9	16	with	with	ADP
ajlm-2681	9	17	covid-19	covid-19	PROPN
ajlm-2681	9	18	receiving	receive	VERB
ajlm-2681	9	19	lmwh	lmwh	NOUN
ajlm-2681	9	20	.	.	PUNCT
ajlm-2681	10	1	methods	method	NOUN
ajlm-2681	10	2	:	:	PUNCT
ajlm-2681	10	3	this	this	PRON
ajlm-2681	10	4	was	be	AUX
ajlm-2681	10	5	a	a	DET
ajlm-2681	10	6	retrospective	retrospective	ADJ
ajlm-2681	10	7	study	study	NOUN
ajlm-2681	10	8	of	of	ADP
ajlm-2681	10	9	patients	patient	NOUN
ajlm-2681	10	10	with	with	ADP
ajlm-2681	10	11	covid-19	covid-19	PROPN
ajlm-2681	10	12	receiving	receive	VERB
ajlm-2681	10	13	lmwh	lmwh	NOUN
ajlm-2681	10	14	at	at	ADP
ajlm-2681	10	15	chris	chris	PROPN
ajlm-2681	10	16	hani	hani	PROPN
ajlm-2681	10	17	baragwanath	baragwanath	PROPN
ajlm-2681	10	18	academic	academic	PROPN
ajlm-2681	10	19	hospital	hospital	PROPN
ajlm-2681	10	20	,	,	PUNCT
ajlm-2681	10	21	johannesburg	johannesburg	PROPN
ajlm-2681	10	22	,	,	PUNCT
ajlm-2681	10	23	south	south	PROPN
ajlm-2681	10	24	africa	africa	PROPN
ajlm-2681	10	25	,	,	PUNCT
ajlm-2681	10	26	between	between	ADP
ajlm-2681	10	27	november	november	PROPN
ajlm-2681	10	28	2020	2020	NUM
ajlm-2681	10	29	and	and	CCONJ
ajlm-2681	10	30	january	january	PROPN
ajlm-2681	10	31	2021	2021	NUM
ajlm-2681	10	32	.	.	PUNCT
ajlm-2681	11	1	blood	blood	NOUN
ajlm-2681	11	2	samples	sample	NOUN
ajlm-2681	11	3	tested	test	VERB
ajlm-2681	11	4	with	with	ADP
ajlm-2681	11	5	thromboelastogram	thromboelastogram	NOUN
ajlm-2681	11	6	and	and	CCONJ
ajlm-2681	11	7	anti	anti	PROPN
ajlm-2681	11	8	-	-	PROPN
ajlm-2681	11	9	xa	xa	PROPN
ajlm-2681	11	10	were	be	AUX
ajlm-2681	11	11	drawn	draw	VERB
ajlm-2681	11	12	at	at	ADP
ajlm-2681	11	13	three	three	NUM
ajlm-2681	11	14	timepoints	timepoint	NOUN
ajlm-2681	11	15	(	(	PUNCT
ajlm-2681	11	16	one	one	NUM
ajlm-2681	11	17	prior	prior	ADV
ajlm-2681	11	18	to	to	ADP
ajlm-2681	11	19	and	and	CCONJ
ajlm-2681	11	20	two	two	NUM
ajlm-2681	11	21	after	after	ADP
ajlm-2681	11	22	administration	administration	NOUN
ajlm-2681	11	23	of	of	ADP
ajlm-2681	11	24	lmwh	lmwh	PROPN
ajlm-2681	11	25	)	)	PUNCT
ajlm-2681	11	26	.	.	PUNCT
ajlm-2681	12	1	thromboelastogram	thromboelastogram	NOUN
ajlm-2681	12	2	parameters	parameter	NOUN
ajlm-2681	12	3	comprised	comprise	VERB
ajlm-2681	12	4	reaction	reaction	NOUN
ajlm-2681	12	5	time	time	NOUN
ajlm-2681	12	6	(	(	PUNCT
ajlm-2681	12	7	r	r	NOUN
ajlm-2681	12	8	-	-	PUNCT
ajlm-2681	12	9	time	time	NOUN
ajlm-2681	12	10	;	;	PUNCT
ajlm-2681	12	11	onset	onset	NOUN
ajlm-2681	12	12	of	of	ADP
ajlm-2681	12	13	testing	test	VERB
ajlm-2681	12	14	to	to	ADP
ajlm-2681	12	15	the	the	DET
ajlm-2681	12	16	start	start	NOUN
ajlm-2681	12	17	of	of	ADP
ajlm-2681	12	18	clot	clot	NOUN
ajlm-2681	12	19	formation	formation	NOUN
ajlm-2681	12	20	)	)	PUNCT
ajlm-2681	12	21	,	,	PUNCT
ajlm-2681	12	22	kinetics	kinetic	NOUN
ajlm-2681	12	23	time	time	NOUN
ajlm-2681	12	24	(	(	PUNCT
ajlm-2681	12	25	k	k	NOUN
ajlm-2681	12	26	-	-	NOUN
ajlm-2681	12	27	time	time	NOUN
ajlm-2681	12	28	;	;	PUNCT
ajlm-2681	12	29	start	start	NOUN
ajlm-2681	12	30	of	of	ADP
ajlm-2681	12	31	clot	clot	NOUN
ajlm-2681	12	32	formation	formation	NOUN
ajlm-2681	12	33	until	until	SCONJ
ajlm-2681	12	34	the	the	DET
ajlm-2681	12	35	clot	clot	NOUN
ajlm-2681	12	36	reached	reach	VERB
ajlm-2681	12	37	20	20	NUM
ajlm-2681	12	38	mm	mm	NOUN
ajlm-2681	12	39	)	)	PUNCT
ajlm-2681	12	40	,	,	PUNCT
ajlm-2681	12	41	and	and	CCONJ
ajlm-2681	12	42	thromboelastogram	thromboelastogram	NOUN
ajlm-2681	12	43	coagulation	coagulation	NOUN
ajlm-2681	12	44	index	index	NOUN
ajlm-2681	12	45	(	(	PUNCT
ajlm-2681	12	46	overall	overall	ADJ
ajlm-2681	12	47	coagulation	coagulation	NOUN
ajlm-2681	12	48	status	status	NOUN
ajlm-2681	12	49	of	of	ADP
ajlm-2681	12	50	whole	whole	ADJ
ajlm-2681	12	51	blood	blood	NOUN
ajlm-2681	12	52	)	)	PUNCT
ajlm-2681	12	53	.	.	PUNCT
ajlm-2681	13	1	results	result	NOUN
ajlm-2681	13	2	:	:	PUNCT
ajlm-2681	13	3	forty	forty	NUM
ajlm-2681	13	4	-	-	PUNCT
ajlm-2681	13	5	two	two	NUM
ajlm-2681	13	6	patients	patient	NOUN
ajlm-2681	13	7	with	with	ADP
ajlm-2681	13	8	covid-19	covid-19	PROPN
ajlm-2681	13	9	(	(	PUNCT
ajlm-2681	13	10	15	15	NUM
ajlm-2681	13	11	male	male	NOUN
ajlm-2681	13	12	and	and	CCONJ
ajlm-2681	13	13	27	27	NUM
ajlm-2681	13	14	female	female	NOUN
ajlm-2681	13	15	)	)	PUNCT
ajlm-2681	13	16	met	meet	VERB
ajlm-2681	13	17	the	the	DET
ajlm-2681	13	18	study	study	NOUN
ajlm-2681	13	19	criteria	criterion	NOUN
ajlm-2681	13	20	.	.	PUNCT
ajlm-2681	14	1	there	there	PRON
ajlm-2681	14	2	was	be	VERB
ajlm-2681	14	3	a	a	DET
ajlm-2681	14	4	statistically	statistically	ADV
ajlm-2681	14	5	significant	significant	ADJ
ajlm-2681	14	6	,	,	PUNCT
ajlm-2681	14	7	low	low	ADJ
ajlm-2681	14	8	to	to	ADP
ajlm-2681	14	9	moderate	moderate	ADJ
ajlm-2681	14	10	correlation	correlation	NOUN
ajlm-2681	14	11	(	(	PUNCT
ajlm-2681	14	12	spearman	spearman	NOUN
ajlm-2681	14	13	’s	’s	PART
ajlm-2681	14	14	correlation	correlation	NOUN
ajlm-2681	14	15	coefficient	coefficient	NOUN
ajlm-2681	15	1	[	[	X
ajlm-2681	15	2	rs	rs	NOUN
ajlm-2681	15	3	0.43	0.43	NUM
ajlm-2681	15	4	,	,	PUNCT
ajlm-2681	15	5	p	p	X
ajlm-2681	15	6	=	=	NOUN
ajlm-2681	15	7	0.014	0.014	NUM
ajlm-2681	15	8	]	]	PUNCT
ajlm-2681	15	9	)	)	PUNCT
ajlm-2681	15	10	between	between	ADP
ajlm-2681	15	11	anti	anti	PROPN
ajlm-2681	15	12	-	-	PROPN
ajlm-2681	15	13	xa	xa	PROPN
ajlm-2681	15	14	and	and	CCONJ
ajlm-2681	15	15	thromboelastogram	thromboelastogram	PROPN
ajlm-2681	15	16	coagulation	coagulation	PROPN
ajlm-2681	15	17	index	index	PROPN
ajlm-2681	15	18	.	.	PUNCT
ajlm-2681	16	1	a	a	DET
ajlm-2681	16	2	statistically	statistically	ADV
ajlm-2681	16	3	significant	significant	ADJ
ajlm-2681	16	4	moderate	moderate	ADJ
ajlm-2681	16	5	correlation	correlation	NOUN
ajlm-2681	16	6	(	(	PUNCT
ajlm-2681	16	7	rs	rs	NOUN
ajlm-2681	16	8	0.52	0.52	NUM
ajlm-2681	16	9	,	,	PUNCT
ajlm-2681	16	10	p	p	X
ajlm-2681	16	11	=	=	NOUN
ajlm-2681	16	12	0.002	0.002	NUM
ajlm-2681	16	13	)	)	PUNCT
ajlm-2681	16	14	between	between	ADP
ajlm-2681	16	15	anti	anti	PROPN
ajlm-2681	16	16	-	-	PROPN
ajlm-2681	16	17	xa	xa	NOUN
ajlm-2681	16	18	and	and	CCONJ
ajlm-2681	16	19	r	r	NOUN
ajlm-2681	16	20	-	-	PUNCT
ajlm-2681	16	21	time	time	NOUN
ajlm-2681	16	22	,	,	PUNCT
ajlm-2681	16	23	and	and	CCONJ
ajlm-2681	16	24	a	a	DET
ajlm-2681	16	25	statistically	statistically	ADV
ajlm-2681	16	26	significant	significant	ADJ
ajlm-2681	16	27	low	low	ADJ
ajlm-2681	16	28	correlation	correlation	NOUN
ajlm-2681	16	29	(	(	PUNCT
ajlm-2681	16	30	rs	rs	NOUN
ajlm-2681	16	31	0.35	0.35	NUM
ajlm-2681	16	32	,	,	PUNCT
ajlm-2681	16	33	p	p	X
ajlm-2681	16	34	=	=	NOUN
ajlm-2681	16	35	0.049	0.049	NUM
ajlm-2681	16	36	)	)	PUNCT
ajlm-2681	16	37	between	between	ADP
ajlm-2681	16	38	anti	anti	PROPN
ajlm-2681	16	39	-	-	PROPN
ajlm-2681	16	40	xa	xa	PROPN
ajlm-2681	16	41	and	and	CCONJ
ajlm-2681	16	42	k	k	NOUN
ajlm-2681	16	43	-	-	PUNCT
ajlm-2681	16	44	time	time	NOUN
ajlm-2681	16	45	,	,	PUNCT
ajlm-2681	16	46	were	be	AUX
ajlm-2681	16	47	found	find	VERB
ajlm-2681	16	48	.	.	PUNCT
ajlm-2681	17	1	all	all	DET
ajlm-2681	17	2	correlations	correlation	NOUN
ajlm-2681	17	3	were	be	AUX
ajlm-2681	17	4	48	48	NUM
ajlm-2681	17	5	h	h	NOUN
ajlm-2681	17	6	post	post	NOUN
ajlm-2681	17	7	admission	admission	NOUN
ajlm-2681	17	8	.	.	PUNCT
ajlm-2681	18	1	conclusion	conclusion	NOUN
ajlm-2681	18	2	:	:	PUNCT
ajlm-2681	18	3	thromboelastogram	thromboelastogram	PROPN
ajlm-2681	18	4	coagulation	coagulation	PROPN
ajlm-2681	18	5	index	index	PROPN
ajlm-2681	18	6	,	,	PUNCT
ajlm-2681	18	7	r	r	NOUN
ajlm-2681	18	8	-	-	PUNCT
ajlm-2681	18	9	times	time	NOUN
ajlm-2681	18	10	and	and	CCONJ
ajlm-2681	18	11	k	k	NOUN
ajlm-2681	18	12	-	-	PUNCT
ajlm-2681	18	13	times	time	NOUN
ajlm-2681	18	14	had	have	VERB
ajlm-2681	18	15	a	a	DET
ajlm-2681	18	16	statistically	statistically	ADV
ajlm-2681	18	17	significant	significant	ADJ
ajlm-2681	18	18	association	association	NOUN
ajlm-2681	18	19	with	with	ADP
ajlm-2681	18	20	anti	anti	ADJ
ajlm-2681	18	21	-	-	ADJ
ajlm-2681	18	22	xa	xa	ADJ
ajlm-2681	18	23	levels	level	NOUN
ajlm-2681	18	24	in	in	ADP
ajlm-2681	18	25	patients	patient	NOUN
ajlm-2681	18	26	with	with	ADP
ajlm-2681	18	27	covid-19	covid-19	PROPN
ajlm-2681	18	28	.	.	PUNCT
ajlm-2681	19	1	further	further	ADJ
ajlm-2681	19	2	research	research	NOUN
ajlm-2681	19	3	is	be	AUX
ajlm-2681	19	4	required	require	VERB
ajlm-2681	19	5	regarding	regard	VERB
ajlm-2681	19	6	their	their	PRON
ajlm-2681	19	7	clinical	clinical	ADJ
ajlm-2681	19	8	utility	utility	NOUN
ajlm-2681	19	9	.	.	PUNCT
ajlm-2681	20	1	what	what	PRON
ajlm-2681	20	2	this	this	DET
ajlm-2681	20	3	study	study	NOUN
ajlm-2681	20	4	adds	add	VERB
ajlm-2681	20	5	:	:	PUNCT
ajlm-2681	20	6	thromboelastograms	thromboelastogram	NOUN
ajlm-2681	20	7	may	may	AUX
ajlm-2681	20	8	represent	represent	VERB
ajlm-2681	20	9	a	a	DET
ajlm-2681	20	10	more	more	ADV
ajlm-2681	20	11	cost	cost	NOUN
ajlm-2681	20	12	-	-	PUNCT
ajlm-2681	20	13	effective	effective	ADJ
ajlm-2681	20	14	and	and	CCONJ
ajlm-2681	20	15	accessible	accessible	ADJ
ajlm-2681	20	16	option	option	NOUN
ajlm-2681	20	17	to	to	ADP
ajlm-2681	20	18	the	the	DET
ajlm-2681	20	19	conventional	conventional	ADJ
ajlm-2681	20	20	anti	anti	ADJ
ajlm-2681	20	21	-	-	ADJ
ajlm-2681	20	22	xa	xa	ADJ
ajlm-2681	20	23	test	test	NOUN
ajlm-2681	20	24	in	in	ADP
ajlm-2681	20	25	patients	patient	NOUN
ajlm-2681	20	26	receiving	receive	VERB
ajlm-2681	20	27	lmwh	lmwh	NOUN
ajlm-2681	20	28	.	.	PUNCT
ajlm-2681	21	1	however	however	ADV
ajlm-2681	21	2	,	,	PUNCT
ajlm-2681	21	3	future	future	ADJ
ajlm-2681	21	4	research	research	NOUN
ajlm-2681	21	5	with	with	ADP
ajlm-2681	21	6	larger	large	ADJ
ajlm-2681	21	7	sample	sample	NOUN
ajlm-2681	21	8	sizes	size	NOUN
ajlm-2681	21	9	,	,	PUNCT
ajlm-2681	21	10	varying	vary	VERB
ajlm-2681	21	11	disease	disease	NOUN
ajlm-2681	21	12	profiles	profile	NOUN
ajlm-2681	21	13	,	,	PUNCT
ajlm-2681	21	14	and	and	CCONJ
ajlm-2681	21	15	severity	severity	NOUN
ajlm-2681	21	16	of	of	ADP
ajlm-2681	21	17	illness	illness	NOUN
ajlm-2681	21	18	is	be	AUX
ajlm-2681	21	19	required	require	VERB
ajlm-2681	21	20	.	.	PUNCT
ajlm-2681	22	1	keywords	keyword	NOUN
ajlm-2681	22	2	:	:	PUNCT
ajlm-2681	22	3	thromboelastogram	thromboelastogram	NOUN
ajlm-2681	22	4	;	;	PUNCT
ajlm-2681	22	5	low	low	ADJ
ajlm-2681	22	6	molecular	molecular	ADJ
ajlm-2681	22	7	weight	weight	NOUN
ajlm-2681	22	8	heparin	heparin	NOUN
ajlm-2681	22	9	;	;	PUNCT
ajlm-2681	22	10	heparin	heparin	NOUN
ajlm-2681	22	11	;	;	PUNCT
ajlm-2681	22	12	coronavirus	coronavirus	NOUN
ajlm-2681	22	13	disease	disease	NOUN
ajlm-2681	22	14	2019	2019	NUM
ajlm-2681	22	15	;	;	PUNCT
ajlm-2681	22	16	viscoelastic	viscoelastic	ADJ
ajlm-2681	22	17	methods	method	NOUN
ajlm-2681	22	18	;	;	PUNCT
ajlm-2681	22	19	coagulopathy	coagulopathy	ADJ
ajlm-2681	22	20	.	.	PUNCT
ajlm-2681	23	1	introduction	introduction	NOUN
ajlm-2681	23	2	coronavirus	coronavirus	NOUN
ajlm-2681	23	3	disease	disease	NOUN
ajlm-2681	23	4	2019	2019	NUM
ajlm-2681	23	5	(	(	PUNCT
ajlm-2681	23	6	covid-19)-infected	covid-19)-infecte	VERB
ajlm-2681	23	7	patients	patient	NOUN
ajlm-2681	23	8	are	be	AUX
ajlm-2681	23	9	known	know	VERB
ajlm-2681	23	10	to	to	PART
ajlm-2681	23	11	be	be	AUX
ajlm-2681	23	12	at	at	ADP
ajlm-2681	23	13	higher	high	ADJ
ajlm-2681	23	14	risk	risk	NOUN
ajlm-2681	23	15	of	of	ADP
ajlm-2681	23	16	venous	venous	ADJ
ajlm-2681	23	17	thromboembolism	thromboembolism	NOUN
ajlm-2681	23	18	(	(	PUNCT
ajlm-2681	23	19	vte).1	vte).1	ADP
ajlm-2681	23	20	an	an	DET
ajlm-2681	23	21	accurate	accurate	ADJ
ajlm-2681	23	22	incidence	incidence	NOUN
ajlm-2681	23	23	rate	rate	NOUN
ajlm-2681	23	24	of	of	ADP
ajlm-2681	23	25	vte	vte	NOUN
ajlm-2681	23	26	in	in	ADP
ajlm-2681	23	27	covid-19	covid-19	PROPN
ajlm-2681	23	28	-	-	PUNCT
ajlm-2681	23	29	positive	positive	ADJ
ajlm-2681	23	30	patients	patient	NOUN
ajlm-2681	23	31	remains	remain	VERB
ajlm-2681	23	32	unknown	unknown	ADJ
ajlm-2681	23	33	,	,	PUNCT
ajlm-2681	23	34	ranging	range	VERB
ajlm-2681	23	35	from	from	ADP
ajlm-2681	23	36	4.8	4.8	NUM
ajlm-2681	23	37	%	%	NOUN
ajlm-2681	23	38	to	to	ADP
ajlm-2681	23	39	85.0%.2	85.0%.2	ADJ
ajlm-2681	23	40	autopsies	autopsy	NOUN
ajlm-2681	23	41	of	of	ADP
ajlm-2681	23	42	12	12	NUM
ajlm-2681	23	43	patients	patient	NOUN
ajlm-2681	23	44	with	with	ADP
ajlm-2681	23	45	severe	severe	ADJ
ajlm-2681	23	46	acute	acute	ADJ
ajlm-2681	23	47	respiratory	respiratory	ADJ
ajlm-2681	23	48	syndrome	syndrome	NOUN
ajlm-2681	23	49	coronavirus	coronavirus	NOUN
ajlm-2681	23	50	2	2	NUM
ajlm-2681	23	51	(	(	PUNCT
ajlm-2681	23	52	sars	sar	NOUN
ajlm-2681	23	53	-	-	PUNCT
ajlm-2681	23	54	cov-2	cov-2	NOUN
ajlm-2681	23	55	)	)	PUNCT
ajlm-2681	23	56	,	,	PUNCT
ajlm-2681	23	57	revealed	reveal	VERB
ajlm-2681	23	58	a	a	DET
ajlm-2681	23	59	vte	vte	NOUN
ajlm-2681	23	60	incidence	incidence	NOUN
ajlm-2681	23	61	of	of	ADP
ajlm-2681	23	62	58.0%.3	58.0%.3	PROPN
ajlm-2681	23	63	in	in	ADP
ajlm-2681	23	64	an	an	DET
ajlm-2681	23	65	observational	observational	ADJ
ajlm-2681	23	66	study	study	NOUN
ajlm-2681	23	67	of	of	ADP
ajlm-2681	23	68	150	150	NUM
ajlm-2681	23	69	patients	patient	NOUN
ajlm-2681	23	70	admitted	admit	VERB
ajlm-2681	23	71	to	to	ADP
ajlm-2681	23	72	the	the	DET
ajlm-2681	23	73	intensive	intensive	ADJ
ajlm-2681	23	74	care	care	NOUN
ajlm-2681	23	75	unit	unit	NOUN
ajlm-2681	23	76	in	in	ADP
ajlm-2681	23	77	france	france	PROPN
ajlm-2681	23	78	,	,	PUNCT
ajlm-2681	23	79	pulmonary	pulmonary	ADJ
ajlm-2681	23	80	emboli	embolus	NOUN
ajlm-2681	23	81	occurred	occur	VERB
ajlm-2681	23	82	in	in	ADP
ajlm-2681	23	83	20.6	20.6	NUM
ajlm-2681	23	84	%	%	NOUN
ajlm-2681	23	85	of	of	ADP
ajlm-2681	23	86	patients.3	patients.3	VERB
ajlm-2681	23	87	a	a	DET
ajlm-2681	23	88	cohort	cohort	NOUN
ajlm-2681	23	89	of	of	ADP
ajlm-2681	23	90	184	184	NUM
ajlm-2681	23	91	patients	patient	NOUN
ajlm-2681	23	92	admitted	admit	VERB
ajlm-2681	23	93	to	to	ADP
ajlm-2681	23	94	intensive	intensive	ADJ
ajlm-2681	23	95	care	care	NOUN
ajlm-2681	23	96	units	unit	NOUN
ajlm-2681	23	97	in	in	ADP
ajlm-2681	23	98	the	the	DET
ajlm-2681	23	99	netherlands	netherlands	PROPN
ajlm-2681	23	100	showed	show	VERB
ajlm-2681	23	101	that	that	SCONJ
ajlm-2681	23	102	pulmonary	pulmonary	ADJ
ajlm-2681	23	103	emboli	embolus	NOUN
ajlm-2681	23	104	occurred	occur	VERB
ajlm-2681	23	105	in	in	ADP
ajlm-2681	23	106	33.3	33.3	NUM
ajlm-2681	23	107	%	%	NOUN
ajlm-2681	23	108	of	of	ADP
ajlm-2681	23	109	all	all	DET
ajlm-2681	23	110	patients	patient	NOUN
ajlm-2681	23	111	suffering	suffer	VERB
ajlm-2681	23	112	from	from	ADP
ajlm-2681	23	113	sars	sar	NOUN
ajlm-2681	23	114	-	-	PUNCT
ajlm-2681	23	115	cov-2	cov-2	NOUN
ajlm-2681	23	116	acute	acute	ADJ
ajlm-2681	23	117	respiratory	respiratory	ADJ
ajlm-2681	23	118	distress	distress	NOUN
ajlm-2681	23	119	syndrome.3	syndrome.3	PRON
ajlm-2681	23	120	the	the	DET
ajlm-2681	23	121	incidence	incidence	NOUN
ajlm-2681	23	122	of	of	ADP
ajlm-2681	23	123	pulmonary	pulmonary	ADJ
ajlm-2681	23	124	embolism	embolism	NOUN
ajlm-2681	23	125	was	be	AUX
ajlm-2681	23	126	found	find	VERB
ajlm-2681	23	127	to	to	PART
ajlm-2681	23	128	be	be	AUX
ajlm-2681	23	129	twice	twice	ADV
ajlm-2681	23	130	as	as	ADV
ajlm-2681	23	131	high	high	ADJ
ajlm-2681	23	132	in	in	ADP
ajlm-2681	23	133	patients	patient	NOUN
ajlm-2681	23	134	with	with	ADP
ajlm-2681	23	135	sars	sar	NOUN
ajlm-2681	23	136	-	-	PUNCT
ajlm-2681	23	137	cov-2	cov-2	NUM
ajlm-2681	23	138	compared	compare	VERB
ajlm-2681	23	139	to	to	ADP
ajlm-2681	23	140	patients	patient	NOUN
ajlm-2681	23	141	with	with	ADP
ajlm-2681	23	142	influenza	influenza	NOUN
ajlm-2681	23	143	.	.	PUNCT
ajlm-2681	24	1	the	the	DET
ajlm-2681	24	2	pathophysiology	pathophysiology	NOUN
ajlm-2681	24	3	of	of	ADP
ajlm-2681	24	4	vte	vte	NOUN
ajlm-2681	24	5	in	in	ADP
ajlm-2681	24	6	covid-19	covid-19	PROPN
ajlm-2681	24	7	is	be	AUX
ajlm-2681	24	8	multifactorial	multifactorial	ADJ
ajlm-2681	24	9	.	.	PUNCT
ajlm-2681	25	1	the	the	DET
ajlm-2681	25	2	infection	infection	NOUN
ajlm-2681	25	3	is	be	AUX
ajlm-2681	25	4	associated	associate	VERB
ajlm-2681	25	5	with	with	ADP
ajlm-2681	25	6	an	an	DET
ajlm-2681	25	7	immune	immune	NOUN
ajlm-2681	25	8	-	-	PUNCT
ajlm-2681	25	9	mediated	mediate	VERB
ajlm-2681	25	10	exaggerated	exaggerated	ADJ
ajlm-2681	25	11	inflammatory	inflammatory	ADJ
ajlm-2681	25	12	response	response	NOUN
ajlm-2681	25	13	,	,	PUNCT
ajlm-2681	25	14	namely	namely	ADV
ajlm-2681	25	15	a	a	DET
ajlm-2681	25	16	cytokine	cytokine	ADJ
ajlm-2681	25	17	storm	storm	NOUN
ajlm-2681	25	18	including	include	VERB
ajlm-2681	25	19	tumour	tumour	NOUN
ajlm-2681	25	20	necrosis	necrosis	NOUN
ajlm-2681	25	21	factor	factor	NOUN
ajlm-2681	25	22	-	-	PUNCT
ajlm-2681	25	23	alpha	alpha	NOUN
ajlm-2681	25	24	,	,	PUNCT
ajlm-2681	25	25	interleukin-8	interleukin-8	NUM
ajlm-2681	25	26	,	,	PUNCT
ajlm-2681	25	27	and	and	CCONJ
ajlm-2681	25	28	interleukin-6.4	interleukin-6.4	ADJ
ajlm-2681	25	29	other	other	ADJ
ajlm-2681	25	30	contributory	contributory	NOUN
ajlm-2681	25	31	factors	factor	NOUN
ajlm-2681	25	32	include	include	VERB
ajlm-2681	25	33	endothelial	endothelial	ADJ
ajlm-2681	25	34	injury	injury	NOUN
ajlm-2681	25	35	,	,	PUNCT
ajlm-2681	25	36	abnormalities	abnormality	NOUN
ajlm-2681	25	37	in	in	ADP
ajlm-2681	25	38	gas	gas	NOUN
ajlm-2681	25	39	exchange	exchange	NOUN
ajlm-2681	25	40	and	and	CCONJ
ajlm-2681	25	41	lung	lung	NOUN
ajlm-2681	25	42	compliance	compliance	NOUN
ajlm-2681	25	43	,	,	PUNCT
ajlm-2681	25	44	as	as	ADV
ajlm-2681	25	45	well	well	ADV
ajlm-2681	25	46	as	as	ADP
ajlm-2681	25	47	haemodynamic	haemodynamic	ADJ
ajlm-2681	25	48	changes.2	changes.2	NOUN
ajlm-2681	25	49	owing	owe	VERB
ajlm-2681	25	50	to	to	ADP
ajlm-2681	25	51	the	the	DET
ajlm-2681	25	52	high	high	ADJ
ajlm-2681	25	53	occurrence	occurrence	NOUN
ajlm-2681	25	54	of	of	ADP
ajlm-2681	25	55	vte	vte	NOUN
ajlm-2681	25	56	in	in	ADP
ajlm-2681	25	57	patients	patient	NOUN
ajlm-2681	25	58	with	with	ADP
ajlm-2681	25	59	sars	sar	NOUN
ajlm-2681	25	60	-	-	PUNCT
ajlm-2681	25	61	cov-2	cov-2	NOUN
ajlm-2681	25	62	,	,	PUNCT
ajlm-2681	25	63	the	the	DET
ajlm-2681	25	64	international	international	ADJ
ajlm-2681	25	65	society	society	NOUN
ajlm-2681	25	66	of	of	ADP
ajlm-2681	25	67	thrombosis	thrombosis	NOUN
ajlm-2681	25	68	and	and	CCONJ
ajlm-2681	25	69	haemostasis	haemostasis	NOUN
ajlm-2681	25	70	recommends	recommend	VERB
ajlm-2681	25	71	that	that	SCONJ
ajlm-2681	25	72	all	all	DET
ajlm-2681	25	73	clinicians	clinician	NOUN
ajlm-2681	25	74	should	should	AUX
ajlm-2681	25	75	employ	employ	VERB
ajlm-2681	25	76	a	a	DET
ajlm-2681	25	77	high	high	ADJ
ajlm-2681	25	78	level	level	NOUN
ajlm-2681	25	79	of	of	ADP
ajlm-2681	25	80	suspicion	suspicion	NOUN
ajlm-2681	25	81	in	in	ADP
ajlm-2681	25	82	the	the	DET
ajlm-2681	25	83	diagnostic	diagnostic	ADJ
ajlm-2681	25	84	work	work	NOUN
ajlm-2681	25	85	-	-	PUNCT
ajlm-2681	25	86	up	up	NOUN
ajlm-2681	25	87	of	of	ADP
ajlm-2681	25	88	deep	deep	ADJ
ajlm-2681	25	89	venous	venous	ADJ
ajlm-2681	25	90	thrombosis	thrombosis	NOUN
ajlm-2681	25	91	and	and	CCONJ
ajlm-2681	25	92	pulmonary	pulmonary	ADJ
ajlm-2681	25	93	embolism.5	embolism.5	PROPN
ajlm-2681	25	94	emphasis	emphasis	NOUN
ajlm-2681	25	95	is	be	AUX
ajlm-2681	25	96	placed	place	VERB
ajlm-2681	25	97	on	on	ADP
ajlm-2681	25	98	both	both	CCONJ
ajlm-2681	25	99	prophylactic	prophylactic	ADJ
ajlm-2681	25	100	and	and	CCONJ
ajlm-2681	25	101	therapeutic	therapeutic	ADJ
ajlm-2681	25	102	dosed	dose	VERB
ajlm-2681	25	103	anticoagulation.5	anticoagulation.5	PROPN
ajlm-2681	25	104	the	the	DET
ajlm-2681	25	105	current	current	ADJ
ajlm-2681	25	106	anticoagulant	anticoagulant	NOUN
ajlm-2681	25	107	of	of	ADP
ajlm-2681	25	108	choice	choice	NOUN
ajlm-2681	25	109	in	in	ADP
ajlm-2681	25	110	the	the	DET
ajlm-2681	25	111	prevention	prevention	NOUN
ajlm-2681	25	112	of	of	ADP
ajlm-2681	25	113	vte	vte	NOUN
ajlm-2681	25	114	amongst	amongst	ADP
ajlm-2681	25	115	hospitalised	hospitalise	VERB
ajlm-2681	25	116	covid-19	covid-19	PROPN
ajlm-2681	25	117	infected	infected	ADJ
ajlm-2681	25	118	patients	patient	NOUN
ajlm-2681	25	119	is	be	AUX
ajlm-2681	25	120	low	low	ADJ
ajlm-2681	25	121	molecular	molecular	ADJ
ajlm-2681	25	122	weight	weight	NOUN
ajlm-2681	25	123	heparin	heparin	NOUN
ajlm-2681	25	124	(	(	PUNCT
ajlm-2681	25	125	lmwh	lmwh	NOUN
ajlm-2681	25	126	)	)	PUNCT
ajlm-2681	25	127	.	.	PUNCT
ajlm-2681	26	1	monitoring	monitoring	NOUN
ajlm-2681	26	2	of	of	ADP
ajlm-2681	26	3	lmwh	lmwh	NOUN
ajlm-2681	26	4	has	have	AUX
ajlm-2681	26	5	been	be	AUX
ajlm-2681	26	6	evaluated	evaluate	VERB
ajlm-2681	26	7	through	through	ADP
ajlm-2681	26	8	assessing	assess	VERB
ajlm-2681	26	9	anti	anti	ADJ
ajlm-2681	26	10	-	-	NOUN
ajlm-2681	26	11	factor	factor	ADJ
ajlm-2681	26	12	xa	xa	PROPN
ajlm-2681	26	13	(	(	PUNCT
ajlm-2681	26	14	anti	anti	PROPN
ajlm-2681	26	15	-	-	PROPN
ajlm-2681	26	16	xa	xa	NOUN
ajlm-2681	26	17	)	)	PUNCT
ajlm-2681	26	18	,	,	PUNCT
ajlm-2681	26	19	through	through	ADP
ajlm-2681	26	20	a	a	DET
ajlm-2681	26	21	measure	measure	NOUN
ajlm-2681	26	22	of	of	ADP
ajlm-2681	26	23	factor	factor	NOUN
ajlm-2681	26	24	xa	xa	PROPN
ajlm-2681	26	25	enzyme	enzyme	PROPN
ajlm-2681	26	26	(	(	PUNCT
ajlm-2681	26	27	xa	xa	NOUN
ajlm-2681	26	28	)	)	PUNCT
ajlm-2681	26	29	inhibition.6	inhibition.6	VERB
ajlm-2681	26	30	anti	anti	ADJ
ajlm-2681	26	31	-	-	ADJ
ajlm-2681	26	32	xa	xa	ADJ
ajlm-2681	26	33	assessment	assessment	NOUN
ajlm-2681	26	34	has	have	AUX
ajlm-2681	26	35	been	be	AUX
ajlm-2681	26	36	found	find	VERB
ajlm-2681	26	37	to	to	PART
ajlm-2681	26	38	improve	improve	VERB
ajlm-2681	26	39	the	the	DET
ajlm-2681	26	40	dosage	dosage	NOUN
ajlm-2681	26	41	regulation	regulation	NOUN
ajlm-2681	26	42	of	of	ADP
ajlm-2681	26	43	lmwh	lmwh	NOUN
ajlm-2681	26	44	in	in	ADP
ajlm-2681	26	45	the	the	DET
ajlm-2681	26	46	treatment	treatment	NOUN
ajlm-2681	26	47	and	and	CCONJ
ajlm-2681	26	48	prevention	prevention	NOUN
ajlm-2681	26	49	of	of	ADP
ajlm-2681	26	50	vte	vte	NOUN
ajlm-2681	26	51	amongst	amongst	ADP
ajlm-2681	26	52	sars	sars	PROPN
ajlm-2681	26	53	-	-	PUNCT
ajlm-2681	26	54	cov2	cov2	PROPN
ajlm-2681	26	55	infected	infect	VERB
ajlm-2681	26	56	patients.7,8,9	patients.7,8,9	PROPN
ajlm-2681	26	57	a	a	DET
ajlm-2681	26	58	study	study	NOUN
ajlm-2681	26	59	by	by	ADP
ajlm-2681	26	60	trunfio	trunfio	NOUN
ajlm-2681	26	61	et	et	PROPN
ajlm-2681	26	62	al.10	al.10	PROPN
ajlm-2681	26	63	revealed	reveal	VERB
ajlm-2681	26	64	that	that	SCONJ
ajlm-2681	26	65	prompt	prompt	ADJ
ajlm-2681	26	66	correction	correction	NOUN
ajlm-2681	26	67	of	of	ADP
ajlm-2681	26	68	lmwh	lmwh	ADJ
ajlm-2681	26	69	dosages	dosage	NOUN
ajlm-2681	26	70	based	base	VERB
ajlm-2681	26	71	on	on	ADP
ajlm-2681	26	72	an	an	DET
ajlm-2681	26	73	initial	initial	ADJ
ajlm-2681	26	74	anti	anti	ADJ
ajlm-2681	26	75	-	-	ADJ
ajlm-2681	26	76	xa	xa	ADJ
ajlm-2681	26	77	level	level	NOUN
ajlm-2681	26	78	measurement	measurement	NOUN
ajlm-2681	26	79	reduced	reduce	VERB
ajlm-2681	26	80	sars	sar	NOUN
ajlm-2681	26	81	-	-	PUNCT
ajlm-2681	26	82	cov-2	cov-2	ADV
ajlm-2681	26	83	related	related	ADJ
ajlm-2681	26	84	mortality	mortality	NOUN
ajlm-2681	26	85	.	.	PUNCT
ajlm-2681	27	1	in	in	ADP
ajlm-2681	27	2	addition	addition	NOUN
ajlm-2681	27	3	to	to	ADP
ajlm-2681	27	4	the	the	DET
ajlm-2681	27	5	current	current	ADJ
ajlm-2681	27	6	gold	gold	NOUN
ajlm-2681	27	7	standard	standard	NOUN
ajlm-2681	27	8	of	of	ADP
ajlm-2681	27	9	anti	anti	ADJ
ajlm-2681	27	10	-	-	ADJ
ajlm-2681	27	11	xa	xa	PROPN
ajlm-2681	27	12	levels	level	NOUN
ajlm-2681	27	13	,	,	PUNCT
ajlm-2681	27	14	current	current	ADJ
ajlm-2681	27	15	tests	test	NOUN
ajlm-2681	27	16	for	for	ADP
ajlm-2681	27	17	monitoring	monitor	VERB
ajlm-2681	27	18	lmwh	lmwh	NOUN
ajlm-2681	27	19	include	include	VERB
ajlm-2681	27	20	activated	activate	VERB
ajlm-2681	27	21	partial	partial	ADJ
ajlm-2681	27	22	thromboplastin	thromboplastin	NOUN
ajlm-2681	27	23	time	time	NOUN
ajlm-2681	27	24	and	and	CCONJ
ajlm-2681	27	25	thrombin	thrombin	NOUN
ajlm-2681	27	26	generation.11	generation.11	ADJ
ajlm-2681	27	27	anti	anti	PROPN
ajlm-2681	27	28	-	-	NOUN
ajlm-2681	27	29	xa	xa	ADJ
ajlm-2681	27	30	assays	assay	NOUN
ajlm-2681	27	31	are	be	AUX
ajlm-2681	27	32	not	not	PART
ajlm-2681	27	33	without	without	ADP
ajlm-2681	27	34	limitations	limitation	NOUN
ajlm-2681	27	35	.	.	PUNCT
ajlm-2681	28	1	importantly	importantly	ADV
ajlm-2681	28	2	,	,	PUNCT
ajlm-2681	28	3	these	these	DET
ajlm-2681	28	4	assays	assay	NOUN
ajlm-2681	28	5	are	be	AUX
ajlm-2681	28	6	not	not	PART
ajlm-2681	28	7	widely	widely	ADV
ajlm-2681	28	8	available	available	ADJ
ajlm-2681	28	9	and	and	CCONJ
ajlm-2681	28	10	often	often	ADV
ajlm-2681	28	11	need	need	VERB
ajlm-2681	28	12	to	to	PART
ajlm-2681	28	13	be	be	AUX
ajlm-2681	28	14	referred	refer	VERB
ajlm-2681	28	15	to	to	ADP
ajlm-2681	28	16	reference	reference	NOUN
ajlm-2681	28	17	laboratories	laboratory	NOUN
ajlm-2681	28	18	,	,	PUNCT
ajlm-2681	28	19	which	which	PRON
ajlm-2681	28	20	prolongs	prolong	VERB
ajlm-2681	28	21	turnaround	turnaround	NOUN
ajlm-2681	28	22	time	time	NOUN
ajlm-2681	28	23	,	,	PUNCT
ajlm-2681	28	24	reducing	reduce	VERB
ajlm-2681	28	25	their	their	PRON
ajlm-2681	28	26	clinical	clinical	ADJ
ajlm-2681	28	27	utility	utility	NOUN
ajlm-2681	28	28	.	.	PUNCT
ajlm-2681	29	1	drawbacks	drawback	NOUN
ajlm-2681	29	2	with	with	ADP
ajlm-2681	29	3	anti	anti	ADJ
ajlm-2681	29	4	-	-	ADJ
ajlm-2681	29	5	xa	xa	ADJ
ajlm-2681	29	6	level	level	NOUN
ajlm-2681	29	7	monitoring	monitoring	NOUN
ajlm-2681	29	8	include	include	VERB
ajlm-2681	29	9	the	the	DET
ajlm-2681	29	10	additional	additional	ADJ
ajlm-2681	29	11	cost	cost	NOUN
ajlm-2681	29	12	of	of	ADP
ajlm-2681	29	13	testing	testing	NOUN
ajlm-2681	29	14	with	with	ADP
ajlm-2681	29	15	estimates	estimate	NOUN
ajlm-2681	29	16	as	as	ADV
ajlm-2681	29	17	high	high	ADJ
ajlm-2681	29	18	as	as	ADP
ajlm-2681	29	19	55	55	NUM
ajlm-2681	29	20	united	united	PROPN
ajlm-2681	29	21	states	states	PROPN
ajlm-2681	29	22	dollars	dollar	NOUN
ajlm-2681	29	23	(	(	PUNCT
ajlm-2681	29	24	usd	usd	NOUN
ajlm-2681	29	25	;	;	PUNCT
ajlm-2681	29	26	approximately	approximately	ADV
ajlm-2681	29	27	500	500	NUM
ajlm-2681	29	28	south	south	ADJ
ajlm-2681	29	29	african	african	ADJ
ajlm-2681	29	30	rand	rand	PROPN
ajlm-2681	30	1	[	[	X
ajlm-2681	30	2	zar	zar	X
ajlm-2681	30	3	]	]	X
ajlm-2681	30	4	–	–	PUNCT
ajlm-2681	30	5	1000	1000	NUM
ajlm-2681	30	6	zar	zar	NOUN
ajlm-2681	30	7	,	,	PUNCT
ajlm-2681	30	8	or	or	CCONJ
ajlm-2681	30	9	approximately	approximately	ADV
ajlm-2681	30	10	27	27	NUM
ajlm-2681	30	11	usd	usd	NOUN
ajlm-2681	30	12	–	–	PUNCT
ajlm-2681	30	13	55	55	NUM
ajlm-2681	30	14	usd	usd	NOUN
ajlm-2681	30	15	)	)	PUNCT
ajlm-2681	30	16	per	per	ADP
ajlm-2681	30	17	patient	patient	NOUN
ajlm-2681	30	18	per	per	ADP
ajlm-2681	30	19	test.6	test.6	PROPN
ajlm-2681	30	20	pre	pre	ADJ
ajlm-2681	30	21	-	-	ADJ
ajlm-2681	30	22	analytic	analytic	ADJ
ajlm-2681	30	23	factors	factor	NOUN
ajlm-2681	30	24	which	which	PRON
ajlm-2681	30	25	may	may	AUX
ajlm-2681	30	26	impair	impair	VERB
ajlm-2681	30	27	the	the	DET
ajlm-2681	30	28	validity	validity	NOUN
ajlm-2681	30	29	of	of	ADP
ajlm-2681	30	30	anti	anti	ADJ
ajlm-2681	30	31	-	-	ADJ
ajlm-2681	30	32	xa	xa	PROPN
ajlm-2681	30	33	levels	level	NOUN
ajlm-2681	30	34	include	include	VERB
ajlm-2681	30	35	poor	poor	ADJ
ajlm-2681	30	36	blood	blood	NOUN
ajlm-2681	30	37	sampling	sample	VERB
ajlm-2681	30	38	technique	technique	NOUN
ajlm-2681	30	39	,	,	PUNCT
ajlm-2681	30	40	delays	delay	NOUN
ajlm-2681	30	41	of	of	ADP
ajlm-2681	30	42	two	two	NUM
ajlm-2681	30	43	or	or	CCONJ
ajlm-2681	30	44	more	more	ADJ
ajlm-2681	30	45	hours	hour	NOUN
ajlm-2681	30	46	in	in	ADP
ajlm-2681	30	47	sample	sample	NOUN
ajlm-2681	30	48	analysis	analysis	NOUN
ajlm-2681	30	49	,	,	PUNCT
ajlm-2681	30	50	inadequate	inadequate	ADJ
ajlm-2681	30	51	centrifugation	centrifugation	NOUN
ajlm-2681	30	52	,	,	PUNCT
ajlm-2681	30	53	as	as	ADV
ajlm-2681	30	54	well	well	ADV
ajlm-2681	30	55	as	as	ADP
ajlm-2681	30	56	haemolysis	haemolysis	NOUN
ajlm-2681	30	57	.	.	PUNCT
ajlm-2681	31	1	repeated	repeat	VERB
ajlm-2681	31	2	tests	test	NOUN
ajlm-2681	31	3	may	may	AUX
ajlm-2681	31	4	be	be	AUX
ajlm-2681	31	5	required	require	VERB
ajlm-2681	31	6	to	to	PART
ajlm-2681	31	7	establish	establish	VERB
ajlm-2681	31	8	a	a	DET
ajlm-2681	31	9	trend	trend	NOUN
ajlm-2681	31	10	in	in	ADP
ajlm-2681	31	11	anti	anti	ADJ
ajlm-2681	31	12	-	-	ADJ
ajlm-2681	31	13	xa	xa	PROPN
ajlm-2681	31	14	levels	level	NOUN
ajlm-2681	31	15	,	,	PUNCT
ajlm-2681	31	16	further	far	ADV
ajlm-2681	31	17	increasing	increase	VERB
ajlm-2681	31	18	costs	cost	NOUN
ajlm-2681	31	19	.	.	PUNCT
ajlm-2681	32	1	biologic	biologic	NOUN
ajlm-2681	32	2	limitations	limitation	NOUN
ajlm-2681	32	3	include	include	VERB
ajlm-2681	32	4	antithrombin	antithrombin	ADJ
ajlm-2681	32	5	deficiency	deficiency	NOUN
ajlm-2681	32	6	,	,	PUNCT
ajlm-2681	32	7	increased	increase	VERB
ajlm-2681	32	8	binding	binding	ADJ
ajlm-2681	32	9	,	,	PUNCT
ajlm-2681	32	10	and	and	CCONJ
ajlm-2681	32	11	inactivation	inactivation	NOUN
ajlm-2681	32	12	of	of	ADP
ajlm-2681	32	13	heparin	heparin	NOUN
ajlm-2681	32	14	-	-	PUNCT
ajlm-2681	32	15	binding	bind	VERB
ajlm-2681	32	16	proteins	protein	NOUN
ajlm-2681	32	17	(	(	PUNCT
ajlm-2681	32	18	as	as	ADP
ajlm-2681	32	19	a	a	DET
ajlm-2681	32	20	result	result	NOUN
ajlm-2681	32	21	of	of	ADP
ajlm-2681	32	22	infection	infection	NOUN
ajlm-2681	32	23	and	and	CCONJ
ajlm-2681	32	24	inflammation	inflammation	NOUN
ajlm-2681	32	25	)	)	PUNCT
ajlm-2681	32	26	,	,	PUNCT
ajlm-2681	32	27	obesity	obesity	NOUN
ajlm-2681	32	28	(	(	PUNCT
ajlm-2681	32	29	linked	link	VERB
ajlm-2681	32	30	to	to	ADP
ajlm-2681	32	31	inadequate	inadequate	ADJ
ajlm-2681	32	32	levels	level	NOUN
ajlm-2681	32	33	of	of	ADP
ajlm-2681	32	34	lmwh	lmwh	NOUN
ajlm-2681	32	35	because	because	SCONJ
ajlm-2681	32	36	of	of	ADP
ajlm-2681	32	37	the	the	DET
ajlm-2681	32	38	increased	increase	VERB
ajlm-2681	32	39	volume	volume	NOUN
ajlm-2681	32	40	of	of	ADP
ajlm-2681	32	41	distribution	distribution	NOUN
ajlm-2681	32	42	)	)	PUNCT
ajlm-2681	32	43	and	and	CCONJ
ajlm-2681	32	44	impaired	impair	VERB
ajlm-2681	32	45	renal	renal	ADJ
ajlm-2681	32	46	function	function	NOUN
ajlm-2681	32	47	(	(	PUNCT
ajlm-2681	32	48	decreased	decrease	VERB
ajlm-2681	32	49	elimination	elimination	NOUN
ajlm-2681	32	50	of	of	ADP
ajlm-2681	32	51	lmwh).12	lmwh).12	PROPN
ajlm-2681	32	52	the	the	DET
ajlm-2681	32	53	prolonged	prolong	VERB
ajlm-2681	32	54	turnaround	turnaround	NOUN
ajlm-2681	32	55	time	time	NOUN
ajlm-2681	32	56	required	require	VERB
ajlm-2681	32	57	to	to	PART
ajlm-2681	32	58	obtain	obtain	VERB
ajlm-2681	32	59	a	a	DET
ajlm-2681	32	60	result	result	NOUN
ajlm-2681	32	61	from	from	ADP
ajlm-2681	32	62	overburdened	overburdened	ADJ
ajlm-2681	32	63	laboratories	laboratory	NOUN
ajlm-2681	32	64	is	be	AUX
ajlm-2681	32	65	problematic	problematic	ADJ
ajlm-2681	32	66	.	.	PUNCT
ajlm-2681	33	1	the	the	DET
ajlm-2681	33	2	meticulous	meticulous	ADJ
ajlm-2681	33	3	timing	timing	NOUN
ajlm-2681	33	4	that	that	PRON
ajlm-2681	33	5	each	each	DET
ajlm-2681	33	6	test	test	NOUN
ajlm-2681	33	7	needs	need	VERB
ajlm-2681	33	8	to	to	PART
ajlm-2681	33	9	adhere	adhere	VERB
ajlm-2681	33	10	to	to	PART
ajlm-2681	33	11	may	may	AUX
ajlm-2681	33	12	be	be	AUX
ajlm-2681	33	13	challenging	challenge	VERB
ajlm-2681	33	14	in	in	ADP
ajlm-2681	33	15	many	many	ADJ
ajlm-2681	33	16	settings.10	settings.10	ADJ
ajlm-2681	33	17	thromboelastography	thromboelastography	NOUN
ajlm-2681	33	18	is	be	AUX
ajlm-2681	33	19	a	a	DET
ajlm-2681	33	20	point	point	NOUN
ajlm-2681	33	21	-	-	PUNCT
ajlm-2681	33	22	of	of	ADP
ajlm-2681	33	23	-	-	PUNCT
ajlm-2681	33	24	care	care	NOUN
ajlm-2681	33	25	non	non	ADJ
ajlm-2681	33	26	-	-	ADJ
ajlm-2681	33	27	invasive	invasive	ADJ
ajlm-2681	33	28	in	in	ADP
ajlm-2681	33	29	vivo	vivo	NOUN
ajlm-2681	33	30	test	test	NOUN
ajlm-2681	33	31	carried	carry	VERB
ajlm-2681	33	32	out	out	ADP
ajlm-2681	33	33	in	in	ADP
ajlm-2681	33	34	a	a	DET
ajlm-2681	33	35	specialised	specialised	ADJ
ajlm-2681	33	36	machine	machine	NOUN
ajlm-2681	33	37	known	know	VERB
ajlm-2681	33	38	as	as	ADP
ajlm-2681	33	39	a	a	DET
ajlm-2681	33	40	thromboelastograph.12	thromboelastograph.12	NOUN
ajlm-2681	33	41	thromboelastograms	thromboelastogram	NOUN
ajlm-2681	33	42	identify	identify	VERB
ajlm-2681	33	43	and	and	CCONJ
ajlm-2681	33	44	measure	measure	VERB
ajlm-2681	33	45	dynamic	dynamic	ADJ
ajlm-2681	33	46	changes	change	NOUN
ajlm-2681	33	47	in	in	ADP
ajlm-2681	33	48	coagulation	coagulation	NOUN
ajlm-2681	33	49	,	,	PUNCT
ajlm-2681	33	50	identifying	identify	VERB
ajlm-2681	33	51	where	where	SCONJ
ajlm-2681	33	52	abnormalities	abnormality	NOUN
ajlm-2681	33	53	in	in	ADP
ajlm-2681	33	54	coagulopathy	coagulopathy	ADJ
ajlm-2681	33	55	are	be	AUX
ajlm-2681	33	56	found	find	VERB
ajlm-2681	33	57	.	.	PUNCT
ajlm-2681	34	1	thromboelastogram	thromboelastogram	NOUN
ajlm-2681	34	2	parameters	parameter	NOUN
ajlm-2681	34	3	consist	consist	VERB
ajlm-2681	34	4	of	of	ADP
ajlm-2681	34	5	a	a	DET
ajlm-2681	34	6	reaction	reaction	NOUN
ajlm-2681	34	7	time	time	NOUN
ajlm-2681	34	8	(	(	PUNCT
ajlm-2681	34	9	r	r	NOUN
ajlm-2681	34	10	-	-	PUNCT
ajlm-2681	34	11	time	time	NOUN
ajlm-2681	34	12	)	)	PUNCT
ajlm-2681	34	13	,	,	PUNCT
ajlm-2681	34	14	kinetics	kinetic	NOUN
ajlm-2681	34	15	time	time	NOUN
ajlm-2681	34	16	(	(	PUNCT
ajlm-2681	34	17	k	k	NOUN
ajlm-2681	34	18	-	-	NOUN
ajlm-2681	34	19	time	time	NOUN
ajlm-2681	34	20	)	)	PUNCT
ajlm-2681	34	21	,	,	PUNCT
ajlm-2681	34	22	alpha	alpha	NOUN
ajlm-2681	34	23	angle	angle	NOUN
ajlm-2681	34	24	,	,	PUNCT
ajlm-2681	34	25	maximum	maximum	ADJ
ajlm-2681	34	26	amplitude	amplitude	NOUN
ajlm-2681	34	27	(	(	PUNCT
ajlm-2681	34	28	ma	ma	PROPN
ajlm-2681	34	29	)	)	PUNCT
ajlm-2681	34	30	,	,	PUNCT
ajlm-2681	34	31	and	and	CCONJ
ajlm-2681	34	32	lysis	lysis	NOUN
ajlm-2681	34	33	at	at	ADP
ajlm-2681	34	34	30	30	NUM
ajlm-2681	34	35	min	min	NOUN
ajlm-2681	34	36	(	(	PUNCT
ajlm-2681	34	37	a30).12	a30).12	NOUN
ajlm-2681	34	38	this	this	PRON
ajlm-2681	34	39	is	be	AUX
ajlm-2681	34	40	performed	perform	VERB
ajlm-2681	34	41	at	at	ADP
ajlm-2681	34	42	the	the	DET
ajlm-2681	34	43	point	point	NOUN
ajlm-2681	34	44	of	of	ADP
ajlm-2681	34	45	care	care	NOUN
ajlm-2681	34	46	,	,	PUNCT
ajlm-2681	34	47	limiting	limit	VERB
ajlm-2681	34	48	the	the	DET
ajlm-2681	34	49	delay	delay	NOUN
ajlm-2681	34	50	expected	expect	VERB
ajlm-2681	34	51	in	in	ADP
ajlm-2681	34	52	laboratory	laboratory	NOUN
ajlm-2681	34	53	-	-	PUNCT
ajlm-2681	34	54	processed	process	VERB
ajlm-2681	34	55	testing.13	testing.13	NOUN
ajlm-2681	34	56	there	there	PRON
ajlm-2681	34	57	may	may	AUX
ajlm-2681	34	58	be	be	AUX
ajlm-2681	34	59	overall	overall	ADJ
ajlm-2681	34	60	cost	cost	NOUN
ajlm-2681	34	61	benefits	benefit	NOUN
ajlm-2681	34	62	to	to	ADP
ajlm-2681	34	63	using	use	VERB
ajlm-2681	34	64	thromboelastograms.14	thromboelastograms.14	NOUN
ajlm-2681	34	65	according	accord	VERB
ajlm-2681	34	66	to	to	ADP
ajlm-2681	34	67	a	a	DET
ajlm-2681	34	68	retrospective	retrospective	ADJ
ajlm-2681	34	69	study	study	NOUN
ajlm-2681	34	70	of	of	ADP
ajlm-2681	34	71	32	32	NUM
ajlm-2681	34	72	sars	sar	NOUN
ajlm-2681	34	73	-	-	PUNCT
ajlm-2681	34	74	cov-2	cov-2	NOUN
ajlm-2681	34	75	infected	infected	ADJ
ajlm-2681	34	76	patients	patient	NOUN
ajlm-2681	34	77	,	,	PUNCT
ajlm-2681	34	78	thromboelastogram	thromboelastogram	NOUN
ajlm-2681	34	79	analysis	analysis	NOUN
ajlm-2681	34	80	has	have	AUX
ajlm-2681	34	81	proven	prove	VERB
ajlm-2681	34	82	to	to	PART
ajlm-2681	34	83	be	be	AUX
ajlm-2681	34	84	useful	useful	ADJ
ajlm-2681	34	85	for	for	ADP
ajlm-2681	34	86	both	both	DET
ajlm-2681	34	87	screening	screen	VERB
ajlm-2681	34	88	for	for	ADP
ajlm-2681	34	89	hypercoagulability	hypercoagulability	NOUN
ajlm-2681	34	90	and	and	CCONJ
ajlm-2681	34	91	vte	vte	NOUN
ajlm-2681	34	92	,	,	PUNCT
ajlm-2681	34	93	and	and	CCONJ
ajlm-2681	34	94	also	also	ADV
ajlm-2681	34	95	for	for	ADP
ajlm-2681	34	96	determining	determine	VERB
ajlm-2681	34	97	appropriate	appropriate	ADJ
ajlm-2681	34	98	dosing	dosing	NOUN
ajlm-2681	34	99	of	of	ADP
ajlm-2681	34	100	anticoagulation	anticoagulation	NOUN
ajlm-2681	34	101	therapy.15	therapy.15	PROPN
ajlm-2681	34	102	a	a	DET
ajlm-2681	34	103	systematic	systematic	ADJ
ajlm-2681	34	104	review	review	NOUN
ajlm-2681	34	105	published	publish	VERB
ajlm-2681	34	106	by	by	ADP
ajlm-2681	34	107	the	the	DET
ajlm-2681	34	108	international	international	ADJ
ajlm-2681	34	109	society	society	NOUN
ajlm-2681	34	110	of	of	ADP
ajlm-2681	34	111	thrombosis	thrombosis	NOUN
ajlm-2681	34	112	and	and	CCONJ
ajlm-2681	34	113	haemostasis	haemostasis	NOUN
ajlm-2681	34	114	,	,	PUNCT
ajlm-2681	34	115	assessing	assess	VERB
ajlm-2681	34	116	153	153	NUM
ajlm-2681	34	117	articles	article	NOUN
ajlm-2681	34	118	,	,	PUNCT
ajlm-2681	34	119	including	include	VERB
ajlm-2681	34	120	841	841	NUM
ajlm-2681	34	121	patients	patient	NOUN
ajlm-2681	34	122	,	,	PUNCT
ajlm-2681	34	123	revealed	reveal	VERB
ajlm-2681	34	124	a	a	DET
ajlm-2681	34	125	good	good	ADJ
ajlm-2681	34	126	thromboelastogram	thromboelastogram	NOUN
ajlm-2681	34	127	detection	detection	NOUN
ajlm-2681	34	128	rate	rate	NOUN
ajlm-2681	34	129	of	of	ADP
ajlm-2681	34	130	hypercoagulability	hypercoagulability	NOUN
ajlm-2681	34	131	associated	associate	VERB
ajlm-2681	34	132	with	with	ADP
ajlm-2681	34	133	sars	sars	PROPN
ajlm-2681	34	134	-	-	PUNCT
ajlm-2681	34	135	cov-2.16	cov-2.16	PROPN
ajlm-2681	34	136	currently	currently	ADV
ajlm-2681	34	137	,	,	PUNCT
ajlm-2681	34	138	there	there	PRON
ajlm-2681	34	139	is	be	VERB
ajlm-2681	34	140	a	a	DET
ajlm-2681	34	141	paucity	paucity	NOUN
ajlm-2681	34	142	of	of	ADP
ajlm-2681	34	143	data	datum	NOUN
ajlm-2681	34	144	exploring	explore	VERB
ajlm-2681	34	145	the	the	DET
ajlm-2681	34	146	relationship	relationship	NOUN
ajlm-2681	34	147	between	between	ADP
ajlm-2681	34	148	thromboelastograms	thromboelastogram	NOUN
ajlm-2681	34	149	,	,	PUNCT
ajlm-2681	34	150	anti	anti	ADJ
ajlm-2681	34	151	-	-	ADJ
ajlm-2681	34	152	xa	xa	PROPN
ajlm-2681	34	153	levels	level	NOUN
ajlm-2681	34	154	and	and	CCONJ
ajlm-2681	34	155	lmwh	lmwh	NOUN
ajlm-2681	34	156	.	.	PUNCT
ajlm-2681	35	1	furthermore	furthermore	ADV
ajlm-2681	35	2	,	,	PUNCT
ajlm-2681	35	3	there	there	PRON
ajlm-2681	35	4	has	have	VERB
ajlm-2681	35	5	yet	yet	ADV
ajlm-2681	35	6	to	to	PART
ajlm-2681	35	7	be	be	AUX
ajlm-2681	35	8	defined	define	VERB
ajlm-2681	35	9	a	a	DET
ajlm-2681	35	10	specified	specified	ADJ
ajlm-2681	35	11	time	time	NOUN
ajlm-2681	35	12	period	period	NOUN
ajlm-2681	35	13	after	after	ADP
ajlm-2681	35	14	the	the	DET
ajlm-2681	35	15	administration	administration	NOUN
ajlm-2681	35	16	of	of	ADP
ajlm-2681	35	17	lmwh	lmwh	PROPN
ajlm-2681	35	18	,	,	PUNCT
ajlm-2681	35	19	when	when	SCONJ
ajlm-2681	35	20	thromboelastography	thromboelastography	NOUN
ajlm-2681	35	21	is	be	AUX
ajlm-2681	35	22	to	to	PART
ajlm-2681	35	23	be	be	AUX
ajlm-2681	35	24	done.17	done.17	NOUN
ajlm-2681	35	25	owing	owe	VERB
ajlm-2681	35	26	to	to	ADP
ajlm-2681	35	27	the	the	DET
ajlm-2681	35	28	potential	potential	ADJ
ajlm-2681	35	29	advantages	advantage	NOUN
ajlm-2681	35	30	of	of	ADP
ajlm-2681	35	31	thromboelastograms	thromboelastogram	NOUN
ajlm-2681	35	32	which	which	PRON
ajlm-2681	35	33	may	may	AUX
ajlm-2681	35	34	address	address	VERB
ajlm-2681	35	35	some	some	DET
ajlm-2681	35	36	limitations	limitation	NOUN
ajlm-2681	35	37	of	of	ADP
ajlm-2681	35	38	anti	anti	ADJ
ajlm-2681	35	39	-	-	ADJ
ajlm-2681	35	40	xa	xa	PROPN
ajlm-2681	35	41	testing	testing	NOUN
ajlm-2681	35	42	,	,	PUNCT
ajlm-2681	35	43	this	this	DET
ajlm-2681	35	44	study	study	NOUN
ajlm-2681	35	45	aimed	aim	VERB
ajlm-2681	35	46	to	to	PART
ajlm-2681	35	47	assess	assess	VERB
ajlm-2681	35	48	the	the	DET
ajlm-2681	35	49	correlation	correlation	NOUN
ajlm-2681	35	50	between	between	ADP
ajlm-2681	35	51	thromboelastograms	thromboelastogram	NOUN
ajlm-2681	35	52	and	and	CCONJ
ajlm-2681	35	53	d	d	NOUN
ajlm-2681	35	54	-	-	NOUN
ajlm-2681	35	55	dimers	dimer	NOUN
ajlm-2681	35	56	,	,	PUNCT
ajlm-2681	35	57	and	and	CCONJ
ajlm-2681	35	58	thromobelastograms	thromobelastogram	NOUN
ajlm-2681	35	59	and	and	CCONJ
ajlm-2681	35	60	anti	anti	ADJ
ajlm-2681	35	61	-	-	ADJ
ajlm-2681	35	62	xa	xa	PROPN
ajlm-2681	35	63	levels	level	NOUN
ajlm-2681	35	64	.	.	PUNCT
ajlm-2681	36	1	the	the	DET
ajlm-2681	36	2	primary	primary	ADJ
ajlm-2681	36	3	objective	objective	NOUN
ajlm-2681	36	4	was	be	AUX
ajlm-2681	36	5	to	to	PART
ajlm-2681	36	6	determine	determine	VERB
ajlm-2681	36	7	if	if	SCONJ
ajlm-2681	36	8	there	there	PRON
ajlm-2681	36	9	is	be	VERB
ajlm-2681	36	10	an	an	DET
ajlm-2681	36	11	association	association	NOUN
ajlm-2681	36	12	between	between	ADP
ajlm-2681	36	13	thromboelastogram	thromboelastogram	NOUN
ajlm-2681	36	14	coagulation	coagulation	NOUN
ajlm-2681	36	15	index	index	NOUN
ajlm-2681	36	16	(	(	PUNCT
ajlm-2681	36	17	tci	tci	PROPN
ajlm-2681	36	18	)	)	PUNCT
ajlm-2681	36	19	and	and	CCONJ
ajlm-2681	36	20	anti	anti	PROPN
ajlm-2681	36	21	-	-	ADJ
ajlm-2681	36	22	xa	xa	PROPN
ajlm-2681	36	23	levels	level	NOUN
ajlm-2681	36	24	among	among	ADP
ajlm-2681	36	25	covid-19	covid-19	PROPN
ajlm-2681	36	26	positive	positive	ADJ
ajlm-2681	36	27	patients	patient	NOUN
ajlm-2681	36	28	.	.	PUNCT
ajlm-2681	37	1	secondary	secondary	ADJ
ajlm-2681	37	2	outcomes	outcome	NOUN
ajlm-2681	37	3	were	be	AUX
ajlm-2681	37	4	to	to	PART
ajlm-2681	37	5	determine	determine	VERB
ajlm-2681	37	6	if	if	SCONJ
ajlm-2681	37	7	there	there	PRON
ajlm-2681	37	8	was	be	VERB
ajlm-2681	37	9	a	a	DET
ajlm-2681	37	10	correlation	correlation	NOUN
ajlm-2681	37	11	between	between	ADP
ajlm-2681	37	12	anti	anti	ADJ
ajlm-2681	37	13	-	-	ADJ
ajlm-2681	37	14	xa	xa	PROPN
ajlm-2681	37	15	levels	level	NOUN
ajlm-2681	37	16	and	and	CCONJ
ajlm-2681	37	17	thromboelastogram	thromboelastogram	NOUN
ajlm-2681	37	18	parameters	parameter	NOUN
ajlm-2681	37	19	,	,	PUNCT
ajlm-2681	37	20	namely	namely	ADV
ajlm-2681	37	21	the	the	DET
ajlm-2681	37	22	r	r	NOUN
ajlm-2681	37	23	-	-	PUNCT
ajlm-2681	37	24	time	time	NOUN
ajlm-2681	37	25	,	,	PUNCT
ajlm-2681	37	26	k	k	NOUN
ajlm-2681	37	27	-	-	NOUN
ajlm-2681	37	28	time	time	NOUN
ajlm-2681	37	29	,	,	PUNCT
ajlm-2681	37	30	and	and	CCONJ
ajlm-2681	37	31	alpha	alpha	NOUN
ajlm-2681	37	32	angle	angle	NOUN
ajlm-2681	37	33	.	.	PUNCT
ajlm-2681	38	1	methods	method	NOUN
ajlm-2681	38	2	ethical	ethical	ADJ
ajlm-2681	38	3	considerations	consideration	NOUN
ajlm-2681	38	4	ethical	ethical	ADJ
ajlm-2681	38	5	clearance	clearance	NOUN
ajlm-2681	38	6	was	be	AUX
ajlm-2681	38	7	obtained	obtain	VERB
ajlm-2681	38	8	from	from	ADP
ajlm-2681	38	9	the	the	DET
ajlm-2681	38	10	university	university	NOUN
ajlm-2681	38	11	of	of	ADP
ajlm-2681	38	12	the	the	DET
ajlm-2681	38	13	witwatersrand	witwatersrand	NOUN
ajlm-2681	38	14	human	human	PROPN
ajlm-2681	38	15	research	research	PROPN
ajlm-2681	38	16	ethics	ethic	NOUN
ajlm-2681	38	17	committee	committee	PROPN
ajlm-2681	38	18	(	(	PUNCT
ajlm-2681	38	19	reference	reference	NOUN
ajlm-2681	38	20	number	number	NOUN
ajlm-2681	38	21	:	:	PUNCT
ajlm-2681	38	22	m230570	m230570	NOUN
ajlm-2681	38	23	)	)	PUNCT
ajlm-2681	38	24	.	.	PUNCT
ajlm-2681	39	1	written	write	VERB
ajlm-2681	39	2	consent	consent	NOUN
ajlm-2681	39	3	was	be	AUX
ajlm-2681	39	4	obtained	obtain	VERB
ajlm-2681	39	5	from	from	ADP
ajlm-2681	39	6	each	each	DET
ajlm-2681	39	7	participant	participant	NOUN
ajlm-2681	39	8	when	when	SCONJ
ajlm-2681	39	9	collecting	collect	VERB
ajlm-2681	39	10	data	datum	NOUN
ajlm-2681	39	11	directly	directly	ADV
ajlm-2681	39	12	from	from	ADP
ajlm-2681	39	13	patients	patient	NOUN
ajlm-2681	39	14	and	and	CCONJ
ajlm-2681	39	15	adding	add	VERB
ajlm-2681	39	16	to	to	ADP
ajlm-2681	39	17	a	a	DET
ajlm-2681	39	18	database	database	NOUN
ajlm-2681	39	19	for	for	ADP
ajlm-2681	39	20	the	the	DET
ajlm-2681	39	21	study	study	NOUN
ajlm-2681	39	22	.	.	PUNCT
ajlm-2681	40	1	measures	measure	NOUN
ajlm-2681	40	2	taken	take	VERB
ajlm-2681	40	3	to	to	PART
ajlm-2681	40	4	ensure	ensure	VERB
ajlm-2681	40	5	confidentiality	confidentiality	NOUN
ajlm-2681	40	6	included	include	VERB
ajlm-2681	40	7	obtaining	obtain	VERB
ajlm-2681	40	8	informed	informed	ADJ
ajlm-2681	40	9	consent	consent	NOUN
ajlm-2681	40	10	,	,	PUNCT
ajlm-2681	40	11	anonymising	anonymising	ADJ
ajlm-2681	40	12	data	datum	NOUN
ajlm-2681	40	13	,	,	PUNCT
ajlm-2681	40	14	strict	strict	ADJ
ajlm-2681	40	15	access	access	NOUN
ajlm-2681	40	16	controls	control	NOUN
ajlm-2681	40	17	to	to	ADP
ajlm-2681	40	18	data	datum	NOUN
ajlm-2681	40	19	,	,	PUNCT
ajlm-2681	40	20	secure	secure	ADJ
ajlm-2681	40	21	storage	storage	NOUN
ajlm-2681	40	22	of	of	ADP
ajlm-2681	40	23	data	datum	NOUN
ajlm-2681	40	24	on	on	ADP
ajlm-2681	40	25	the	the	DET
ajlm-2681	40	26	redcap	redcap	NOUN
ajlm-2681	40	27	®	®	NOUN
ajlm-2681	40	28	electronic	electronic	ADJ
ajlm-2681	40	29	data	datum	NOUN
ajlm-2681	40	30	capture	capture	NOUN
ajlm-2681	40	31	system	system	NOUN
ajlm-2681	40	32	,	,	PUNCT
ajlm-2681	40	33	clear	clear	ADJ
ajlm-2681	40	34	confidentiality	confidentiality	NOUN
ajlm-2681	40	35	policies	policy	NOUN
ajlm-2681	40	36	for	for	ADP
ajlm-2681	40	37	all	all	DET
ajlm-2681	40	38	researchers	researcher	NOUN
ajlm-2681	40	39	involved	involve	VERB
ajlm-2681	40	40	and	and	CCONJ
ajlm-2681	40	41	the	the	DET
ajlm-2681	40	42	signing	signing	NOUN
ajlm-2681	40	43	of	of	ADP
ajlm-2681	40	44	a	a	DET
ajlm-2681	40	45	confidentiality	confidentiality	NOUN
ajlm-2681	40	46	agreement	agreement	NOUN
ajlm-2681	40	47	.	.	PUNCT
ajlm-2681	41	1	the	the	DET
ajlm-2681	41	2	necessary	necessary	ADJ
ajlm-2681	41	3	ethical	ethical	ADJ
ajlm-2681	41	4	clearance	clearance	NOUN
ajlm-2681	41	5	documentation	documentation	NOUN
ajlm-2681	41	6	has	have	AUX
ajlm-2681	41	7	been	be	AUX
ajlm-2681	41	8	provided	provide	VERB
ajlm-2681	41	9	.	.	PUNCT
ajlm-2681	42	1	setting	set	VERB
ajlm-2681	42	2	the	the	DET
ajlm-2681	42	3	study	study	NOUN
ajlm-2681	42	4	was	be	AUX
ajlm-2681	42	5	a	a	DET
ajlm-2681	42	6	retrospective	retrospective	ADJ
ajlm-2681	42	7	cross	cross	ADJ
ajlm-2681	42	8	-	-	ADJ
ajlm-2681	42	9	sectional	sectional	ADJ
ajlm-2681	42	10	observational	observational	ADJ
ajlm-2681	42	11	study	study	NOUN
ajlm-2681	42	12	at	at	ADP
ajlm-2681	42	13	chris	chris	PROPN
ajlm-2681	42	14	hani	hani	PROPN
ajlm-2681	42	15	baragwanath	baragwanath	PROPN
ajlm-2681	42	16	academic	academic	PROPN
ajlm-2681	42	17	hospital	hospital	NOUN
ajlm-2681	42	18	covid-19	covid-19	PROPN
ajlm-2681	42	19	and	and	CCONJ
ajlm-2681	42	20	intensive	intensive	ADJ
ajlm-2681	42	21	care	care	NOUN
ajlm-2681	42	22	unit	unit	NOUN
ajlm-2681	42	23	wards	ward	NOUN
ajlm-2681	42	24	,	,	PUNCT
ajlm-2681	42	25	between	between	ADP
ajlm-2681	42	26	november	november	PROPN
ajlm-2681	42	27	2020	2020	NUM
ajlm-2681	42	28	and	and	CCONJ
ajlm-2681	42	29	january	january	PROPN
ajlm-2681	42	30	2021	2021	NUM
ajlm-2681	42	31	.	.	PUNCT
ajlm-2681	43	1	chris	chris	PROPN
ajlm-2681	43	2	hani	hani	PROPN
ajlm-2681	43	3	baragwanath	baragwanath	PROPN
ajlm-2681	43	4	academic	academic	PROPN
ajlm-2681	43	5	hospital	hospital	NOUN
ajlm-2681	43	6	is	be	AUX
ajlm-2681	43	7	a	a	DET
ajlm-2681	43	8	tertiary	tertiary	ADJ
ajlm-2681	43	9	hospital	hospital	NOUN
ajlm-2681	43	10	located	locate	VERB
ajlm-2681	43	11	in	in	ADP
ajlm-2681	43	12	johannesburg	johannesburg	PROPN
ajlm-2681	43	13	,	,	PUNCT
ajlm-2681	43	14	gauteng	gauteng	PROPN
ajlm-2681	43	15	,	,	PUNCT
ajlm-2681	43	16	south	south	PROPN
ajlm-2681	43	17	africa	africa	PROPN
ajlm-2681	43	18	.	.	PUNCT
ajlm-2681	44	1	patient	patient	ADJ
ajlm-2681	44	2	inclusion	inclusion	NOUN
ajlm-2681	44	3	and	and	CCONJ
ajlm-2681	44	4	exclusion	exclusion	NOUN
ajlm-2681	44	5	criteria	criterion	NOUN
ajlm-2681	44	6	patients	patient	NOUN
ajlm-2681	44	7	included	include	VERB
ajlm-2681	44	8	in	in	ADP
ajlm-2681	44	9	the	the	DET
ajlm-2681	44	10	study	study	NOUN
ajlm-2681	44	11	had	have	VERB
ajlm-2681	44	12	reverse	reverse	ADJ
ajlm-2681	44	13	transcription	transcription	NOUN
ajlm-2681	44	14	polymerase	polymerase	NOUN
ajlm-2681	44	15	chain	chain	NOUN
ajlm-2681	44	16	reaction	reaction	NOUN
ajlm-2681	44	17	-	-	PUNCT
ajlm-2681	44	18	confirmed	confirm	VERB
ajlm-2681	44	19	sars	sar	NOUN
ajlm-2681	44	20	-	-	PUNCT
ajlm-2681	44	21	cov-2	cov-2	PART
ajlm-2681	44	22	infection	infection	NOUN
ajlm-2681	44	23	,	,	PUNCT
ajlm-2681	44	24	were	be	AUX
ajlm-2681	44	25	≥	≥	NOUN
ajlm-2681	44	26	18	18	NUM
ajlm-2681	44	27	years	year	NOUN
ajlm-2681	44	28	old	old	ADJ
ajlm-2681	44	29	,	,	PUNCT
ajlm-2681	44	30	and	and	CCONJ
ajlm-2681	44	31	had	have	VERB
ajlm-2681	44	32	severe	severe	ADJ
ajlm-2681	44	33	sars	sar	NOUN
ajlm-2681	44	34	-	-	PUNCT
ajlm-2681	44	35	cov-2	cov-2	PART
ajlm-2681	44	36	disease	disease	NOUN
ajlm-2681	44	37	.	.	PUNCT
ajlm-2681	45	1	severe	severe	ADJ
ajlm-2681	45	2	disease	disease	NOUN
ajlm-2681	45	3	was	be	AUX
ajlm-2681	45	4	defined	define	VERB
ajlm-2681	45	5	as	as	ADP
ajlm-2681	45	6	oxygen	oxygen	NOUN
ajlm-2681	45	7	saturation	saturation	NOUN
ajlm-2681	45	8	<	<	X
ajlm-2681	45	9	93	93	NUM
ajlm-2681	45	10	%	%	NOUN
ajlm-2681	45	11	with	with	ADP
ajlm-2681	45	12	a	a	DET
ajlm-2681	45	13	respiratory	respiratory	ADJ
ajlm-2681	45	14	rate	rate	NOUN
ajlm-2681	45	15	≥	≥	NOUN
ajlm-2681	45	16	25	25	NUM
ajlm-2681	45	17	breaths	breath	NOUN
ajlm-2681	45	18	per	per	ADP
ajlm-2681	45	19	min	min	NOUN
ajlm-2681	45	20	,	,	PUNCT
ajlm-2681	45	21	requiring	require	VERB
ajlm-2681	45	22	supplemental	supplemental	ADJ
ajlm-2681	45	23	oxygen	oxygen	NOUN
ajlm-2681	45	24	support	support	NOUN
ajlm-2681	45	25	without	without	ADP
ajlm-2681	45	26	the	the	DET
ajlm-2681	45	27	need	need	NOUN
ajlm-2681	45	28	for	for	ADP
ajlm-2681	45	29	invasive	invasive	ADJ
ajlm-2681	45	30	or	or	CCONJ
ajlm-2681	45	31	non	non	ADJ
ajlm-2681	45	32	-	-	ADJ
ajlm-2681	45	33	invasive	invasive	ADJ
ajlm-2681	45	34	ventilation	ventilation	NOUN
ajlm-2681	45	35	.	.	PUNCT
ajlm-2681	46	1	critical	critical	ADJ
ajlm-2681	46	2	illness	illness	NOUN
ajlm-2681	46	3	was	be	AUX
ajlm-2681	46	4	defined	define	VERB
ajlm-2681	46	5	as	as	ADP
ajlm-2681	46	6	hypoxaemia	hypoxaemia	NOUN
ajlm-2681	46	7	and	and	CCONJ
ajlm-2681	46	8	the	the	DET
ajlm-2681	46	9	need	need	NOUN
ajlm-2681	46	10	for	for	ADP
ajlm-2681	46	11	additional	additional	ADJ
ajlm-2681	46	12	ventilatory	ventilatory	ADJ
ajlm-2681	46	13	support	support	NOUN
ajlm-2681	46	14	,	,	PUNCT
ajlm-2681	46	15	in	in	ADP
ajlm-2681	46	16	the	the	DET
ajlm-2681	46	17	form	form	NOUN
ajlm-2681	46	18	of	of	ADP
ajlm-2681	46	19	non	non	ADJ
ajlm-2681	46	20	-	-	ADJ
ajlm-2681	46	21	invasive	invasive	ADJ
ajlm-2681	46	22	or	or	CCONJ
ajlm-2681	46	23	invasive	invasive	ADJ
ajlm-2681	46	24	ventilation	ventilation	NOUN
ajlm-2681	46	25	.	.	PUNCT
ajlm-2681	47	1	exclusion	exclusion	NOUN
ajlm-2681	47	2	criteria	criterion	NOUN
ajlm-2681	47	3	for	for	ADP
ajlm-2681	47	4	patients	patient	NOUN
ajlm-2681	47	5	were	be	AUX
ajlm-2681	47	6	:	:	PUNCT
ajlm-2681	47	7	a	a	DET
ajlm-2681	47	8	prolonged	prolonged	ADJ
ajlm-2681	47	9	activated	activate	VERB
ajlm-2681	47	10	partial	partial	ADJ
ajlm-2681	47	11	thromboplastin	thromboplastin	NOUN
ajlm-2681	47	12	time	time	NOUN
ajlm-2681	47	13	of	of	ADP
ajlm-2681	47	14	>	>	X
ajlm-2681	47	15	50	50	NUM
ajlm-2681	47	16	s	s	NOUN
ajlm-2681	47	17	;	;	PUNCT
ajlm-2681	47	18	patients	patient	NOUN
ajlm-2681	47	19	receiving	receive	VERB
ajlm-2681	47	20	chronic	chronic	ADJ
ajlm-2681	47	21	anticoagulation	anticoagulation	NOUN
ajlm-2681	47	22	therapy	therapy	NOUN
ajlm-2681	47	23	(	(	PUNCT
ajlm-2681	47	24	including	include	VERB
ajlm-2681	47	25	,	,	PUNCT
ajlm-2681	47	26	but	but	CCONJ
ajlm-2681	47	27	not	not	PART
ajlm-2681	47	28	limited	limit	VERB
ajlm-2681	47	29	to	to	ADP
ajlm-2681	47	30	,	,	PUNCT
ajlm-2681	47	31	aspirin	aspirin	NOUN
ajlm-2681	47	32	,	,	PUNCT
ajlm-2681	47	33	warfarin	warfarin	NOUN
ajlm-2681	47	34	,	,	PUNCT
ajlm-2681	47	35	clopidogrel	clopidogrel	NOUN
ajlm-2681	47	36	,	,	PUNCT
ajlm-2681	47	37	lmwh	lmwh	NOUN
ajlm-2681	47	38	such	such	ADJ
ajlm-2681	47	39	as	as	ADP
ajlm-2681	47	40	enoxaparin	enoxaparin	NOUN
ajlm-2681	47	41	and	and	CCONJ
ajlm-2681	47	42	direct	direct	ADJ
ajlm-2681	47	43	-	-	PUNCT
ajlm-2681	47	44	acting	act	VERB
ajlm-2681	47	45	oral	oral	ADJ
ajlm-2681	47	46	anticoagulants	anticoagulant	NOUN
ajlm-2681	47	47	such	such	ADJ
ajlm-2681	47	48	as	as	ADP
ajlm-2681	47	49	rivaroxiban	rivaroxiban	NOUN
ajlm-2681	47	50	)	)	PUNCT
ajlm-2681	47	51	;	;	PUNCT
ajlm-2681	48	1	patients	patient	NOUN
ajlm-2681	48	2	with	with	ADP
ajlm-2681	48	3	prior	prior	ADJ
ajlm-2681	48	4	vte	vte	NOUN
ajlm-2681	48	5	,	,	PUNCT
ajlm-2681	48	6	currently	currently	ADV
ajlm-2681	48	7	receiving	receive	VERB
ajlm-2681	48	8	quinine	quinine	NOUN
ajlm-2681	48	9	or	or	CCONJ
ajlm-2681	48	10	a	a	DET
ajlm-2681	48	11	derivative	derivative	NOUN
ajlm-2681	48	12	thereof	thereof	ADV
ajlm-2681	48	13	;	;	PUNCT
ajlm-2681	48	14	known	know	VERB
ajlm-2681	48	15	thrombotic	thrombotic	ADJ
ajlm-2681	48	16	thrombocytopenia	thrombocytopenia	PROPN
ajlm-2681	48	17	purpura	purpura	NOUN
ajlm-2681	48	18	or	or	CCONJ
ajlm-2681	48	19	thrombotic	thrombotic	ADJ
ajlm-2681	48	20	thrombocytopenia	thrombocytopenia	PROPN
ajlm-2681	48	21	purpura	purpura	NOUN
ajlm-2681	48	22	-	-	PUNCT
ajlm-2681	48	23	like	like	ADJ
ajlm-2681	48	24	disease	disease	NOUN
ajlm-2681	48	25	;	;	PUNCT
ajlm-2681	48	26	known	known	ADJ
ajlm-2681	48	27	haemoglobinopathies	haemoglobinopathy	NOUN
ajlm-2681	48	28	;	;	PUNCT
ajlm-2681	48	29	pregnancy	pregnancy	NOUN
ajlm-2681	48	30	;	;	PUNCT
ajlm-2681	48	31	oestrogen	oestrogen	NOUN
ajlm-2681	48	32	replacement	replacement	NOUN
ajlm-2681	48	33	therapy	therapy	NOUN
ajlm-2681	48	34	;	;	PUNCT
ajlm-2681	48	35	and	and	CCONJ
ajlm-2681	48	36	patients	patient	NOUN
ajlm-2681	48	37	not	not	PART
ajlm-2681	48	38	receiving	receive	VERB
ajlm-2681	48	39	anticoagulation	anticoagulation	NOUN
ajlm-2681	48	40	acutely	acutely	ADV
ajlm-2681	48	41	or	or	CCONJ
ajlm-2681	48	42	having	have	VERB
ajlm-2681	48	43	any	any	DET
ajlm-2681	48	44	contraindication	contraindication	NOUN
ajlm-2681	48	45	to	to	ADP
ajlm-2681	48	46	anticoagulation	anticoagulation	NOUN
ajlm-2681	48	47	.	.	PUNCT
ajlm-2681	49	1	sample	sample	NOUN
ajlm-2681	49	2	size	size	NOUN
ajlm-2681	49	3	to	to	PART
ajlm-2681	49	4	achieve	achieve	VERB
ajlm-2681	49	5	a	a	DET
ajlm-2681	49	6	correlation	correlation	NOUN
ajlm-2681	49	7	coefficient	coefficient	NOUN
ajlm-2681	49	8	of	of	ADP
ajlm-2681	49	9	0.5	0.5	NUM
ajlm-2681	49	10	with	with	ADP
ajlm-2681	49	11	80	80	NUM
ajlm-2681	49	12	%	%	NOUN
ajlm-2681	49	13	confidence	confidence	NOUN
ajlm-2681	49	14	and	and	CCONJ
ajlm-2681	49	15	precision	precision	NOUN
ajlm-2681	49	16	of	of	ADP
ajlm-2681	49	17	approximately	approximately	ADV
ajlm-2681	49	18	10	10	NUM
ajlm-2681	49	19	%	%	NOUN
ajlm-2681	49	20	between	between	ADP
ajlm-2681	49	21	thromboelastograms	thromboelastogram	NOUN
ajlm-2681	49	22	and	and	CCONJ
ajlm-2681	49	23	anti	anti	ADJ
ajlm-2681	49	24	-	-	ADJ
ajlm-2681	49	25	xa	xa	PROPN
ajlm-2681	49	26	levels	level	NOUN
ajlm-2681	49	27	,	,	PUNCT
ajlm-2681	49	28	as	as	SCONJ
ajlm-2681	49	29	shown	show	VERB
ajlm-2681	49	30	previously	previously	ADV
ajlm-2681	49	31	by	by	ADP
ajlm-2681	49	32	tekkesin	tekkesin	NOUN
ajlm-2681	49	33	et	et	PROPN
ajlm-2681	49	34	al	al	PROPN
ajlm-2681	49	35	.	.	PROPN
ajlm-2681	49	36	,18	,18	PUNCT
ajlm-2681	50	1	a	a	DET
ajlm-2681	50	2	sample	sample	NOUN
ajlm-2681	50	3	size	size	NOUN
ajlm-2681	50	4	of	of	ADP
ajlm-2681	50	5	40	40	NUM
ajlm-2681	50	6	was	be	AUX
ajlm-2681	50	7	required	require	VERB
ajlm-2681	50	8	.	.	PUNCT
ajlm-2681	51	1	we	we	PRON
ajlm-2681	51	2	collected	collect	VERB
ajlm-2681	51	3	an	an	DET
ajlm-2681	51	4	additional	additional	ADJ
ajlm-2681	51	5	5	5	NUM
ajlm-2681	51	6	%	%	NOUN
ajlm-2681	51	7	(	(	PUNCT
ajlm-2681	51	8	2	2	NUM
ajlm-2681	51	9	samples	sample	NOUN
ajlm-2681	51	10	)	)	PUNCT
ajlm-2681	51	11	to	to	PART
ajlm-2681	51	12	allow	allow	VERB
ajlm-2681	51	13	for	for	ADP
ajlm-2681	51	14	test	test	NOUN
ajlm-2681	51	15	failures	failure	NOUN
ajlm-2681	51	16	,	,	PUNCT
ajlm-2681	51	17	thereby	thereby	ADV
ajlm-2681	51	18	arriving	arrive	VERB
ajlm-2681	51	19	at	at	ADP
ajlm-2681	51	20	42	42	NUM
ajlm-2681	51	21	samples	sample	NOUN
ajlm-2681	51	22	in	in	ADP
ajlm-2681	51	23	total	total	NOUN
ajlm-2681	51	24	.	.	PUNCT
ajlm-2681	52	1	data	datum	NOUN
ajlm-2681	52	2	collection	collection	NOUN
ajlm-2681	52	3	data	datum	NOUN
ajlm-2681	52	4	collection	collection	NOUN
ajlm-2681	52	5	was	be	AUX
ajlm-2681	52	6	carried	carry	VERB
ajlm-2681	52	7	out	out	ADP
ajlm-2681	52	8	by	by	ADP
ajlm-2681	52	9	the	the	DET
ajlm-2681	52	10	primary	primary	ADJ
ajlm-2681	52	11	investigator	investigator	NOUN
ajlm-2681	52	12	and	and	CCONJ
ajlm-2681	52	13	supervisors	supervisor	NOUN
ajlm-2681	52	14	.	.	PUNCT
ajlm-2681	53	1	a	a	DET
ajlm-2681	53	2	database	database	NOUN
ajlm-2681	53	3	was	be	AUX
ajlm-2681	53	4	created	create	VERB
ajlm-2681	53	5	as	as	ADP
ajlm-2681	53	6	part	part	NOUN
ajlm-2681	53	7	of	of	ADP
ajlm-2681	53	8	a	a	DET
ajlm-2681	53	9	phd	phd	NOUN
ajlm-2681	53	10	for	for	ADP
ajlm-2681	53	11	one	one	NUM
ajlm-2681	53	12	of	of	ADP
ajlm-2681	53	13	the	the	DET
ajlm-2681	53	14	supervisors	supervisor	NOUN
ajlm-2681	53	15	,	,	PUNCT
ajlm-2681	53	16	with	with	ADP
ajlm-2681	53	17	data	datum	NOUN
ajlm-2681	53	18	being	be	AUX
ajlm-2681	53	19	collected	collect	VERB
ajlm-2681	53	20	from	from	ADP
ajlm-2681	53	21	01	01	NUM
ajlm-2681	53	22	november	november	PROPN
ajlm-2681	53	23	2020	2020	NUM
ajlm-2681	53	24	to	to	ADP
ajlm-2681	53	25	31	31	NUM
ajlm-2681	53	26	january	january	PROPN
ajlm-2681	53	27	2021	2021	NUM
ajlm-2681	53	28	.	.	PUNCT
ajlm-2681	54	1	the	the	DET
ajlm-2681	54	2	data	datum	NOUN
ajlm-2681	54	3	were	be	AUX
ajlm-2681	54	4	collected	collect	VERB
ajlm-2681	54	5	by	by	ADP
ajlm-2681	54	6	both	both	CCONJ
ajlm-2681	54	7	the	the	DET
ajlm-2681	54	8	primary	primary	ADJ
ajlm-2681	54	9	investigator	investigator	NOUN
ajlm-2681	54	10	and	and	CCONJ
ajlm-2681	54	11	the	the	DET
ajlm-2681	54	12	supervisors	supervisor	NOUN
ajlm-2681	54	13	during	during	ADP
ajlm-2681	54	14	this	this	DET
ajlm-2681	54	15	period	period	NOUN
ajlm-2681	54	16	and	and	CCONJ
ajlm-2681	54	17	entered	enter	VERB
ajlm-2681	54	18	directly	directly	ADV
ajlm-2681	54	19	into	into	ADP
ajlm-2681	54	20	the	the	DET
ajlm-2681	54	21	redcap	redcap	NOUN
ajlm-2681	54	22	®	®	NOUN
ajlm-2681	54	23	electronic	electronic	ADJ
ajlm-2681	54	24	data	datum	NOUN
ajlm-2681	54	25	capture	capture	VERB
ajlm-2681	54	26	tool.19	tool.19	ADP
ajlm-2681	54	27	the	the	DET
ajlm-2681	54	28	data	datum	NOUN
ajlm-2681	54	29	were	be	AUX
ajlm-2681	54	30	then	then	ADV
ajlm-2681	54	31	exported	export	VERB
ajlm-2681	54	32	into	into	ADP
ajlm-2681	54	33	statistica	statistica	PROPN
ajlm-2681	54	34	®	®	NOUN
ajlm-2681	54	35	version	version	NOUN
ajlm-2681	54	36	13.3	13.3	NUM
ajlm-2681	54	37	(	(	PUNCT
ajlm-2681	54	38	tibco	tibco	PROPN
ajlm-2681	54	39	software	software	PROPN
ajlm-2681	54	40	inc	inc	PROPN
ajlm-2681	54	41	.	.	PROPN
ajlm-2681	54	42	,	,	PUNCT
ajlm-2681	54	43	santa	santa	PROPN
ajlm-2681	54	44	clara	clara	PROPN
ajlm-2681	54	45	,	,	PUNCT
ajlm-2681	54	46	california	california	PROPN
ajlm-2681	54	47	,	,	PUNCT
ajlm-2681	54	48	united	united	PROPN
ajlm-2681	54	49	states	states	PROPN
ajlm-2681	54	50	)	)	PUNCT
ajlm-2681	54	51	for	for	ADP
ajlm-2681	54	52	data	data	NOUN
ajlm-2681	54	53	interpretation	interpretation	NOUN
ajlm-2681	54	54	.	.	PUNCT
ajlm-2681	55	1	data	datum	NOUN
ajlm-2681	55	2	extraction	extraction	NOUN
ajlm-2681	55	3	from	from	ADP
ajlm-2681	55	4	this	this	DET
ajlm-2681	55	5	database	database	NOUN
ajlm-2681	55	6	was	be	AUX
ajlm-2681	55	7	conducted	conduct	VERB
ajlm-2681	55	8	from	from	ADP
ajlm-2681	55	9	01	01	NUM
ajlm-2681	55	10	march	march	NOUN
ajlm-2681	55	11	2021	2021	NUM
ajlm-2681	55	12	to	to	ADP
ajlm-2681	55	13	31	31	NUM
ajlm-2681	55	14	may	may	PROPN
ajlm-2681	55	15	2021	2021	NUM
ajlm-2681	55	16	.	.	PUNCT
ajlm-2681	56	1	sociodemographic	sociodemographic	ADJ
ajlm-2681	56	2	data	datum	NOUN
ajlm-2681	56	3	were	be	AUX
ajlm-2681	56	4	collected	collect	VERB
ajlm-2681	56	5	directly	directly	ADV
ajlm-2681	56	6	from	from	ADP
ajlm-2681	56	7	patients	patient	NOUN
ajlm-2681	56	8	,	,	PUNCT
ajlm-2681	56	9	including	include	VERB
ajlm-2681	56	10	age	age	NOUN
ajlm-2681	56	11	,	,	PUNCT
ajlm-2681	56	12	gender	gender	NOUN
ajlm-2681	56	13	and	and	CCONJ
ajlm-2681	56	14	ethnicity	ethnicity	NOUN
ajlm-2681	56	15	.	.	PUNCT
ajlm-2681	57	1	whole	whole	ADJ
ajlm-2681	57	2	venous	venous	ADJ
ajlm-2681	57	3	blood	blood	NOUN
ajlm-2681	57	4	samples	sample	NOUN
ajlm-2681	57	5	were	be	AUX
ajlm-2681	57	6	drawn	draw	VERB
ajlm-2681	57	7	directly	directly	ADV
ajlm-2681	57	8	from	from	ADP
ajlm-2681	57	9	patients	patient	NOUN
ajlm-2681	57	10	from	from	ADP
ajlm-2681	57	11	the	the	DET
ajlm-2681	57	12	antecubital	antecubital	ADJ
ajlm-2681	57	13	vein	vein	NOUN
ajlm-2681	57	14	using	use	VERB
ajlm-2681	57	15	a	a	DET
ajlm-2681	57	16	tourniquet	tourniquet	NOUN
ajlm-2681	57	17	and	and	CCONJ
ajlm-2681	57	18	syringe	syringe	NOUN
ajlm-2681	57	19	for	for	ADP
ajlm-2681	57	20	thromboelastogram	thromboelastogram	NOUN
ajlm-2681	57	21	,	,	PUNCT
ajlm-2681	57	22	d	d	NOUN
ajlm-2681	57	23	-	-	PUNCT
ajlm-2681	57	24	dimer	dimer	ADJ
ajlm-2681	57	25	,	,	PUNCT
ajlm-2681	57	26	and	and	CCONJ
ajlm-2681	57	27	anti	anti	PROPN
ajlm-2681	57	28	-	-	PROPN
ajlm-2681	57	29	xa	xa	PROPN
ajlm-2681	57	30	.	.	PUNCT
ajlm-2681	58	1	these	these	DET
ajlm-2681	58	2	blood	blood	NOUN
ajlm-2681	58	3	samples	sample	NOUN
ajlm-2681	58	4	were	be	AUX
ajlm-2681	58	5	drawn	draw	VERB
ajlm-2681	58	6	on	on	ADP
ajlm-2681	58	7	admission	admission	NOUN
ajlm-2681	58	8	(	(	PUNCT
ajlm-2681	58	9	prior	prior	ADV
ajlm-2681	58	10	to	to	ADP
ajlm-2681	58	11	enoxaparin	enoxaparin	PROPN
ajlm-2681	58	12	administration	administration	PROPN
ajlm-2681	58	13	)	)	PUNCT
ajlm-2681	58	14	,	,	PUNCT
ajlm-2681	58	15	48	48	NUM
ajlm-2681	58	16	h	h	NOUN
ajlm-2681	58	17	post	post	NOUN
ajlm-2681	58	18	admission	admission	NOUN
ajlm-2681	58	19	(	(	PUNCT
ajlm-2681	58	20	3	3	NUM
ajlm-2681	58	21	h	h	NOUN
ajlm-2681	58	22	after	after	ADP
ajlm-2681	58	23	enoxaparin	enoxaparin	PROPN
ajlm-2681	58	24	administration	administration	PROPN
ajlm-2681	58	25	)	)	PUNCT
ajlm-2681	58	26	;	;	PUNCT
ajlm-2681	58	27	and	and	CCONJ
ajlm-2681	58	28	at	at	ADP
ajlm-2681	58	29	clinical	clinical	ADJ
ajlm-2681	58	30	resolution	resolution	NOUN
ajlm-2681	58	31	(	(	PUNCT
ajlm-2681	58	32	defined	define	VERB
ajlm-2681	58	33	as	as	ADP
ajlm-2681	58	34	resolution	resolution	NOUN
ajlm-2681	58	35	of	of	ADP
ajlm-2681	58	36	hypoxia	hypoxia	NOUN
ajlm-2681	58	37	)	)	PUNCT
ajlm-2681	58	38	or	or	CCONJ
ajlm-2681	58	39	day	day	NOUN
ajlm-2681	58	40	10	10	NUM
ajlm-2681	58	41	of	of	ADP
ajlm-2681	58	42	illness	illness	NOUN
ajlm-2681	58	43	.	.	PUNCT
ajlm-2681	59	1	thromboelastograms	thromboelastogram	NOUN
ajlm-2681	59	2	were	be	AUX
ajlm-2681	59	3	processed	process	VERB
ajlm-2681	59	4	within	within	ADP
ajlm-2681	59	5	5	5	NUM
ajlm-2681	59	6	min	min	NOUN
ajlm-2681	59	7	of	of	ADP
ajlm-2681	59	8	whole	whole	ADJ
ajlm-2681	59	9	blood	blood	NOUN
ajlm-2681	59	10	being	be	AUX
ajlm-2681	59	11	taken	take	VERB
ajlm-2681	59	12	,	,	PUNCT
ajlm-2681	59	13	and	and	CCONJ
ajlm-2681	59	14	the	the	DET
ajlm-2681	59	15	corresponding	correspond	VERB
ajlm-2681	59	16	sample	sample	NOUN
ajlm-2681	59	17	was	be	AUX
ajlm-2681	59	18	taken	take	VERB
ajlm-2681	59	19	to	to	ADP
ajlm-2681	59	20	the	the	DET
ajlm-2681	59	21	laboratory	laboratory	NOUN
ajlm-2681	59	22	for	for	ADP
ajlm-2681	59	23	anti	anti	ADJ
ajlm-2681	59	24	-	-	ADJ
ajlm-2681	59	25	xa	xa	ADJ
ajlm-2681	59	26	testing	testing	NOUN
ajlm-2681	59	27	within	within	ADP
ajlm-2681	59	28	the	the	DET
ajlm-2681	59	29	specified	specified	ADJ
ajlm-2681	59	30	5	5	NUM
ajlm-2681	59	31	min	min	NOUN
ajlm-2681	59	32	as	as	ADP
ajlm-2681	59	33	per	per	ADP
ajlm-2681	59	34	manufacturer	manufacturer	NOUN
ajlm-2681	59	35	’s	’s	PART
ajlm-2681	59	36	instructions	instruction	NOUN
ajlm-2681	59	37	.	.	PUNCT
ajlm-2681	60	1	the	the	DET
ajlm-2681	60	2	teg	teg	PROPN
ajlm-2681	60	3	®	®	PROPN
ajlm-2681	60	4	6s	6s	NUM
ajlm-2681	60	5	machine	machine	NOUN
ajlm-2681	60	6	(	(	PUNCT
ajlm-2681	60	7	haemonetics	haemonetic	NOUN
ajlm-2681	60	8	®	®	PROPN
ajlm-2681	60	9	,	,	PUNCT
ajlm-2681	60	10	boston	boston	PROPN
ajlm-2681	60	11	,	,	PUNCT
ajlm-2681	60	12	massachusetts	massachusetts	PROPN
ajlm-2681	60	13	,	,	PUNCT
ajlm-2681	60	14	united	united	PROPN
ajlm-2681	60	15	states	states	PROPN
ajlm-2681	60	16	)	)	PUNCT
ajlm-2681	60	17	was	be	AUX
ajlm-2681	60	18	then	then	ADV
ajlm-2681	60	19	used	use	VERB
ajlm-2681	60	20	by	by	ADP
ajlm-2681	60	21	filling	fill	VERB
ajlm-2681	60	22	a	a	DET
ajlm-2681	60	23	droplet	droplet	NOUN
ajlm-2681	60	24	of	of	ADP
ajlm-2681	60	25	blood	blood	NOUN
ajlm-2681	60	26	and	and	CCONJ
ajlm-2681	60	27	a	a	DET
ajlm-2681	60	28	droplet	droplet	NOUN
ajlm-2681	60	29	of	of	ADP
ajlm-2681	60	30	reagent	reagent	NOUN
ajlm-2681	60	31	into	into	ADP
ajlm-2681	60	32	a	a	DET
ajlm-2681	60	33	cartridge	cartridge	NOUN
ajlm-2681	60	34	which	which	PRON
ajlm-2681	60	35	is	be	AUX
ajlm-2681	60	36	then	then	ADV
ajlm-2681	60	37	processed	process	VERB
ajlm-2681	60	38	.	.	PUNCT
ajlm-2681	61	1	the	the	DET
ajlm-2681	61	2	result	result	NOUN
ajlm-2681	61	3	was	be	AUX
ajlm-2681	61	4	displayed	display	VERB
ajlm-2681	61	5	and	and	CCONJ
ajlm-2681	61	6	printed	print	VERB
ajlm-2681	61	7	revealing	reveal	VERB
ajlm-2681	61	8	an	an	DET
ajlm-2681	61	9	r	r	NOUN
ajlm-2681	61	10	-	-	PUNCT
ajlm-2681	61	11	time	time	NOUN
ajlm-2681	61	12	,	,	PUNCT
ajlm-2681	61	13	k	k	NOUN
ajlm-2681	61	14	-	-	NOUN
ajlm-2681	61	15	time	time	NOUN
ajlm-2681	61	16	,	,	PUNCT
ajlm-2681	61	17	alpha	alpha	NOUN
ajlm-2681	61	18	angle	angle	NOUN
ajlm-2681	61	19	,	,	PUNCT
ajlm-2681	61	20	ma	ma	PROPN
ajlm-2681	61	21	,	,	PUNCT
ajlm-2681	61	22	and	and	CCONJ
ajlm-2681	61	23	tci	tci	PROPN
ajlm-2681	61	24	.	.	PUNCT
ajlm-2681	62	1	only	only	ADV
ajlm-2681	62	2	results	result	NOUN
ajlm-2681	62	3	from	from	ADP
ajlm-2681	62	4	the	the	DET
ajlm-2681	62	5	standard	standard	ADJ
ajlm-2681	62	6	kaolin	kaolin	PROPN
ajlm-2681	62	7	thromboelastograms	thromboelastogram	NOUN
ajlm-2681	62	8	were	be	AUX
ajlm-2681	62	9	considered	consider	VERB
ajlm-2681	62	10	.	.	PUNCT
ajlm-2681	63	1	blood	blood	NOUN
ajlm-2681	63	2	samples	sample	NOUN
ajlm-2681	63	3	for	for	ADP
ajlm-2681	63	4	d	d	NOUN
ajlm-2681	63	5	-	-	PUNCT
ajlm-2681	63	6	dimer	dimer	NOUN
ajlm-2681	63	7	and	and	CCONJ
ajlm-2681	63	8	anti	anti	ADJ
ajlm-2681	63	9	-	-	ADJ
ajlm-2681	63	10	xa	xa	ADJ
ajlm-2681	63	11	tests	test	NOUN
ajlm-2681	63	12	were	be	AUX
ajlm-2681	63	13	stored	store	VERB
ajlm-2681	63	14	in	in	ADP
ajlm-2681	63	15	citrate	citrate	NOUN
ajlm-2681	63	16	tubes	tube	NOUN
ajlm-2681	63	17	(	(	PUNCT
ajlm-2681	63	18	becton	becton	PROPN
ajlm-2681	63	19	-	-	PUNCT
ajlm-2681	63	20	dickinson	dickinson	PROPN
ajlm-2681	63	21	,	,	PUNCT
ajlm-2681	63	22	oxford	oxford	PROPN
ajlm-2681	63	23	,	,	PUNCT
ajlm-2681	63	24	uk	uk	PROPN
ajlm-2681	63	25	)	)	PUNCT
ajlm-2681	63	26	.	.	PUNCT
ajlm-2681	64	1	d	d	X
ajlm-2681	64	2	-	-	PUNCT
ajlm-2681	64	3	dimer	dimer	ADJ
ajlm-2681	64	4	,	,	PUNCT
ajlm-2681	64	5	and	and	CCONJ
ajlm-2681	64	6	anti	anti	ADJ
ajlm-2681	64	7	-	-	ADJ
ajlm-2681	64	8	xa	xa	ADJ
ajlm-2681	64	9	tests	test	NOUN
ajlm-2681	64	10	were	be	AUX
ajlm-2681	64	11	done	do	VERB
ajlm-2681	64	12	by	by	ADP
ajlm-2681	64	13	the	the	DET
ajlm-2681	64	14	chris	chris	PROPN
ajlm-2681	64	15	hani	hani	PROPN
ajlm-2681	64	16	baragwanath	baragwanath	PROPN
ajlm-2681	64	17	academic	academic	PROPN
ajlm-2681	64	18	hospital	hospital	PROPN
ajlm-2681	64	19	national	national	PROPN
ajlm-2681	64	20	health	health	PROPN
ajlm-2681	64	21	laboratory	laboratory	PROPN
ajlm-2681	64	22	service	service	PROPN
ajlm-2681	64	23	haematology	haematology	PROPN
ajlm-2681	64	24	department	department	NOUN
ajlm-2681	64	25	,	,	PUNCT
ajlm-2681	64	26	accredited	accredit	VERB
ajlm-2681	64	27	by	by	ADP
ajlm-2681	64	28	the	the	DET
ajlm-2681	64	29	south	south	ADJ
ajlm-2681	64	30	african	african	ADJ
ajlm-2681	64	31	national	national	ADJ
ajlm-2681	64	32	accreditation	accreditation	NOUN
ajlm-2681	64	33	system	system	NOUN
ajlm-2681	64	34	(	(	PUNCT
ajlm-2681	64	35	sanas	sanas	PROPN
ajlm-2681	64	36	)	)	PUNCT
ajlm-2681	64	37	,	,	PUNCT
ajlm-2681	64	38	iso	iso	NOUN
ajlm-2681	64	39	15189	15189	NUM
ajlm-2681	64	40	.	.	PUNCT
ajlm-2681	65	1	d	d	X
ajlm-2681	65	2	-	-	PUNCT
ajlm-2681	65	3	dimers	dimer	NOUN
ajlm-2681	65	4	were	be	AUX
ajlm-2681	65	5	measured	measure	VERB
ajlm-2681	65	6	using	use	VERB
ajlm-2681	65	7	the	the	DET
ajlm-2681	65	8	d	d	NOUN
ajlm-2681	65	9	-	-	PUNCT
ajlm-2681	65	10	dimer	dimer	NOUN
ajlm-2681	65	11	plus	plus	CCONJ
ajlm-2681	65	12	assay	assay	PROPN
ajlm-2681	65	13	(	(	PUNCT
ajlm-2681	65	14	siemens	siemens	PROPN
ajlm-2681	65	15	healthcare	healthcare	NOUN
ajlm-2681	65	16	diagnostics	diagnostic	NOUN
ajlm-2681	65	17	products	product	NOUN
ajlm-2681	65	18	gmbh	gmbh	PROPN
ajlm-2681	65	19	,	,	PUNCT
ajlm-2681	65	20	marburg	marburg	PROPN
ajlm-2681	65	21	,	,	PUNCT
ajlm-2681	65	22	germany	germany	PROPN
ajlm-2681	65	23	)	)	PUNCT
ajlm-2681	65	24	.	.	PUNCT
ajlm-2681	66	1	the	the	DET
ajlm-2681	66	2	test	test	NOUN
ajlm-2681	66	3	requires	require	VERB
ajlm-2681	66	4	a	a	DET
ajlm-2681	66	5	latex	latex	NOUN
ajlm-2681	66	6	-	-	PUNCT
ajlm-2681	66	7	agglutination	agglutination	NOUN
ajlm-2681	66	8	test	test	NOUN
ajlm-2681	66	9	which	which	PRON
ajlm-2681	66	10	is	be	AUX
ajlm-2681	66	11	then	then	ADV
ajlm-2681	66	12	processed	process	VERB
ajlm-2681	66	13	using	use	VERB
ajlm-2681	66	14	an	an	DET
ajlm-2681	66	15	automated	automate	VERB
ajlm-2681	66	16	quantitative	quantitative	ADJ
ajlm-2681	66	17	turbidimetric	turbidimetric	ADJ
ajlm-2681	66	18	d	d	NOUN
ajlm-2681	66	19	-	-	PUNCT
ajlm-2681	66	20	dimer	dimer	NOUN
ajlm-2681	66	21	assay	assay	NOUN
ajlm-2681	66	22	.	.	PUNCT
ajlm-2681	67	1	anti	anti	ADJ
ajlm-2681	67	2	-	-	ADJ
ajlm-2681	67	3	xa	xa	PROPN
ajlm-2681	67	4	levels	level	NOUN
ajlm-2681	67	5	were	be	AUX
ajlm-2681	67	6	measured	measure	VERB
ajlm-2681	67	7	using	use	VERB
ajlm-2681	67	8	the	the	DET
ajlm-2681	67	9	sta	sta	PROPN
ajlm-2681	67	10	®	®	PROPN
ajlm-2681	67	11	-liquid	-liquid	ADJ
ajlm-2681	67	12	anti	anti	X
ajlm-2681	67	13	xa	xa	PROPN
ajlm-2681	67	14	assay	assay	PROPN
ajlm-2681	67	15	(	(	PUNCT
ajlm-2681	67	16	diagnostica	diagnostica	PROPN
ajlm-2681	67	17	stago	stago	PROPN
ajlm-2681	67	18	pty	pty	PROPN
ajlm-2681	67	19	ltd	ltd	PROPN
ajlm-2681	67	20	,	,	PUNCT
ajlm-2681	67	21	doncaster	doncaster	PROPN
ajlm-2681	67	22	,	,	PUNCT
ajlm-2681	67	23	australia	australia	PROPN
ajlm-2681	67	24	)	)	PUNCT
ajlm-2681	67	25	.	.	PUNCT
ajlm-2681	68	1	the	the	DET
ajlm-2681	68	2	recommended	recommend	VERB
ajlm-2681	68	3	target	target	NOUN
ajlm-2681	68	4	reference	reference	NOUN
ajlm-2681	68	5	ranges	range	VERB
ajlm-2681	68	6	for	for	SCONJ
ajlm-2681	68	7	adults	adult	NOUN
ajlm-2681	68	8	on	on	ADP
ajlm-2681	68	9	treatment	treatment	NOUN
ajlm-2681	68	10	is	be	AUX
ajlm-2681	68	11	0.6	0.6	NUM
ajlm-2681	68	12	iu	iu	ADP
ajlm-2681	68	13	/	/	SYM
ajlm-2681	68	14	ml	ml	PROPN
ajlm-2681	68	15	–	–	PUNCT
ajlm-2681	68	16	1.0	1.0	NUM
ajlm-2681	68	17	iu	iu	NOUN
ajlm-2681	68	18	/	/	SYM
ajlm-2681	68	19	ml	ml	NOUN
ajlm-2681	68	20	,	,	PUNCT
ajlm-2681	68	21	and	and	CCONJ
ajlm-2681	68	22	0.2	0.2	NUM
ajlm-2681	68	23	iu	iu	ADV
ajlm-2681	68	24	/	/	SYM
ajlm-2681	68	25	ml	ml	PROPN
ajlm-2681	68	26	–	–	PUNCT
ajlm-2681	68	27	0.6	0.6	NUM
ajlm-2681	68	28	iu	iu	ADP
ajlm-2681	68	29	/	/	SYM
ajlm-2681	68	30	ml	ml	X
ajlm-2681	68	31	for	for	ADP
ajlm-2681	68	32	prophylaxis	prophylaxis	NOUN
ajlm-2681	68	33	.	.	PUNCT
ajlm-2681	69	1	reaction	reaction	NOUN
ajlm-2681	69	2	time	time	NOUN
ajlm-2681	69	3	evaluates	evaluate	VERB
ajlm-2681	69	4	the	the	DET
ajlm-2681	69	5	time	time	NOUN
ajlm-2681	69	6	from	from	ADP
ajlm-2681	69	7	coagulation	coagulation	NOUN
ajlm-2681	69	8	cascade	cascade	NOUN
ajlm-2681	69	9	initiation	initiation	NOUN
ajlm-2681	69	10	to	to	PART
ajlm-2681	69	11	fibrin	fibrin	NOUN
ajlm-2681	69	12	generation	generation	NOUN
ajlm-2681	69	13	and	and	CCONJ
ajlm-2681	69	14	clot	clot	NOUN
ajlm-2681	69	15	propagation	propagation	NOUN
ajlm-2681	69	16	.	.	PUNCT
ajlm-2681	70	1	it	it	PRON
ajlm-2681	70	2	reflects	reflect	VERB
ajlm-2681	70	3	activity	activity	NOUN
ajlm-2681	70	4	of	of	ADP
ajlm-2681	70	5	the	the	DET
ajlm-2681	70	6	coagulation	coagulation	NOUN
ajlm-2681	70	7	cascade	cascade	NOUN
ajlm-2681	70	8	.	.	PUNCT
ajlm-2681	71	1	a	a	DET
ajlm-2681	71	2	shorter	short	ADJ
ajlm-2681	71	3	r	r	NOUN
ajlm-2681	71	4	-	-	PUNCT
ajlm-2681	71	5	time	time	NOUN
ajlm-2681	71	6	reflects	reflect	VERB
ajlm-2681	71	7	hypercoagulability	hypercoagulability	NOUN
ajlm-2681	71	8	.	.	PUNCT
ajlm-2681	72	1	it	it	PRON
ajlm-2681	72	2	is	be	AUX
ajlm-2681	72	3	calculated	calculate	VERB
ajlm-2681	72	4	from	from	ADP
ajlm-2681	72	5	the	the	DET
ajlm-2681	72	6	beginning	beginning	NOUN
ajlm-2681	72	7	of	of	ADP
ajlm-2681	72	8	the	the	DET
ajlm-2681	72	9	test	test	NOUN
ajlm-2681	72	10	to	to	ADP
ajlm-2681	72	11	the	the	DET
ajlm-2681	72	12	first	first	ADJ
ajlm-2681	72	13	detectable	detectable	ADJ
ajlm-2681	72	14	clot	clot	NOUN
ajlm-2681	72	15	formation	formation	NOUN
ajlm-2681	72	16	(	(	PUNCT
ajlm-2681	72	17	2	2	NUM
ajlm-2681	72	18	mm	mm	NOUN
ajlm-2681	72	19	)	)	PUNCT
ajlm-2681	72	20	.	.	PUNCT
ajlm-2681	73	1	the	the	DET
ajlm-2681	73	2	normal	normal	ADJ
ajlm-2681	73	3	reference	reference	NOUN
ajlm-2681	73	4	range	range	NOUN
ajlm-2681	73	5	is	be	AUX
ajlm-2681	73	6	5	5	NUM
ajlm-2681	73	7	min	min	NOUN
ajlm-2681	73	8	–	–	PUNCT
ajlm-2681	73	9	10	10	NUM
ajlm-2681	73	10	min.20	min.20	PROPN
ajlm-2681	73	11	kinetics	kinetic	NOUN
ajlm-2681	73	12	time	time	NOUN
ajlm-2681	73	13	determines	determine	VERB
ajlm-2681	73	14	the	the	DET
ajlm-2681	73	15	rate	rate	NOUN
ajlm-2681	73	16	at	at	ADP
ajlm-2681	73	17	which	which	PRON
ajlm-2681	73	18	a	a	DET
ajlm-2681	73	19	clot	clot	NOUN
ajlm-2681	73	20	is	be	AUX
ajlm-2681	73	21	formed	form	VERB
ajlm-2681	73	22	and	and	CCONJ
ajlm-2681	73	23	is	be	AUX
ajlm-2681	73	24	measured	measure	VERB
ajlm-2681	73	25	from	from	ADP
ajlm-2681	73	26	the	the	DET
ajlm-2681	73	27	beginning	beginning	NOUN
ajlm-2681	73	28	of	of	ADP
ajlm-2681	73	29	clotting	clot	VERB
ajlm-2681	73	30	to	to	ADP
ajlm-2681	73	31	the	the	DET
ajlm-2681	73	32	proper	proper	ADJ
ajlm-2681	73	33	formation	formation	NOUN
ajlm-2681	73	34	of	of	ADP
ajlm-2681	73	35	a	a	DET
ajlm-2681	73	36	clot	clot	NOUN
ajlm-2681	73	37	(	(	PUNCT
ajlm-2681	73	38	20	20	NUM
ajlm-2681	73	39	mm	mm	NOUN
ajlm-2681	73	40	)	)	PUNCT
ajlm-2681	73	41	.	.	PUNCT
ajlm-2681	74	1	it	it	PRON
ajlm-2681	74	2	measures	measure	VERB
ajlm-2681	74	3	fibrin	fibrin	NOUN
ajlm-2681	74	4	deposition	deposition	NOUN
ajlm-2681	74	5	and	and	CCONJ
ajlm-2681	74	6	cross	cross	NOUN
ajlm-2681	74	7	-	-	ADJ
ajlm-2681	74	8	linking	linking	ADJ
ajlm-2681	74	9	.	.	PUNCT
ajlm-2681	75	1	the	the	DET
ajlm-2681	75	2	normal	normal	ADJ
ajlm-2681	75	3	reference	reference	NOUN
ajlm-2681	75	4	range	range	NOUN
ajlm-2681	75	5	is	be	AUX
ajlm-2681	75	6	1	1	NUM
ajlm-2681	75	7	min	min	NOUN
ajlm-2681	75	8	–	–	PUNCT
ajlm-2681	75	9	2	2	NUM
ajlm-2681	75	10	min.20	min.20	NOUN
ajlm-2681	75	11	the	the	DET
ajlm-2681	75	12	alpha	alpha	NOUN
ajlm-2681	75	13	angle	angle	NOUN
ajlm-2681	75	14	determines	determine	VERB
ajlm-2681	75	15	the	the	DET
ajlm-2681	75	16	speed	speed	NOUN
ajlm-2681	75	17	of	of	ADP
ajlm-2681	75	18	clot	clot	NOUN
ajlm-2681	75	19	growth	growth	NOUN
ajlm-2681	75	20	and	and	CCONJ
ajlm-2681	75	21	strengthening	strengthening	NOUN
ajlm-2681	75	22	.	.	PUNCT
ajlm-2681	76	1	it	it	PRON
ajlm-2681	76	2	is	be	AUX
ajlm-2681	76	3	the	the	DET
ajlm-2681	76	4	angle	angle	NOUN
ajlm-2681	76	5	between	between	ADP
ajlm-2681	76	6	r	r	NOUN
ajlm-2681	76	7	-	-	PUNCT
ajlm-2681	76	8	time	time	NOUN
ajlm-2681	76	9	and	and	CCONJ
ajlm-2681	76	10	a	a	DET
ajlm-2681	76	11	line	line	NOUN
ajlm-2681	76	12	from	from	ADP
ajlm-2681	76	13	the	the	DET
ajlm-2681	76	14	time	time	NOUN
ajlm-2681	76	15	of	of	ADP
ajlm-2681	76	16	clotting	clot	VERB
ajlm-2681	76	17	initiation	initiation	NOUN
ajlm-2681	76	18	to	to	ADP
ajlm-2681	76	19	the	the	DET
ajlm-2681	76	20	point	point	NOUN
ajlm-2681	76	21	of	of	ADP
ajlm-2681	76	22	maximal	maximal	ADJ
ajlm-2681	76	23	clot	clot	NOUN
ajlm-2681	76	24	formation	formation	NOUN
ajlm-2681	76	25	speed	speed	NOUN
ajlm-2681	76	26	.	.	PUNCT
ajlm-2681	77	1	the	the	DET
ajlm-2681	77	2	normal	normal	ADJ
ajlm-2681	77	3	angle	angle	NOUN
ajlm-2681	77	4	is	be	AUX
ajlm-2681	77	5	53	53	NUM
ajlm-2681	77	6	°	°	NUM
ajlm-2681	77	7	–72	–72	NOUN
ajlm-2681	77	8	°	°	NOUN
ajlm-2681	77	9	.	.	PUNCT
ajlm-2681	78	1	when	when	SCONJ
ajlm-2681	78	2	decreased	decrease	VERB
ajlm-2681	78	3	,	,	PUNCT
ajlm-2681	78	4	it	it	PRON
ajlm-2681	78	5	suggests	suggest	VERB
ajlm-2681	78	6	a	a	DET
ajlm-2681	78	7	deficiency	deficiency	NOUN
ajlm-2681	78	8	in	in	ADP
ajlm-2681	78	9	fibrinogen.20,21	fibrinogen.20,21	NOUN
ajlm-2681	78	10	maximum	maximum	ADJ
ajlm-2681	78	11	amplitude	amplitude	NOUN
ajlm-2681	78	12	refers	refer	VERB
ajlm-2681	78	13	to	to	ADP
ajlm-2681	78	14	the	the	DET
ajlm-2681	78	15	maximal	maximal	ADJ
ajlm-2681	78	16	amplitude	amplitude	NOUN
ajlm-2681	78	17	of	of	ADP
ajlm-2681	78	18	the	the	DET
ajlm-2681	78	19	thromboelastograph	thromboelastograph	NOUN
ajlm-2681	78	20	curve	curve	NOUN
ajlm-2681	78	21	;	;	PUNCT
ajlm-2681	78	22	the	the	DET
ajlm-2681	78	23	normal	normal	ADJ
ajlm-2681	78	24	range	range	NOUN
ajlm-2681	78	25	is	be	AUX
ajlm-2681	78	26	50	50	NUM
ajlm-2681	78	27	mm	mm	NOUN
ajlm-2681	78	28	–	–	PUNCT
ajlm-2681	78	29	70	70	NUM
ajlm-2681	78	30	mm.20	mm.20	NOUN
ajlm-2681	78	31	lysis	lysis	NOUN
ajlm-2681	78	32	at	at	ADP
ajlm-2681	78	33	30	30	NUM
ajlm-2681	78	34	min	min	NOUN
ajlm-2681	78	35	depicts	depict	VERB
ajlm-2681	78	36	the	the	DET
ajlm-2681	78	37	speed	speed	NOUN
ajlm-2681	78	38	of	of	ADP
ajlm-2681	78	39	fibrinolysis	fibrinolysis	NOUN
ajlm-2681	78	40	and	and	CCONJ
ajlm-2681	78	41	shows	show	VERB
ajlm-2681	78	42	the	the	DET
ajlm-2681	78	43	percentage	percentage	NOUN
ajlm-2681	78	44	of	of	ADP
ajlm-2681	78	45	reduction	reduction	NOUN
ajlm-2681	78	46	30	30	NUM
ajlm-2681	78	47	min	min	NOUN
ajlm-2681	78	48	after	after	ADP
ajlm-2681	78	49	ma	ma	PROPN
ajlm-2681	78	50	.	.	PUNCT
ajlm-2681	79	1	the	the	DET
ajlm-2681	79	2	normal	normal	ADJ
ajlm-2681	79	3	range	range	NOUN
ajlm-2681	79	4	is	be	AUX
ajlm-2681	79	5	0	0	NUM
ajlm-2681	79	6	%	%	NOUN
ajlm-2681	79	7	–	–	PUNCT
ajlm-2681	79	8	8%.20	8%.20	NUM
ajlm-2681	79	9	the	the	DET
ajlm-2681	79	10	tci	tci	PROPN
ajlm-2681	79	11	assesses	assess	VERB
ajlm-2681	79	12	overall	overall	ADJ
ajlm-2681	79	13	coagulation	coagulation	NOUN
ajlm-2681	79	14	status	status	NOUN
ajlm-2681	79	15	,	,	PUNCT
ajlm-2681	79	16	and	and	CCONJ
ajlm-2681	79	17	the	the	DET
ajlm-2681	79	18	formula	formula	NOUN
ajlm-2681	79	19	(	(	PUNCT
ajlm-2681	79	20	equation	equation	NOUN
ajlm-2681	79	21	1	1	NUM
ajlm-2681	79	22	)	)	PUNCT
ajlm-2681	79	23	is	be	AUX
ajlm-2681	79	24	as	as	SCONJ
ajlm-2681	79	25	follows	follow	VERB
ajlm-2681	79	26	:	:	PUNCT
ajlm-2681	79	27	the	the	DET
ajlm-2681	79	28	normal	normal	ADJ
ajlm-2681	79	29	tci	tci	NOUN
ajlm-2681	79	30	range	range	NOUN
ajlm-2681	79	31	is	be	AUX
ajlm-2681	79	32	within	within	ADP
ajlm-2681	79	33	−3.0	−3.0	PROPN
ajlm-2681	79	34	and	and	CCONJ
ajlm-2681	79	35	+3.0	+3.0	NUM
ajlm-2681	79	36	(	(	PUNCT
ajlm-2681	79	37	3	3	NUM
ajlm-2681	79	38	standard	standard	ADJ
ajlm-2681	79	39	deviations	deviation	NOUN
ajlm-2681	79	40	from	from	ADP
ajlm-2681	79	41	the	the	DET
ajlm-2681	79	42	mean	mean	NOUN
ajlm-2681	79	43	of	of	ADP
ajlm-2681	79	44	zero	zero	NUM
ajlm-2681	79	45	)	)	PUNCT
ajlm-2681	79	46	.	.	PUNCT
ajlm-2681	80	1	hypercoagulability	hypercoagulability	NOUN
ajlm-2681	80	2	is	be	AUX
ajlm-2681	80	3	a	a	DET
ajlm-2681	80	4	tci	tci	NOUN
ajlm-2681	80	5	greater	great	ADJ
ajlm-2681	80	6	than	than	ADP
ajlm-2681	80	7	+3.0	+3.0	NUM
ajlm-2681	80	8	,	,	PUNCT
ajlm-2681	80	9	and	and	CCONJ
ajlm-2681	80	10	coagulopathy	coagulopathy	ADJ
ajlm-2681	80	11	is	be	AUX
ajlm-2681	80	12	a	a	DET
ajlm-2681	80	13	tci	tci	NOUN
ajlm-2681	80	14	less	less	ADJ
ajlm-2681	80	15	than	than	SCONJ
ajlm-2681	80	16	−3.0.20	−3.0.20	NOUN
ajlm-2681	80	17	statistical	statistical	ADJ
ajlm-2681	80	18	analysis	analysis	NOUN
ajlm-2681	80	19	data	datum	NOUN
ajlm-2681	80	20	were	be	AUX
ajlm-2681	80	21	collected	collect	VERB
ajlm-2681	80	22	and	and	CCONJ
ajlm-2681	80	23	managed	manage	VERB
ajlm-2681	80	24	using	use	VERB
ajlm-2681	80	25	redcap	redcap	ADJ
ajlm-2681	80	26	®	®	NOUN
ajlm-2681	80	27	19	19	NUM
ajlm-2681	80	28	electronic	electronic	ADJ
ajlm-2681	80	29	data	datum	NOUN
ajlm-2681	80	30	capture	capture	NOUN
ajlm-2681	80	31	tools	tool	NOUN
ajlm-2681	80	32	hosted	host	VERB
ajlm-2681	80	33	at	at	ADP
ajlm-2681	80	34	the	the	DET
ajlm-2681	80	35	university	university	NOUN
ajlm-2681	80	36	of	of	ADP
ajlm-2681	80	37	the	the	DET
ajlm-2681	80	38	witwatersrand	witwatersrand	NOUN
ajlm-2681	80	39	,	,	PUNCT
ajlm-2681	80	40	and	and	CCONJ
ajlm-2681	80	41	statistical	statistical	ADJ
ajlm-2681	80	42	analyses	analysis	NOUN
ajlm-2681	80	43	was	be	AUX
ajlm-2681	80	44	performed	perform	VERB
ajlm-2681	80	45	using	use	VERB
ajlm-2681	80	46	statsoft	statsoft	PROPN
ajlm-2681	80	47	,	,	PUNCT
ajlm-2681	80	48	inc	inc	PROPN
ajlm-2681	80	49	.	.	PROPN
ajlm-2681	80	50	data	datum	NOUN
ajlm-2681	80	51	analysis	analysis	NOUN
ajlm-2681	80	52	system	system	NOUN
ajlm-2681	80	53	,	,	PUNCT
ajlm-2681	80	54	statistica	statistica	PROPN
ajlm-2681	80	55	version	version	PROPN
ajlm-2681	80	56	13.3	13.3	NUM
ajlm-2681	80	57	(	(	PUNCT
ajlm-2681	80	58	www.statsoft.com	www.statsoft.com	NOUN
ajlm-2681	80	59	;	;	PUNCT
ajlm-2681	80	60	tibco	tibco	PROPN
ajlm-2681	80	61	software	software	PROPN
ajlm-2681	80	62	inc	inc	PROPN
ajlm-2681	80	63	.	.	PROPN
ajlm-2681	80	64	,	,	PUNCT
ajlm-2681	80	65	santa	santa	PROPN
ajlm-2681	80	66	clara	clara	PROPN
ajlm-2681	80	67	,	,	PUNCT
ajlm-2681	80	68	california	california	PROPN
ajlm-2681	80	69	,	,	PUNCT
ajlm-2681	80	70	united	united	PROPN
ajlm-2681	80	71	states).spearman	states).spearman	PROPN
ajlm-2681	80	72	’s	’s	PART
ajlm-2681	80	73	correlation	correlation	NOUN
ajlm-2681	80	74	was	be	AUX
ajlm-2681	80	75	used	use	VERB
ajlm-2681	80	76	to	to	PART
ajlm-2681	80	77	determine	determine	VERB
ajlm-2681	80	78	if	if	SCONJ
ajlm-2681	80	79	there	there	PRON
ajlm-2681	80	80	was	be	VERB
ajlm-2681	80	81	an	an	DET
ajlm-2681	80	82	association	association	NOUN
ajlm-2681	80	83	between	between	ADP
ajlm-2681	80	84	anticoagulation	anticoagulation	NOUN
ajlm-2681	80	85	test	test	NOUN
ajlm-2681	80	86	parameters	parameter	NOUN
ajlm-2681	80	87	.	.	PUNCT
ajlm-2681	81	1	student	student	NOUN
ajlm-2681	81	2	’s	’s	PART
ajlm-2681	81	3	t	t	PROPN
ajlm-2681	81	4	-	-	PUNCT
ajlm-2681	81	5	test	test	NOUN
ajlm-2681	81	6	and	and	CCONJ
ajlm-2681	81	7	mann	mann	PROPN
ajlm-2681	81	8	whitney	whitney	PROPN
ajlm-2681	81	9	u	u	PROPN
ajlm-2681	81	10	test	test	NOUN
ajlm-2681	81	11	were	be	AUX
ajlm-2681	81	12	used	use	VERB
ajlm-2681	81	13	to	to	PART
ajlm-2681	81	14	determine	determine	VERB
ajlm-2681	81	15	the	the	DET
ajlm-2681	81	16	relationship	relationship	NOUN
ajlm-2681	81	17	between	between	ADP
ajlm-2681	81	18	the	the	DET
ajlm-2681	81	19	dosing	dose	VERB
ajlm-2681	81	20	groups	group	NOUN
ajlm-2681	81	21	of	of	ADP
ajlm-2681	81	22	enoxaparin	enoxaparin	NOUN
ajlm-2681	81	23	and	and	CCONJ
ajlm-2681	81	24	coagulation	coagulation	NOUN
ajlm-2681	81	25	tests	test	NOUN
ajlm-2681	81	26	.	.	PUNCT
ajlm-2681	82	1	a	a	DET
ajlm-2681	82	2	multiple	multiple	ADJ
ajlm-2681	82	3	linear	linear	ADJ
ajlm-2681	82	4	regression	regression	NOUN
ajlm-2681	82	5	model	model	NOUN
ajlm-2681	82	6	was	be	AUX
ajlm-2681	82	7	performed	perform	VERB
ajlm-2681	82	8	(	(	PUNCT
ajlm-2681	82	9	online	online	ADJ
ajlm-2681	82	10	supplementary	supplementary	ADJ
ajlm-2681	82	11	table	table	NOUN
ajlm-2681	82	12	1	1	NUM
ajlm-2681	82	13	)	)	PUNCT
ajlm-2681	82	14	using	use	VERB
ajlm-2681	82	15	the	the	DET
ajlm-2681	82	16	thromboelastogram	thromboelastogram	NOUN
ajlm-2681	82	17	parameters	parameter	NOUN
ajlm-2681	82	18	(	(	PUNCT
ajlm-2681	82	19	r	r	NOUN
ajlm-2681	82	20	-	-	PUNCT
ajlm-2681	82	21	time	time	NOUN
ajlm-2681	82	22	,	,	PUNCT
ajlm-2681	82	23	k	k	NOUN
ajlm-2681	82	24	-	-	NOUN
ajlm-2681	82	25	time	time	NOUN
ajlm-2681	82	26	,	,	PUNCT
ajlm-2681	82	27	alpha	alpha	NOUN
ajlm-2681	82	28	angle	angle	NOUN
ajlm-2681	82	29	,	,	PUNCT
ajlm-2681	82	30	ma	ma	PROPN
ajlm-2681	82	31	and	and	CCONJ
ajlm-2681	82	32	a30	a30	NOUN
ajlm-2681	82	33	)	)	PUNCT
ajlm-2681	82	34	to	to	PART
ajlm-2681	82	35	predict	predict	VERB
ajlm-2681	82	36	anti	anti	ADJ
ajlm-2681	82	37	-	-	ADJ
ajlm-2681	82	38	xa	xa	ADJ
ajlm-2681	82	39	levels	level	NOUN
ajlm-2681	82	40	(	(	PUNCT
ajlm-2681	82	41	table	table	NOUN
ajlm-2681	82	42	1	1	NUM
ajlm-2681	82	43	)	)	PUNCT
ajlm-2681	82	44	.	.	PUNCT
ajlm-2681	83	1	only	only	ADV
ajlm-2681	83	2	r	r	NOUN
ajlm-2681	83	3	-	-	PUNCT
ajlm-2681	83	4	time	time	NOUN
ajlm-2681	83	5	,	,	PUNCT
ajlm-2681	83	6	k	k	NOUN
ajlm-2681	83	7	-	-	PUNCT
ajlm-2681	83	8	time	time	NOUN
ajlm-2681	83	9	and	and	CCONJ
ajlm-2681	83	10	a30	a30	NOUN
ajlm-2681	83	11	were	be	AUX
ajlm-2681	83	12	included	include	VERB
ajlm-2681	83	13	in	in	ADP
ajlm-2681	83	14	the	the	DET
ajlm-2681	83	15	final	final	ADJ
ajlm-2681	83	16	model	model	NOUN
ajlm-2681	83	17	,	,	PUNCT
ajlm-2681	83	18	as	as	SCONJ
ajlm-2681	83	19	p	p	NOUN
ajlm-2681	83	20	-	-	PUNCT
ajlm-2681	83	21	values	value	NOUN
ajlm-2681	83	22	were	be	AUX
ajlm-2681	83	23	≤	≤	NUM
ajlm-2681	83	24	0.2	0.2	NUM
ajlm-2681	83	25	(	(	PUNCT
ajlm-2681	83	26	a	a	DET
ajlm-2681	83	27	20	20	NUM
ajlm-2681	83	28	%	%	NOUN
ajlm-2681	83	29	probability	probability	NOUN
ajlm-2681	83	30	that	that	SCONJ
ajlm-2681	83	31	the	the	DET
ajlm-2681	83	32	correlation	correlation	NOUN
ajlm-2681	83	33	was	be	AUX
ajlm-2681	83	34	a	a	DET
ajlm-2681	83	35	result	result	NOUN
ajlm-2681	83	36	of	of	ADP
ajlm-2681	83	37	chance	chance	NOUN
ajlm-2681	83	38	was	be	AUX
ajlm-2681	83	39	considered	consider	VERB
ajlm-2681	83	40	acceptable	acceptable	ADJ
ajlm-2681	83	41	)	)	PUNCT
ajlm-2681	83	42	.	.	PUNCT
ajlm-2681	84	1	alpha	alpha	PROPN
ajlm-2681	84	2	angle	angle	NOUN
ajlm-2681	84	3	was	be	AUX
ajlm-2681	84	4	omitted	omit	VERB
ajlm-2681	84	5	,	,	PUNCT
ajlm-2681	84	6	as	as	SCONJ
ajlm-2681	84	7	this	this	PRON
ajlm-2681	84	8	is	be	AUX
ajlm-2681	84	9	dependent	dependent	ADJ
ajlm-2681	84	10	on	on	ADP
ajlm-2681	84	11	k	k	NOUN
ajlm-2681	84	12	-	-	NOUN
ajlm-2681	84	13	time	time	NOUN
ajlm-2681	84	14	.	.	PUNCT
ajlm-2681	85	1	only	only	ADV
ajlm-2681	85	2	r	r	NOUN
ajlm-2681	85	3	-	-	PUNCT
ajlm-2681	85	4	time	time	NOUN
ajlm-2681	85	5	was	be	AUX
ajlm-2681	85	6	significantly	significantly	ADV
ajlm-2681	85	7	associated	associate	VERB
ajlm-2681	85	8	with	with	ADP
ajlm-2681	85	9	anti	anti	ADJ
ajlm-2681	85	10	-	-	ADJ
ajlm-2681	85	11	xa	xa	ADJ
ajlm-2681	85	12	level	level	NOUN
ajlm-2681	85	13	,	,	PUNCT
ajlm-2681	85	14	with	with	ADP
ajlm-2681	85	15	a	a	DET
ajlm-2681	85	16	p	p	NOUN
ajlm-2681	85	17	-	-	PUNCT
ajlm-2681	85	18	value	value	NOUN
ajlm-2681	85	19	of	of	ADP
ajlm-2681	85	20	<	<	X
ajlm-2681	85	21	0.05	0.05	NUM
ajlm-2681	85	22	.	.	PUNCT
ajlm-2681	85	23	table	table	NOUN
ajlm-2681	85	24	1	1	NUM
ajlm-2681	85	25	:	:	PUNCT
ajlm-2681	85	26	 	 	SPACE
ajlm-2681	85	27	regression	regression	NOUN
ajlm-2681	85	28	summary	summary	NOUN
ajlm-2681	85	29	of	of	ADP
ajlm-2681	85	30	thromboelastogram	thromboelastogram	NOUN
ajlm-2681	85	31	results	result	NOUN
ajlm-2681	85	32	and	and	CCONJ
ajlm-2681	85	33	anti	anti	ADJ
ajlm-2681	85	34	-	-	ADJ
ajlm-2681	85	35	xa	xa	ADJ
ajlm-2681	85	36	levels	level	NOUN
ajlm-2681	85	37	of	of	ADP
ajlm-2681	85	38	patients	patient	NOUN
ajlm-2681	85	39	at	at	ADP
ajlm-2681	85	40	48	48	NUM
ajlm-2681	85	41	h	h	NOUN
ajlm-2681	85	42	post	post	NOUN
ajlm-2681	85	43	admission	admission	NOUN
ajlm-2681	85	44	(	(	PUNCT
ajlm-2681	85	45	n	n	NOUN
ajlm-2681	85	46	=	=	SYM
ajlm-2681	85	47	42	42	NUM
ajlm-2681	85	48	)	)	PUNCT
ajlm-2681	85	49	,	,	PUNCT
ajlm-2681	85	50	chris	chris	PROPN
ajlm-2681	85	51	hani	hani	PROPN
ajlm-2681	85	52	baragwanath	baragwanath	PROPN
ajlm-2681	85	53	hospital	hospital	PROPN
ajlm-2681	85	54	,	,	PUNCT
ajlm-2681	85	55	johannesburg	johannesburg	PROPN
ajlm-2681	85	56	,	,	PUNCT
ajlm-2681	85	57	gauteng	gauteng	PROPN
ajlm-2681	85	58	,	,	PUNCT
ajlm-2681	85	59	south	south	PROPN
ajlm-2681	85	60	africa	africa	PROPN
ajlm-2681	85	61	,	,	PUNCT
ajlm-2681	85	62	01	01	NUM
ajlm-2681	85	63	november	november	PROPN
ajlm-2681	85	64	2020	2020	NUM
ajlm-2681	85	65	to	to	ADP
ajlm-2681	85	66	31	31	NUM
ajlm-2681	85	67	january	january	PROPN
ajlm-2681	85	68	2021	2021	NUM
ajlm-2681	85	69	.	.	PUNCT
ajlm-2681	86	1	results	result	NOUN
ajlm-2681	86	2	baseline	baseline	VERB
ajlm-2681	86	3	characteristics	characteristic	NOUN
ajlm-2681	86	4	forty	forty	NUM
ajlm-2681	86	5	-	-	PUNCT
ajlm-2681	86	6	two	two	NUM
ajlm-2681	86	7	participants	participant	NOUN
ajlm-2681	86	8	were	be	AUX
ajlm-2681	86	9	enrolled	enrol	VERB
ajlm-2681	86	10	into	into	ADP
ajlm-2681	86	11	the	the	DET
ajlm-2681	86	12	study	study	NOUN
ajlm-2681	86	13	(	(	PUNCT
ajlm-2681	86	14	figure	figure	NOUN
ajlm-2681	86	15	1	1	NUM
ajlm-2681	86	16	)	)	PUNCT
ajlm-2681	86	17	.	.	PUNCT
ajlm-2681	87	1	a	a	DET
ajlm-2681	87	2	total	total	NOUN
ajlm-2681	87	3	of	of	ADP
ajlm-2681	87	4	22	22	NUM
ajlm-2681	87	5	patients	patient	NOUN
ajlm-2681	87	6	required	require	VERB
ajlm-2681	87	7	a	a	DET
ajlm-2681	87	8	prophylactic	prophylactic	ADJ
ajlm-2681	87	9	dose	dose	NOUN
ajlm-2681	87	10	(	(	PUNCT
ajlm-2681	87	11	≤	≤	NUM
ajlm-2681	87	12	40	40	NUM
ajlm-2681	87	13	mg	mg	NUM
ajlm-2681	87	14	/	/	SYM
ajlm-2681	87	15	day	day	NOUN
ajlm-2681	87	16	)	)	PUNCT
ajlm-2681	87	17	of	of	ADP
ajlm-2681	87	18	enoxaparin	enoxaparin	NOUN
ajlm-2681	87	19	(	(	PUNCT
ajlm-2681	87	20	52.38	52.38	NUM
ajlm-2681	87	21	%	%	NOUN
ajlm-2681	87	22	)	)	PUNCT
ajlm-2681	87	23	,	,	PUNCT
ajlm-2681	87	24	while	while	SCONJ
ajlm-2681	87	25	20	20	NUM
ajlm-2681	87	26	patients	patient	NOUN
ajlm-2681	87	27	were	be	AUX
ajlm-2681	87	28	treated	treat	VERB
ajlm-2681	87	29	with	with	ADP
ajlm-2681	87	30	a	a	DET
ajlm-2681	87	31	therapeutic	therapeutic	ADJ
ajlm-2681	87	32	dose	dose	NOUN
ajlm-2681	87	33	(	(	PUNCT
ajlm-2681	87	34	>	>	X
ajlm-2681	87	35	40	40	NUM
ajlm-2681	87	36	mg	mg	NUM
ajlm-2681	87	37	/	/	SYM
ajlm-2681	87	38	day	day	NOUN
ajlm-2681	87	39	)	)	PUNCT
ajlm-2681	87	40	of	of	ADP
ajlm-2681	87	41	enoxaparin	enoxaparin	NOUN
ajlm-2681	87	42	(	(	PUNCT
ajlm-2681	87	43	47.61	47.61	NUM
ajlm-2681	87	44	%	%	NOUN
ajlm-2681	87	45	)	)	PUNCT
ajlm-2681	87	46	(	(	PUNCT
ajlm-2681	87	47	table	table	NOUN
ajlm-2681	87	48	2	2	NUM
ajlm-2681	87	49	)	)	PUNCT
ajlm-2681	87	50	.	.	PUNCT
ajlm-2681	88	1	fifteen	fifteen	NUM
ajlm-2681	88	2	men	man	NOUN
ajlm-2681	88	3	and	and	CCONJ
ajlm-2681	88	4	27	27	NUM
ajlm-2681	88	5	women	woman	NOUN
ajlm-2681	88	6	,	,	PUNCT
ajlm-2681	88	7	with	with	ADP
ajlm-2681	88	8	ages	age	NOUN
ajlm-2681	88	9	ranging	range	VERB
ajlm-2681	88	10	from	from	ADP
ajlm-2681	88	11	33	33	NUM
ajlm-2681	88	12	years	year	NOUN
ajlm-2681	88	13	to	to	ADP
ajlm-2681	88	14	74	74	NUM
ajlm-2681	88	15	years	year	NOUN
ajlm-2681	88	16	,	,	PUNCT
ajlm-2681	88	17	met	meet	VERB
ajlm-2681	88	18	the	the	DET
ajlm-2681	88	19	entry	entry	NOUN
ajlm-2681	88	20	and	and	CCONJ
ajlm-2681	88	21	exit	exit	NOUN
ajlm-2681	88	22	criteria	criterion	NOUN
ajlm-2681	88	23	,	,	PUNCT
ajlm-2681	88	24	enrolling	enrol	VERB
ajlm-2681	88	25	them	they	PRON
ajlm-2681	88	26	into	into	ADP
ajlm-2681	88	27	the	the	DET
ajlm-2681	88	28	study	study	NOUN
ajlm-2681	88	29	.	.	PUNCT
ajlm-2681	89	1	patients	patient	NOUN
ajlm-2681	89	2	with	with	ADP
ajlm-2681	89	3	prior	prior	ADJ
ajlm-2681	89	4	vte	vte	NOUN
ajlm-2681	89	5	,	,	PUNCT
ajlm-2681	89	6	bleeding	bleed	VERB
ajlm-2681	89	7	disorders	disorder	NOUN
ajlm-2681	89	8	,	,	PUNCT
ajlm-2681	89	9	or	or	CCONJ
ajlm-2681	89	10	on	on	ADP
ajlm-2681	89	11	any	any	DET
ajlm-2681	89	12	anticoagulants	anticoagulant	NOUN
ajlm-2681	89	13	,	,	PUNCT
ajlm-2681	89	14	were	be	AUX
ajlm-2681	89	15	excluded	exclude	VERB
ajlm-2681	89	16	from	from	ADP
ajlm-2681	89	17	the	the	DET
ajlm-2681	89	18	study	study	NOUN
ajlm-2681	89	19	to	to	PART
ajlm-2681	89	20	ensure	ensure	VERB
ajlm-2681	89	21	a	a	DET
ajlm-2681	89	22	population	population	NOUN
ajlm-2681	89	23	which	which	PRON
ajlm-2681	89	24	would	would	AUX
ajlm-2681	89	25	not	not	PART
ajlm-2681	89	26	be	be	AUX
ajlm-2681	89	27	biased	bias	VERB
ajlm-2681	89	28	towards	towards	ADP
ajlm-2681	89	29	bleeding	bleeding	NOUN
ajlm-2681	89	30	or	or	CCONJ
ajlm-2681	89	31	thrombosis	thrombosis	NOUN
ajlm-2681	89	32	.	.	PUNCT
ajlm-2681	90	1	figure	figure	NOUN
ajlm-2681	90	2	1	1	NUM
ajlm-2681	90	3	:	:	PUNCT
ajlm-2681	90	4	study	study	NOUN
ajlm-2681	90	5	flow	flow	NOUN
ajlm-2681	90	6	diagram	diagram	NOUN
ajlm-2681	90	7	of	of	ADP
ajlm-2681	90	8	records	record	NOUN
ajlm-2681	90	9	reviewed	review	VERB
ajlm-2681	90	10	of	of	ADP
ajlm-2681	90	11	patients	patient	NOUN
ajlm-2681	90	12	enrolled	enrol	VERB
ajlm-2681	90	13	into	into	ADP
ajlm-2681	90	14	the	the	DET
ajlm-2681	90	15	study	study	NOUN
ajlm-2681	90	16	between	between	ADP
ajlm-2681	90	17	01	01	NUM
ajlm-2681	90	18	november	november	PROPN
ajlm-2681	90	19	2020	2020	NUM
ajlm-2681	90	20	and	and	CCONJ
ajlm-2681	90	21	31	31	NUM
ajlm-2681	90	22	january	january	NOUN
ajlm-2681	90	23	2021	2021	NUM
ajlm-2681	90	24	at	at	ADP
ajlm-2681	90	25	chris	chris	PROPN
ajlm-2681	90	26	hani	hani	PROPN
ajlm-2681	90	27	baragwanath	baragwanath	PROPN
ajlm-2681	90	28	hospital	hospital	PROPN
ajlm-2681	90	29	,	,	PUNCT
ajlm-2681	90	30	johannesburg	johannesburg	PROPN
ajlm-2681	90	31	,	,	PUNCT
ajlm-2681	90	32	gauteng	gauteng	PROPN
ajlm-2681	90	33	,	,	PUNCT
ajlm-2681	90	34	south	south	PROPN
ajlm-2681	90	35	africa	africa	PROPN
ajlm-2681	90	36	.	.	PUNCT
ajlm-2681	91	1	table	table	NOUN
ajlm-2681	91	2	2	2	NUM
ajlm-2681	91	3	:	:	PUNCT
ajlm-2681	91	4	 	 	SPACE
ajlm-2681	91	5	baseline	baseline	VERB
ajlm-2681	91	6	patient	patient	ADJ
ajlm-2681	91	7	characteristics	characteristic	NOUN
ajlm-2681	91	8	(	(	PUNCT
ajlm-2681	91	9	n	n	NOUN
ajlm-2681	91	10	=	=	NUM
ajlm-2681	91	11	42	42	NUM
ajlm-2681	91	12	)	)	PUNCT
ajlm-2681	91	13	.	.	PUNCT
ajlm-2681	92	1	anti	anti	PROPN
ajlm-2681	92	2	-	-	ADJ
ajlm-2681	92	3	xa	xa	PROPN
ajlm-2681	92	4	levels	level	NOUN
ajlm-2681	92	5	and	and	CCONJ
ajlm-2681	92	6	thromboelastogram	thromboelastogram	NOUN
ajlm-2681	92	7	coagulation	coagulation	NOUN
ajlm-2681	92	8	index	index	NOUN
ajlm-2681	92	9	there	there	PRON
ajlm-2681	92	10	was	be	VERB
ajlm-2681	92	11	a	a	DET
ajlm-2681	92	12	statistically	statistically	ADV
ajlm-2681	92	13	significant	significant	ADJ
ajlm-2681	92	14	low	low	ADJ
ajlm-2681	92	15	to	to	ADP
ajlm-2681	92	16	moderate	moderate	ADJ
ajlm-2681	92	17	correlation	correlation	NOUN
ajlm-2681	92	18	between	between	ADP
ajlm-2681	92	19	anti	anti	ADJ
ajlm-2681	92	20	-	-	ADJ
ajlm-2681	92	21	xa	xa	PROPN
ajlm-2681	92	22	levels	level	NOUN
ajlm-2681	92	23	and	and	CCONJ
ajlm-2681	92	24	tci	tci	PROPN
ajlm-2681	92	25	,	,	PUNCT
ajlm-2681	92	26	using	use	VERB
ajlm-2681	92	27	spearman	spearman	NOUN
ajlm-2681	92	28	’s	’s	PART
ajlm-2681	92	29	correlation	correlation	NOUN
ajlm-2681	92	30	=	=	NOUN
ajlm-2681	92	31	0.43	0.43	NUM
ajlm-2681	92	32	(	(	PUNCT
ajlm-2681	92	33	p	p	X
ajlm-2681	92	34	=	=	NOUN
ajlm-2681	92	35	0.014	0.014	NUM
ajlm-2681	92	36	)	)	PUNCT
ajlm-2681	92	37	among	among	ADP
ajlm-2681	92	38	patients	patient	NOUN
ajlm-2681	92	39	admitted	admit	VERB
ajlm-2681	92	40	for	for	ADP
ajlm-2681	92	41	suspected	suspect	VERB
ajlm-2681	92	42	covid-19	covid-19	PROPN
ajlm-2681	92	43	pneumonia	pneumonia	NOUN
ajlm-2681	92	44	(	(	PUNCT
ajlm-2681	92	45	figure	figure	NOUN
ajlm-2681	92	46	2	2	NUM
ajlm-2681	92	47	)	)	PUNCT
ajlm-2681	92	48	.	.	PUNCT
ajlm-2681	93	1	figure	figure	VERB
ajlm-2681	93	2	2	2	NUM
ajlm-2681	93	3	:	:	PUNCT
ajlm-2681	93	4	correlation	correlation	NOUN
ajlm-2681	93	5	between	between	ADP
ajlm-2681	93	6	anti	anti	ADJ
ajlm-2681	93	7	-	-	NOUN
ajlm-2681	93	8	factor	factor	ADJ
ajlm-2681	93	9	xa	xa	PROPN
ajlm-2681	93	10	and	and	CCONJ
ajlm-2681	93	11	thromboelastogram	thromboelastogram	NOUN
ajlm-2681	93	12	coagulation	coagulation	NOUN
ajlm-2681	93	13	index	index	NOUN
ajlm-2681	93	14	of	of	ADP
ajlm-2681	93	15	the	the	DET
ajlm-2681	93	16	42	42	NUM
ajlm-2681	93	17	patients	patient	NOUN
ajlm-2681	93	18	enrolled	enrol	VERB
ajlm-2681	93	19	between	between	ADP
ajlm-2681	93	20	01	01	NUM
ajlm-2681	93	21	november	november	PROPN
ajlm-2681	93	22	2020	2020	NUM
ajlm-2681	93	23	and	and	CCONJ
ajlm-2681	93	24	31	31	NUM
ajlm-2681	93	25	january	january	NOUN
ajlm-2681	93	26	2021	2021	NUM
ajlm-2681	93	27	at	at	ADP
ajlm-2681	93	28	chris	chris	PROPN
ajlm-2681	93	29	hani	hani	PROPN
ajlm-2681	93	30	baragwanath	baragwanath	PROPN
ajlm-2681	93	31	hospital	hospital	PROPN
ajlm-2681	93	32	,	,	PUNCT
ajlm-2681	93	33	johannesburg	johannesburg	PROPN
ajlm-2681	93	34	,	,	PUNCT
ajlm-2681	93	35	gauteng	gauteng	PROPN
ajlm-2681	93	36	,	,	PUNCT
ajlm-2681	93	37	south	south	PROPN
ajlm-2681	93	38	africa	africa	PROPN
ajlm-2681	93	39	.	.	PUNCT
ajlm-2681	94	1	anti	anti	PROPN
ajlm-2681	94	2	-	-	PROPN
ajlm-2681	94	3	xa	xa	ADP
ajlm-2681	94	4	and	and	CCONJ
ajlm-2681	94	5	thromboelastogram	thromboelastogram	NOUN
ajlm-2681	94	6	parameters	parameter	NOUN
ajlm-2681	94	7	there	there	PRON
ajlm-2681	94	8	was	be	VERB
ajlm-2681	94	9	a	a	DET
ajlm-2681	94	10	statistically	statistically	ADV
ajlm-2681	94	11	significant	significant	ADJ
ajlm-2681	94	12	moderate	moderate	ADJ
ajlm-2681	94	13	correlation	correlation	NOUN
ajlm-2681	94	14	between	between	ADP
ajlm-2681	94	15	anti	anti	ADJ
ajlm-2681	94	16	-	-	ADJ
ajlm-2681	94	17	xa	xa	ADJ
ajlm-2681	94	18	levels	level	NOUN
ajlm-2681	94	19	and	and	CCONJ
ajlm-2681	94	20	r	r	NOUN
ajlm-2681	94	21	-	-	PUNCT
ajlm-2681	94	22	time	time	NOUN
ajlm-2681	94	23	,	,	PUNCT
ajlm-2681	94	24	with	with	ADP
ajlm-2681	94	25	spearman	spearman	NOUN
ajlm-2681	94	26	’s	’s	PART
ajlm-2681	94	27	correlation	correlation	NOUN
ajlm-2681	94	28	=	=	NOUN
ajlm-2681	94	29	0.52	0.52	NUM
ajlm-2681	94	30	,	,	PUNCT
ajlm-2681	94	31	p	p	X
ajlm-2681	94	32	=	=	SYM
ajlm-2681	94	33	0.002	0.002	NUM
ajlm-2681	94	34	(	(	PUNCT
ajlm-2681	94	35	figure	figure	NOUN
ajlm-2681	94	36	3	3	NUM
ajlm-2681	94	37	)	)	PUNCT
ajlm-2681	94	38	.	.	PUNCT
ajlm-2681	95	1	figure	figure	VERB
ajlm-2681	95	2	3	3	NUM
ajlm-2681	95	3	:	:	PUNCT
ajlm-2681	95	4	correlation	correlation	NOUN
ajlm-2681	95	5	between	between	ADP
ajlm-2681	95	6	anti	anti	ADJ
ajlm-2681	95	7	-	-	NOUN
ajlm-2681	95	8	factor	factor	ADJ
ajlm-2681	95	9	xa	xa	PROPN
ajlm-2681	95	10	and	and	CCONJ
ajlm-2681	95	11	reaction	reaction	NOUN
ajlm-2681	95	12	time	time	NOUN
ajlm-2681	95	13	of	of	ADP
ajlm-2681	95	14	the	the	DET
ajlm-2681	95	15	42	42	NUM
ajlm-2681	95	16	patients	patient	NOUN
ajlm-2681	95	17	enrolled	enrol	VERB
ajlm-2681	95	18	between	between	ADP
ajlm-2681	95	19	01	01	NUM
ajlm-2681	95	20	november	november	PROPN
ajlm-2681	95	21	2020	2020	NUM
ajlm-2681	95	22	and	and	CCONJ
ajlm-2681	95	23	31	31	NUM
ajlm-2681	95	24	january	january	NOUN
ajlm-2681	95	25	2021	2021	NUM
ajlm-2681	95	26	at	at	ADP
ajlm-2681	95	27	chris	chris	PROPN
ajlm-2681	95	28	hani	hani	PROPN
ajlm-2681	95	29	baragwanath	baragwanath	PROPN
ajlm-2681	95	30	hospital	hospital	PROPN
ajlm-2681	95	31	,	,	PUNCT
ajlm-2681	95	32	johannesburg	johannesburg	PROPN
ajlm-2681	95	33	,	,	PUNCT
ajlm-2681	95	34	gauteng	gauteng	PROPN
ajlm-2681	95	35	,	,	PUNCT
ajlm-2681	95	36	south	south	PROPN
ajlm-2681	95	37	africa	africa	PROPN
ajlm-2681	95	38	.	.	PUNCT
ajlm-2681	96	1	there	there	PRON
ajlm-2681	96	2	was	be	VERB
ajlm-2681	96	3	a	a	DET
ajlm-2681	96	4	statistically	statistically	ADV
ajlm-2681	96	5	significant	significant	ADJ
ajlm-2681	96	6	low	low	ADJ
ajlm-2681	96	7	correlation	correlation	NOUN
ajlm-2681	96	8	between	between	ADP
ajlm-2681	96	9	anti	anti	ADJ
ajlm-2681	96	10	-	-	ADJ
ajlm-2681	96	11	xa	xa	PROPN
ajlm-2681	96	12	levels	level	NOUN
ajlm-2681	96	13	and	and	CCONJ
ajlm-2681	96	14	k	k	NOUN
ajlm-2681	96	15	-	-	NOUN
ajlm-2681	96	16	time	time	NOUN
ajlm-2681	96	17	.	.	PUNCT
ajlm-2681	97	1	with	with	ADP
ajlm-2681	97	2	spearman	spearman	NOUN
ajlm-2681	97	3	’s	’s	PART
ajlm-2681	97	4	correlation	correlation	NOUN
ajlm-2681	97	5	=	=	NOUN
ajlm-2681	97	6	0.35	0.35	NUM
ajlm-2681	97	7	,	,	PUNCT
ajlm-2681	97	8	p	p	X
ajlm-2681	97	9	=	=	NOUN
ajlm-2681	97	10	0.049	0.049	NUM
ajlm-2681	97	11	(	(	PUNCT
ajlm-2681	97	12	figure	figure	NOUN
ajlm-2681	97	13	4	4	NUM
ajlm-2681	97	14	)	)	PUNCT
ajlm-2681	97	15	.	.	PUNCT
ajlm-2681	98	1	figure	figure	VERB
ajlm-2681	98	2	4	4	NUM
ajlm-2681	98	3	:	:	PUNCT
ajlm-2681	98	4	correlation	correlation	NOUN
ajlm-2681	98	5	between	between	ADP
ajlm-2681	98	6	anti	anti	ADJ
ajlm-2681	98	7	-	-	NOUN
ajlm-2681	98	8	factor	factor	ADJ
ajlm-2681	98	9	xa	xa	PROPN
ajlm-2681	98	10	and	and	CCONJ
ajlm-2681	98	11	kinetics	kinetic	NOUN
ajlm-2681	98	12	time	time	NOUN
ajlm-2681	98	13	of	of	ADP
ajlm-2681	98	14	the	the	DET
ajlm-2681	98	15	42	42	NUM
ajlm-2681	98	16	patients	patient	NOUN
ajlm-2681	98	17	enrolled	enrol	VERB
ajlm-2681	98	18	between	between	ADP
ajlm-2681	98	19	01	01	NUM
ajlm-2681	98	20	november	november	PROPN
ajlm-2681	98	21	2020	2020	NUM
ajlm-2681	98	22	to	to	ADP
ajlm-2681	98	23	31	31	NUM
ajlm-2681	98	24	january	january	PROPN
ajlm-2681	98	25	2021	2021	NUM
ajlm-2681	98	26	at	at	ADP
ajlm-2681	98	27	chris	chris	PROPN
ajlm-2681	98	28	hani	hani	PROPN
ajlm-2681	98	29	baragwanath	baragwanath	PROPN
ajlm-2681	98	30	hospital	hospital	PROPN
ajlm-2681	98	31	,	,	PUNCT
ajlm-2681	98	32	johannesburg	johannesburg	PROPN
ajlm-2681	98	33	,	,	PUNCT
ajlm-2681	98	34	gauteng	gauteng	PROPN
ajlm-2681	98	35	,	,	PUNCT
ajlm-2681	98	36	south	south	PROPN
ajlm-2681	98	37	africa	africa	PROPN
ajlm-2681	98	38	.	.	PUNCT
ajlm-2681	99	1	although	although	SCONJ
ajlm-2681	99	2	the	the	DET
ajlm-2681	99	3	k	k	NOUN
ajlm-2681	99	4	-	-	PUNCT
ajlm-2681	99	5	time	time	NOUN
ajlm-2681	99	6	and	and	CCONJ
ajlm-2681	99	7	alpha	alpha	NOUN
ajlm-2681	99	8	angle	angle	NOUN
ajlm-2681	99	9	are	be	AUX
ajlm-2681	99	10	mathematically	mathematically	ADV
ajlm-2681	99	11	correlated	correlate	VERB
ajlm-2681	99	12	,	,	PUNCT
ajlm-2681	99	13	we	we	PRON
ajlm-2681	99	14	did	do	AUX
ajlm-2681	99	15	not	not	PART
ajlm-2681	99	16	find	find	VERB
ajlm-2681	99	17	a	a	DET
ajlm-2681	99	18	statistical	statistical	ADJ
ajlm-2681	99	19	correlation	correlation	NOUN
ajlm-2681	99	20	between	between	ADP
ajlm-2681	99	21	anti	anti	ADJ
ajlm-2681	99	22	-	-	ADJ
ajlm-2681	99	23	xa	xa	PROPN
ajlm-2681	99	24	levels	level	NOUN
ajlm-2681	99	25	and	and	CCONJ
ajlm-2681	99	26	alpha	alpha	NOUN
ajlm-2681	99	27	angle	angle	NOUN
ajlm-2681	99	28	.	.	PUNCT
ajlm-2681	100	1	there	there	PRON
ajlm-2681	100	2	were	be	VERB
ajlm-2681	100	3	also	also	ADV
ajlm-2681	100	4	no	no	DET
ajlm-2681	100	5	significant	significant	ADJ
ajlm-2681	100	6	correlations	correlation	NOUN
ajlm-2681	100	7	between	between	ADP
ajlm-2681	100	8	d	d	NOUN
ajlm-2681	100	9	-	-	PUNCT
ajlm-2681	100	10	dimer	dimer	NOUN
ajlm-2681	100	11	and	and	CCONJ
ajlm-2681	100	12	thromboelastogram	thromboelastogram	NOUN
ajlm-2681	100	13	parameters	parameter	NOUN
ajlm-2681	100	14	.	.	PUNCT
ajlm-2681	101	1	spearman	spearman	NOUN
ajlm-2681	101	2	rank	rank	PROPN
ajlm-2681	101	3	order	order	NOUN
ajlm-2681	101	4	correlations	correlation	NOUN
ajlm-2681	101	5	revealed	reveal	VERB
ajlm-2681	101	6	no	no	DET
ajlm-2681	101	7	marked	mark	VERB
ajlm-2681	101	8	correlations	correlation	NOUN
ajlm-2681	101	9	between	between	ADP
ajlm-2681	101	10	thromboelastogram	thromboelastogram	NOUN
ajlm-2681	101	11	and	and	CCONJ
ajlm-2681	101	12	d	d	NOUN
ajlm-2681	101	13	-	-	NOUN
ajlm-2681	101	14	dimers	dimer	NOUN
ajlm-2681	101	15	,	,	PUNCT
ajlm-2681	101	16	at	at	ADP
ajlm-2681	101	17	a	a	DET
ajlm-2681	101	18	significance	significance	NOUN
ajlm-2681	101	19	of	of	ADP
ajlm-2681	101	20	p	p	NOUN
ajlm-2681	101	21	<	<	X
ajlm-2681	101	22	0.05	0.05	NUM
ajlm-2681	101	23	.	.	PUNCT
ajlm-2681	101	24	enoxaparin	enoxaparin	PROPN
ajlm-2681	101	25	dose	dose	PROPN
ajlm-2681	101	26	,	,	PUNCT
ajlm-2681	101	27	thromboelastogram	thromboelastogram	NOUN
ajlm-2681	101	28	parameters	parameter	NOUN
ajlm-2681	101	29	,	,	PUNCT
ajlm-2681	101	30	and	and	CCONJ
ajlm-2681	101	31	anti	anti	ADJ
ajlm-2681	101	32	-	-	ADJ
ajlm-2681	101	33	xa	xa	PROPN
ajlm-2681	101	34	levels	level	NOUN
ajlm-2681	101	35	only	only	ADV
ajlm-2681	101	36	anti	anti	ADJ
ajlm-2681	101	37	-	-	ADJ
ajlm-2681	101	38	xa	xa	ADJ
ajlm-2681	101	39	levels	level	NOUN
ajlm-2681	101	40	were	be	AUX
ajlm-2681	101	41	significantly	significantly	ADV
ajlm-2681	101	42	associated	associate	VERB
ajlm-2681	101	43	with	with	ADP
ajlm-2681	101	44	the	the	DET
ajlm-2681	101	45	dose	dose	NOUN
ajlm-2681	101	46	of	of	ADP
ajlm-2681	101	47	enoxaparin	enoxaparin	NOUN
ajlm-2681	101	48	,	,	PUNCT
ajlm-2681	101	49	while	while	SCONJ
ajlm-2681	101	50	amongst	amongst	ADP
ajlm-2681	101	51	the	the	DET
ajlm-2681	101	52	thromboelastogram	thromboelastogram	NOUN
ajlm-2681	101	53	parameters	parameter	NOUN
ajlm-2681	101	54	,	,	PUNCT
ajlm-2681	101	55	lysis	lysis	NOUN
ajlm-2681	101	56	time	time	NOUN
ajlm-2681	101	57	at	at	ADP
ajlm-2681	101	58	30	30	NUM
ajlm-2681	101	59	min	min	NOUN
ajlm-2681	101	60	was	be	AUX
ajlm-2681	101	61	significantly	significantly	ADV
ajlm-2681	101	62	associated	associate	VERB
ajlm-2681	101	63	with	with	ADP
ajlm-2681	101	64	the	the	DET
ajlm-2681	101	65	dose	dose	NOUN
ajlm-2681	101	66	of	of	ADP
ajlm-2681	101	67	enoxaparin	enoxaparin	NOUN
ajlm-2681	101	68	(	(	PUNCT
ajlm-2681	101	69	online	online	PROPN
ajlm-2681	101	70	supplementary	supplementary	ADJ
ajlm-2681	101	71	table	table	NOUN
ajlm-2681	101	72	2	2	NUM
ajlm-2681	101	73	)	)	PUNCT
ajlm-2681	101	74	.	.	PUNCT
ajlm-2681	102	1	discussion	discussion	NOUN
ajlm-2681	102	2	the	the	DET
ajlm-2681	102	3	main	main	ADJ
ajlm-2681	102	4	finding	finding	NOUN
ajlm-2681	102	5	of	of	ADP
ajlm-2681	102	6	our	our	PRON
ajlm-2681	102	7	study	study	NOUN
ajlm-2681	102	8	demonstrated	demonstrate	VERB
ajlm-2681	102	9	an	an	DET
ajlm-2681	102	10	association	association	NOUN
ajlm-2681	102	11	between	between	ADP
ajlm-2681	102	12	thromboelastogram	thromboelastogram	NOUN
ajlm-2681	102	13	parameters	parameter	NOUN
ajlm-2681	102	14	and	and	CCONJ
ajlm-2681	102	15	anti	anti	PROPN
ajlm-2681	102	16	-	-	ADJ
ajlm-2681	102	17	xa	xa	PROPN
ajlm-2681	102	18	levels	level	NOUN
ajlm-2681	102	19	48	48	NUM
ajlm-2681	102	20	h	h	NOUN
ajlm-2681	102	21	after	after	ADP
ajlm-2681	102	22	admission	admission	NOUN
ajlm-2681	102	23	and	and	CCONJ
ajlm-2681	102	24	anticoagulation	anticoagulation	NOUN
ajlm-2681	102	25	with	with	ADP
ajlm-2681	102	26	enoxaparin	enoxaparin	NOUN
ajlm-2681	102	27	.	.	PUNCT
ajlm-2681	103	1	using	use	VERB
ajlm-2681	103	2	tci	tci	PROPN
ajlm-2681	103	3	,	,	PUNCT
ajlm-2681	103	4	we	we	PRON
ajlm-2681	103	5	found	find	VERB
ajlm-2681	103	6	that	that	SCONJ
ajlm-2681	103	7	higher	high	ADJ
ajlm-2681	103	8	anti	anti	ADJ
ajlm-2681	103	9	-	-	ADJ
ajlm-2681	103	10	xa	xa	PROPN
ajlm-2681	103	11	levels	level	NOUN
ajlm-2681	103	12	were	be	AUX
ajlm-2681	103	13	associated	associate	VERB
ajlm-2681	103	14	with	with	ADP
ajlm-2681	103	15	higher	high	ADJ
ajlm-2681	103	16	tci	tci	NOUN
ajlm-2681	103	17	values	value	NOUN
ajlm-2681	103	18	.	.	PUNCT
ajlm-2681	104	1	this	this	PRON
ajlm-2681	104	2	does	do	AUX
ajlm-2681	104	3	not	not	PART
ajlm-2681	104	4	necessarily	necessarily	ADV
ajlm-2681	104	5	mean	mean	VERB
ajlm-2681	104	6	that	that	SCONJ
ajlm-2681	104	7	tci	tci	PROPN
ajlm-2681	104	8	can	can	AUX
ajlm-2681	104	9	be	be	AUX
ajlm-2681	104	10	used	use	VERB
ajlm-2681	104	11	as	as	ADP
ajlm-2681	104	12	a	a	DET
ajlm-2681	104	13	surrogate	surrogate	ADJ
ajlm-2681	104	14	marker	marker	NOUN
ajlm-2681	104	15	for	for	ADP
ajlm-2681	104	16	anti	anti	ADJ
ajlm-2681	104	17	-	-	ADJ
ajlm-2681	104	18	xa	xa	ADJ
ajlm-2681	104	19	levels	level	NOUN
ajlm-2681	104	20	;	;	PUNCT
ajlm-2681	104	21	it	it	PRON
ajlm-2681	104	22	merely	merely	ADV
ajlm-2681	104	23	indicates	indicate	VERB
ajlm-2681	104	24	that	that	SCONJ
ajlm-2681	104	25	patients	patient	NOUN
ajlm-2681	104	26	with	with	ADP
ajlm-2681	104	27	higher	high	ADJ
ajlm-2681	104	28	thrombotic	thrombotic	ADJ
ajlm-2681	104	29	risk	risk	NOUN
ajlm-2681	104	30	(	(	PUNCT
ajlm-2681	104	31	higher	high	ADJ
ajlm-2681	104	32	tci	tci	PROPN
ajlm-2681	104	33	values	value	NOUN
ajlm-2681	104	34	)	)	PUNCT
ajlm-2681	104	35	were	be	AUX
ajlm-2681	104	36	correctly	correctly	ADV
ajlm-2681	104	37	put	put	VERB
ajlm-2681	104	38	onto	onto	ADP
ajlm-2681	104	39	therapeutic	therapeutic	ADJ
ajlm-2681	104	40	lmwh	lmwh	NOUN
ajlm-2681	104	41	.	.	PUNCT
ajlm-2681	105	1	the	the	DET
ajlm-2681	105	2	mean	mean	ADJ
ajlm-2681	105	3	tci	tci	NOUN
ajlm-2681	105	4	of	of	ADP
ajlm-2681	105	5	our	our	PRON
ajlm-2681	105	6	sample	sample	NOUN
ajlm-2681	105	7	was	be	AUX
ajlm-2681	105	8	5.67	5.67	NUM
ajlm-2681	105	9	(	(	PUNCT
ajlm-2681	105	10	5.14–6.27	5.14–6.27	NUM
ajlm-2681	105	11	)	)	PUNCT
ajlm-2681	105	12	.	.	PUNCT
ajlm-2681	106	1	this	this	PRON
ajlm-2681	106	2	is	be	AUX
ajlm-2681	106	3	significantly	significantly	ADV
ajlm-2681	106	4	higher	high	ADJ
ajlm-2681	106	5	than	than	ADP
ajlm-2681	106	6	the	the	DET
ajlm-2681	106	7	normal	normal	ADJ
ajlm-2681	106	8	range	range	NOUN
ajlm-2681	106	9	of	of	ADP
ajlm-2681	106	10	−3.0	−3.0	PROPN
ajlm-2681	106	11	to	to	PART
ajlm-2681	106	12	+3.0	+3.0	NUM
ajlm-2681	106	13	,	,	PUNCT
ajlm-2681	106	14	indicating	indicate	VERB
ajlm-2681	106	15	hypercoagulability	hypercoagulability	NOUN
ajlm-2681	106	16	.	.	PUNCT
ajlm-2681	107	1	this	this	PRON
ajlm-2681	107	2	is	be	AUX
ajlm-2681	107	3	likely	likely	ADV
ajlm-2681	107	4	indicative	indicative	ADJ
ajlm-2681	107	5	of	of	ADP
ajlm-2681	107	6	the	the	DET
ajlm-2681	107	7	hypercoagulability	hypercoagulability	NOUN
ajlm-2681	107	8	associated	associate	VERB
ajlm-2681	107	9	with	with	ADP
ajlm-2681	107	10	covid-19	covid-19	PROPN
ajlm-2681	107	11	and	and	CCONJ
ajlm-2681	107	12	the	the	DET
ajlm-2681	107	13	need	need	NOUN
ajlm-2681	107	14	for	for	ADP
ajlm-2681	107	15	lmwh	lmwh	NOUN
ajlm-2681	107	16	.	.	PUNCT
ajlm-2681	108	1	tekkesin	tekkesin	NOUN
ajlm-2681	108	2	et	et	PROPN
ajlm-2681	109	1	al	al	PROPN
ajlm-2681	109	2	.	.	PROPN
ajlm-2681	109	3	,18	,18	PUNCT
ajlm-2681	109	4	in	in	ADP
ajlm-2681	109	5	a	a	DET
ajlm-2681	109	6	study	study	NOUN
ajlm-2681	109	7	conducted	conduct	VERB
ajlm-2681	109	8	in	in	ADP
ajlm-2681	109	9	turkey	turkey	NOUN
ajlm-2681	109	10	in	in	ADP
ajlm-2681	109	11	2015	2015	NUM
ajlm-2681	109	12	,	,	PUNCT
ajlm-2681	109	13	report	report	VERB
ajlm-2681	109	14	all	all	DET
ajlm-2681	109	15	tci	tci	NOUN
ajlm-2681	109	16	values	value	NOUN
ajlm-2681	109	17	in	in	ADP
ajlm-2681	109	18	their	their	PRON
ajlm-2681	109	19	sample	sample	NOUN
ajlm-2681	109	20	to	to	PART
ajlm-2681	109	21	be	be	AUX
ajlm-2681	109	22	below	below	ADP
ajlm-2681	109	23	0.0	0.0	NUM
ajlm-2681	109	24	following	follow	VERB
ajlm-2681	109	25	administration	administration	NOUN
ajlm-2681	109	26	of	of	ADP
ajlm-2681	109	27	enoxaparin	enoxaparin	NOUN
ajlm-2681	109	28	.	.	PUNCT
ajlm-2681	110	1	this	this	PRON
ajlm-2681	110	2	is	be	AUX
ajlm-2681	110	3	a	a	DET
ajlm-2681	110	4	large	large	ADJ
ajlm-2681	110	5	discrepancy	discrepancy	NOUN
ajlm-2681	110	6	which	which	PRON
ajlm-2681	110	7	could	could	AUX
ajlm-2681	110	8	be	be	AUX
ajlm-2681	110	9	explained	explain	VERB
ajlm-2681	110	10	by	by	ADP
ajlm-2681	110	11	various	various	ADJ
ajlm-2681	110	12	factors	factor	NOUN
ajlm-2681	110	13	,	,	PUNCT
ajlm-2681	110	14	ranging	range	VERB
ajlm-2681	110	15	from	from	ADP
ajlm-2681	110	16	severity	severity	NOUN
ajlm-2681	110	17	of	of	ADP
ajlm-2681	110	18	illness	illness	NOUN
ajlm-2681	110	19	of	of	ADP
ajlm-2681	110	20	participants	participant	NOUN
ajlm-2681	110	21	to	to	PART
ajlm-2681	110	22	enoxaparin	enoxaparin	VERB
ajlm-2681	110	23	preparations	preparation	NOUN
ajlm-2681	110	24	,	,	PUNCT
ajlm-2681	110	25	and	and	CCONJ
ajlm-2681	110	26	requires	require	VERB
ajlm-2681	110	27	further	further	ADJ
ajlm-2681	110	28	investigation	investigation	NOUN
ajlm-2681	110	29	.	.	PUNCT
ajlm-2681	111	1	tekkesin	tekkesin	NOUN
ajlm-2681	111	2	et	et	PROPN
ajlm-2681	111	3	al.18	al.18	PROPN
ajlm-2681	111	4	found	find	VERB
ajlm-2681	111	5	a	a	DET
ajlm-2681	111	6	correlation	correlation	NOUN
ajlm-2681	111	7	of	of	ADP
ajlm-2681	111	8	0.38	0.38	NUM
ajlm-2681	111	9	between	between	ADP
ajlm-2681	111	10	tci	tci	PROPN
ajlm-2681	111	11	and	and	CCONJ
ajlm-2681	111	12	anti	anti	PROPN
ajlm-2681	111	13	-	-	ADJ
ajlm-2681	111	14	xa	xa	ADJ
ajlm-2681	111	15	levels	level	NOUN
ajlm-2681	111	16	24	24	NUM
ajlm-2681	111	17	h	h	NOUN
ajlm-2681	111	18	post	post	NOUN
ajlm-2681	111	19	initiation	initiation	NOUN
ajlm-2681	111	20	of	of	ADP
ajlm-2681	111	21	anticoagulation	anticoagulation	NOUN
ajlm-2681	111	22	in	in	ADP
ajlm-2681	111	23	turkey	turkey	PROPN
ajlm-2681	111	24	.	.	PUNCT
ajlm-2681	112	1	the	the	DET
ajlm-2681	112	2	tci	tci	PROPN
ajlm-2681	112	3	values	value	NOUN
ajlm-2681	112	4	,	,	PUNCT
ajlm-2681	112	5	as	as	SCONJ
ajlm-2681	112	6	expected	expect	VERB
ajlm-2681	112	7	,	,	PUNCT
ajlm-2681	112	8	predictably	predictably	ADV
ajlm-2681	112	9	dropped	drop	VERB
ajlm-2681	112	10	at	at	ADP
ajlm-2681	112	11	higher	high	ADJ
ajlm-2681	112	12	anti	anti	ADJ
ajlm-2681	112	13	-	-	ADJ
ajlm-2681	112	14	xa	xa	ADJ
ajlm-2681	112	15	levels	level	NOUN
ajlm-2681	112	16	.	.	PUNCT
ajlm-2681	113	1	in	in	ADP
ajlm-2681	113	2	our	our	PRON
ajlm-2681	113	3	study	study	NOUN
ajlm-2681	113	4	,	,	PUNCT
ajlm-2681	113	5	higher	high	ADJ
ajlm-2681	113	6	anti	anti	ADJ
ajlm-2681	113	7	-	-	ADJ
ajlm-2681	113	8	xa	xa	PROPN
ajlm-2681	113	9	levels	level	NOUN
ajlm-2681	113	10	appear	appear	VERB
ajlm-2681	113	11	to	to	PART
ajlm-2681	113	12	either	either	CCONJ
ajlm-2681	113	13	be	be	AUX
ajlm-2681	113	14	associated	associate	VERB
ajlm-2681	113	15	with	with	ADP
ajlm-2681	113	16	higher	high	ADJ
ajlm-2681	113	17	tcis	tcis	NOUN
ajlm-2681	113	18	or	or	CCONJ
ajlm-2681	113	19	there	there	PRON
ajlm-2681	113	20	appears	appear	VERB
ajlm-2681	113	21	to	to	PART
ajlm-2681	113	22	be	be	AUX
ajlm-2681	113	23	no	no	DET
ajlm-2681	113	24	association	association	NOUN
ajlm-2681	113	25	at	at	ADV
ajlm-2681	113	26	all	all	ADV
ajlm-2681	113	27	.	.	PUNCT
ajlm-2681	114	1	our	our	PRON
ajlm-2681	114	2	study	study	NOUN
ajlm-2681	114	3	population	population	NOUN
ajlm-2681	114	4	comprised	comprise	VERB
ajlm-2681	114	5	a	a	DET
ajlm-2681	114	6	group	group	NOUN
ajlm-2681	114	7	of	of	ADP
ajlm-2681	114	8	patients	patient	NOUN
ajlm-2681	114	9	with	with	ADP
ajlm-2681	114	10	a	a	DET
ajlm-2681	114	11	higher	high	ADJ
ajlm-2681	114	12	pro	pro	ADJ
ajlm-2681	114	13	-	-	ADJ
ajlm-2681	114	14	coagulable	coagulable	ADJ
ajlm-2681	114	15	phenotype	phenotype	NOUN
ajlm-2681	114	16	;	;	PUNCT
ajlm-2681	114	17	patients	patient	NOUN
ajlm-2681	114	18	were	be	AUX
ajlm-2681	114	19	not	not	PART
ajlm-2681	114	20	excluded	exclude	VERB
ajlm-2681	114	21	on	on	ADP
ajlm-2681	114	22	the	the	DET
ajlm-2681	114	23	basis	basis	NOUN
ajlm-2681	114	24	of	of	ADP
ajlm-2681	114	25	comorbidities	comorbiditie	NOUN
ajlm-2681	114	26	and	and	CCONJ
ajlm-2681	114	27	organ	organ	NOUN
ajlm-2681	114	28	dysfunction	dysfunction	NOUN
ajlm-2681	114	29	.	.	PUNCT
ajlm-2681	115	1	our	our	PRON
ajlm-2681	115	2	data	datum	NOUN
ajlm-2681	115	3	included	include	VERB
ajlm-2681	115	4	subgroups	subgroup	NOUN
ajlm-2681	115	5	with	with	ADP
ajlm-2681	115	6	both	both	CCONJ
ajlm-2681	115	7	prophylactic	prophylactic	ADJ
ajlm-2681	115	8	and	and	CCONJ
ajlm-2681	115	9	therapeutic	therapeutic	ADJ
ajlm-2681	115	10	enoxaparin	enoxaparin	NOUN
ajlm-2681	115	11	dosing	dosing	NOUN
ajlm-2681	115	12	.	.	PUNCT
ajlm-2681	116	1	these	these	DET
ajlm-2681	116	2	differences	difference	NOUN
ajlm-2681	116	3	may	may	AUX
ajlm-2681	116	4	account	account	VERB
ajlm-2681	116	5	for	for	ADP
ajlm-2681	116	6	the	the	DET
ajlm-2681	116	7	variance	variance	NOUN
ajlm-2681	116	8	in	in	ADP
ajlm-2681	116	9	correlation	correlation	NOUN
ajlm-2681	116	10	between	between	ADP
ajlm-2681	116	11	the	the	DET
ajlm-2681	116	12	two	two	NUM
ajlm-2681	116	13	studies	study	NOUN
ajlm-2681	116	14	.	.	PUNCT
ajlm-2681	117	1	our	our	PRON
ajlm-2681	117	2	study	study	NOUN
ajlm-2681	117	3	measured	measure	VERB
ajlm-2681	117	4	tci	tci	NOUN
ajlm-2681	117	5	and	and	CCONJ
ajlm-2681	117	6	anti	anti	PROPN
ajlm-2681	117	7	-	-	ADJ
ajlm-2681	117	8	xa	xa	PROPN
ajlm-2681	117	9	levels	level	NOUN
ajlm-2681	117	10	at	at	ADP
ajlm-2681	117	11	48	48	NUM
ajlm-2681	117	12	h	h	NOUN
ajlm-2681	117	13	post	post	NOUN
ajlm-2681	117	14	initial	initial	ADJ
ajlm-2681	117	15	enoxaparin	enoxaparin	NOUN
ajlm-2681	117	16	dosing	dosing	PROPN
ajlm-2681	117	17	.	.	PUNCT
ajlm-2681	118	1	buckley	buckley	PROPN
ajlm-2681	118	2	et	et	PROPN
ajlm-2681	118	3	al	al	PROPN
ajlm-2681	118	4	.	.	PROPN
ajlm-2681	118	5	,	,	PUNCT
ajlm-2681	118	6	in	in	ADP
ajlm-2681	118	7	the	the	DET
ajlm-2681	118	8	united	united	PROPN
ajlm-2681	118	9	states	states	PROPN
ajlm-2681	118	10	,	,	PUNCT
ajlm-2681	118	11	2021	2021	NUM
ajlm-2681	118	12	,	,	PUNCT
ajlm-2681	118	13	looked	look	VERB
ajlm-2681	118	14	at	at	ADP
ajlm-2681	118	15	a	a	DET
ajlm-2681	118	16	similar	similar	ADJ
ajlm-2681	118	17	population	population	NOUN
ajlm-2681	118	18	to	to	ADP
ajlm-2681	118	19	ours	ours	PRON
ajlm-2681	118	20	(	(	PUNCT
ajlm-2681	118	21	covid-19	covid-19	PROPN
ajlm-2681	118	22	)	)	PUNCT
ajlm-2681	118	23	,	,	PUNCT
ajlm-2681	118	24	and	and	CCONJ
ajlm-2681	118	25	also	also	ADV
ajlm-2681	118	26	found	find	VERB
ajlm-2681	118	27	a	a	DET
ajlm-2681	118	28	weak	weak	ADJ
ajlm-2681	118	29	correlation	correlation	NOUN
ajlm-2681	118	30	(	(	PUNCT
ajlm-2681	118	31	r	r	NOUN
ajlm-2681	118	32	=	=	SYM
ajlm-2681	118	33	0.30	0.30	NUM
ajlm-2681	118	34	)	)	PUNCT
ajlm-2681	118	35	between	between	ADP
ajlm-2681	118	36	tci	tci	NOUN
ajlm-2681	118	37	and	and	CCONJ
ajlm-2681	118	38	anti	anti	PROPN
ajlm-2681	118	39	-	-	PROPN
ajlm-2681	118	40	xa	xa	ADJ
ajlm-2681	118	41	levels.22	levels.22	NOUN
ajlm-2681	118	42	the	the	DET
ajlm-2681	118	43	important	important	ADJ
ajlm-2681	118	44	differences	difference	NOUN
ajlm-2681	118	45	in	in	ADP
ajlm-2681	118	46	their	their	PRON
ajlm-2681	118	47	study	study	NOUN
ajlm-2681	118	48	was	be	AUX
ajlm-2681	118	49	that	that	SCONJ
ajlm-2681	118	50	therapeutic	therapeutic	ADJ
ajlm-2681	118	51	anticoagulation	anticoagulation	NOUN
ajlm-2681	118	52	was	be	AUX
ajlm-2681	118	53	targeted	target	VERB
ajlm-2681	118	54	using	use	VERB
ajlm-2681	118	55	a	a	DET
ajlm-2681	118	56	continuous	continuous	ADJ
ajlm-2681	118	57	enoxaparin	enoxaparin	NOUN
ajlm-2681	118	58	infusion	infusion	NOUN
ajlm-2681	118	59	for	for	ADP
ajlm-2681	118	60	more	more	ADJ
ajlm-2681	118	61	than	than	ADP
ajlm-2681	118	62	24	24	NUM
ajlm-2681	118	63	h	h	NOUN
ajlm-2681	118	64	at	at	ADP
ajlm-2681	118	65	the	the	DET
ajlm-2681	118	66	discretion	discretion	NOUN
ajlm-2681	118	67	of	of	ADP
ajlm-2681	118	68	the	the	DET
ajlm-2681	118	69	treating	treat	VERB
ajlm-2681	118	70	physician	physician	NOUN
ajlm-2681	118	71	,	,	PUNCT
ajlm-2681	118	72	rather	rather	ADV
ajlm-2681	118	73	than	than	ADP
ajlm-2681	118	74	radiologically	radiologically	ADV
ajlm-2681	118	75	confirmed	confirm	VERB
ajlm-2681	118	76	vte	vte	NOUN
ajlm-2681	118	77	.	.	PUNCT
ajlm-2681	119	1	no	no	DET
ajlm-2681	119	2	standardised	standardised	ADJ
ajlm-2681	119	3	anticoagulation	anticoagulation	NOUN
ajlm-2681	119	4	protocol	protocol	NOUN
ajlm-2681	119	5	was	be	AUX
ajlm-2681	119	6	used	use	VERB
ajlm-2681	119	7	among	among	ADP
ajlm-2681	119	8	different	different	ADJ
ajlm-2681	119	9	patients	patient	NOUN
ajlm-2681	119	10	in	in	ADP
ajlm-2681	119	11	the	the	DET
ajlm-2681	119	12	population	population	NOUN
ajlm-2681	119	13	,	,	PUNCT
ajlm-2681	119	14	rather	rather	ADV
ajlm-2681	119	15	enoxaparin	enoxaparin	NOUN
ajlm-2681	119	16	infusion	infusion	NOUN
ajlm-2681	119	17	rates	rate	NOUN
ajlm-2681	119	18	were	be	AUX
ajlm-2681	119	19	altered	alter	VERB
ajlm-2681	119	20	depending	depend	VERB
ajlm-2681	119	21	on	on	ADP
ajlm-2681	119	22	anti	anti	ADJ
ajlm-2681	119	23	-	-	ADJ
ajlm-2681	119	24	xa	xa	ADJ
ajlm-2681	119	25	levels	level	NOUN
ajlm-2681	119	26	.	.	PUNCT
ajlm-2681	120	1	the	the	DET
ajlm-2681	120	2	differences	difference	NOUN
ajlm-2681	120	3	in	in	ADP
ajlm-2681	120	4	population	population	NOUN
ajlm-2681	120	5	characteristics	characteristic	NOUN
ajlm-2681	120	6	may	may	AUX
ajlm-2681	120	7	allude	allude	VERB
ajlm-2681	120	8	to	to	ADP
ajlm-2681	120	9	the	the	DET
ajlm-2681	120	10	reasoning	reasoning	NOUN
ajlm-2681	120	11	for	for	ADP
ajlm-2681	120	12	our	our	PRON
ajlm-2681	120	13	differences	difference	NOUN
ajlm-2681	120	14	in	in	ADP
ajlm-2681	120	15	results	result	NOUN
ajlm-2681	120	16	,	,	PUNCT
ajlm-2681	120	17	such	such	ADJ
ajlm-2681	120	18	as	as	ADP
ajlm-2681	120	19	:	:	PUNCT
ajlm-2681	120	20	all	all	DET
ajlm-2681	120	21	patients	patient	NOUN
ajlm-2681	120	22	in	in	ADP
ajlm-2681	120	23	their	their	PRON
ajlm-2681	120	24	study	study	NOUN
ajlm-2681	120	25	were	be	AUX
ajlm-2681	120	26	admitted	admit	VERB
ajlm-2681	120	27	to	to	ADP
ajlm-2681	120	28	the	the	DET
ajlm-2681	120	29	intensive	intensive	ADJ
ajlm-2681	120	30	care	care	NOUN
ajlm-2681	120	31	unit	unit	NOUN
ajlm-2681	120	32	as	as	SCONJ
ajlm-2681	120	33	opposed	oppose	VERB
ajlm-2681	120	34	to	to	ADP
ajlm-2681	120	35	52	52	NUM
ajlm-2681	120	36	%	%	NOUN
ajlm-2681	120	37	in	in	ADP
ajlm-2681	120	38	our	our	PRON
ajlm-2681	120	39	study	study	NOUN
ajlm-2681	120	40	,	,	PUNCT
ajlm-2681	120	41	and	and	CCONJ
ajlm-2681	120	42	almost	almost	ADV
ajlm-2681	120	43	60	60	NUM
ajlm-2681	120	44	%	%	NOUN
ajlm-2681	120	45	of	of	ADP
ajlm-2681	120	46	their	their	PRON
ajlm-2681	120	47	population	population	NOUN
ajlm-2681	120	48	was	be	AUX
ajlm-2681	120	49	male	male	ADJ
ajlm-2681	120	50	compared	compare	VERB
ajlm-2681	120	51	to	to	ADP
ajlm-2681	120	52	35	35	NUM
ajlm-2681	120	53	%	%	NOUN
ajlm-2681	120	54	in	in	ADP
ajlm-2681	120	55	our	our	PRON
ajlm-2681	120	56	data	datum	NOUN
ajlm-2681	120	57	.	.	PUNCT
ajlm-2681	121	1	we	we	PRON
ajlm-2681	121	2	had	have	VERB
ajlm-2681	121	3	a	a	DET
ajlm-2681	121	4	predominantly	predominantly	ADV
ajlm-2681	121	5	black	black	ADJ
ajlm-2681	121	6	african	african	ADJ
ajlm-2681	121	7	population	population	NOUN
ajlm-2681	121	8	,	,	PUNCT
ajlm-2681	121	9	while	while	SCONJ
ajlm-2681	121	10	less	less	ADJ
ajlm-2681	121	11	than	than	ADP
ajlm-2681	121	12	10	10	NUM
ajlm-2681	121	13	%	%	NOUN
ajlm-2681	121	14	of	of	ADP
ajlm-2681	121	15	their	their	PRON
ajlm-2681	121	16	study	study	NOUN
ajlm-2681	121	17	population	population	NOUN
ajlm-2681	121	18	was	be	AUX
ajlm-2681	121	19	black	black	ADJ
ajlm-2681	121	20	.	.	PUNCT
ajlm-2681	122	1	finally	finally	ADV
ajlm-2681	122	2	,	,	PUNCT
ajlm-2681	122	3	median	median	ADJ
ajlm-2681	122	4	sequential	sequential	ADJ
ajlm-2681	122	5	organ	organ	NOUN
ajlm-2681	122	6	failure	failure	NOUN
ajlm-2681	122	7	assessment	assessment	NOUN
ajlm-2681	122	8	scores	score	NOUN
ajlm-2681	122	9	differed	differ	VERB
ajlm-2681	122	10	,	,	PUNCT
ajlm-2681	122	11	with	with	ADP
ajlm-2681	122	12	5	5	NUM
ajlm-2681	122	13	versus	versus	ADP
ajlm-2681	122	14	3	3	NUM
ajlm-2681	122	15	in	in	ADP
ajlm-2681	122	16	our	our	PRON
ajlm-2681	122	17	study	study	NOUN
ajlm-2681	122	18	data.22	data.22	NOUN
ajlm-2681	122	19	we	we	PRON
ajlm-2681	122	20	found	find	VERB
ajlm-2681	122	21	a	a	DET
ajlm-2681	122	22	significant	significant	ADJ
ajlm-2681	122	23	correlation	correlation	NOUN
ajlm-2681	122	24	between	between	ADP
ajlm-2681	122	25	anti	anti	ADJ
ajlm-2681	122	26	-	-	ADJ
ajlm-2681	122	27	xa	xa	ADJ
ajlm-2681	122	28	levels	level	NOUN
ajlm-2681	122	29	and	and	CCONJ
ajlm-2681	122	30	r	r	NOUN
ajlm-2681	122	31	-	-	PUNCT
ajlm-2681	122	32	time	time	NOUN
ajlm-2681	122	33	at	at	ADP
ajlm-2681	122	34	48	48	NUM
ajlm-2681	122	35	h	h	NOUN
ajlm-2681	122	36	,	,	PUNCT
ajlm-2681	122	37	where	where	SCONJ
ajlm-2681	122	38	higher	high	ADJ
ajlm-2681	122	39	anti	anti	ADJ
ajlm-2681	122	40	-	-	ADJ
ajlm-2681	122	41	xa	xa	PROPN
ajlm-2681	122	42	levels	level	NOUN
ajlm-2681	122	43	appear	appear	VERB
ajlm-2681	122	44	to	to	PART
ajlm-2681	122	45	coincide	coincide	VERB
ajlm-2681	122	46	with	with	ADP
ajlm-2681	122	47	longer	long	ADJ
ajlm-2681	122	48	r	r	NOUN
ajlm-2681	122	49	-	-	PUNCT
ajlm-2681	122	50	time	time	NOUN
ajlm-2681	122	51	.	.	PUNCT
ajlm-2681	123	1	but	but	CCONJ
ajlm-2681	123	2	this	this	PRON
ajlm-2681	123	3	does	do	AUX
ajlm-2681	123	4	not	not	PART
ajlm-2681	123	5	mean	mean	VERB
ajlm-2681	123	6	r	r	NOUN
ajlm-2681	123	7	-	-	PUNCT
ajlm-2681	123	8	times	time	NOUN
ajlm-2681	123	9	can	can	AUX
ajlm-2681	123	10	be	be	AUX
ajlm-2681	123	11	used	use	VERB
ajlm-2681	123	12	as	as	ADP
ajlm-2681	123	13	a	a	DET
ajlm-2681	123	14	surrogate	surrogate	NOUN
ajlm-2681	123	15	for	for	ADP
ajlm-2681	123	16	anti	anti	ADJ
ajlm-2681	123	17	-	-	ADJ
ajlm-2681	123	18	xa	xa	PROPN
ajlm-2681	123	19	levels	level	NOUN
ajlm-2681	123	20	.	.	PUNCT
ajlm-2681	124	1	tekkesin	tekkesin	NOUN
ajlm-2681	124	2	et	et	PROPN
ajlm-2681	124	3	al	al	PROPN
ajlm-2681	124	4	.	.	PROPN
ajlm-2681	124	5	found	find	VERB
ajlm-2681	124	6	a	a	DET
ajlm-2681	124	7	correlation	correlation	NOUN
ajlm-2681	124	8	between	between	ADP
ajlm-2681	124	9	anti	anti	ADJ
ajlm-2681	124	10	-	-	ADJ
ajlm-2681	124	11	xa	xa	ADJ
ajlm-2681	124	12	levels	level	NOUN
ajlm-2681	124	13	and	and	CCONJ
ajlm-2681	124	14	r	r	NOUN
ajlm-2681	124	15	-	-	PUNCT
ajlm-2681	124	16	time	time	NOUN
ajlm-2681	124	17	,	,	PUNCT
ajlm-2681	124	18	which	which	PRON
ajlm-2681	124	19	was	be	AUX
ajlm-2681	124	20	only	only	ADV
ajlm-2681	124	21	significant	significant	ADJ
ajlm-2681	124	22	at	at	ADP
ajlm-2681	124	23	4	4	NUM
ajlm-2681	124	24	h	h	NOUN
ajlm-2681	124	25	post	post	NOUN
ajlm-2681	124	26	first	first	ADV
ajlm-2681	124	27	dose	dose	PROPN
ajlm-2681	124	28	of	of	ADP
ajlm-2681	124	29	anticoagulation	anticoagulation	NOUN
ajlm-2681	124	30	and	and	CCONJ
ajlm-2681	124	31	normalised	normalise	VERB
ajlm-2681	124	32	by	by	ADP
ajlm-2681	124	33	12	12	NUM
ajlm-2681	124	34	h.18	h.18	NOUN
ajlm-2681	124	35	this	this	DET
ajlm-2681	124	36	discrepant	discrepant	NOUN
ajlm-2681	124	37	finding	finding	NOUN
ajlm-2681	124	38	between	between	ADP
ajlm-2681	124	39	our	our	PRON
ajlm-2681	124	40	study	study	NOUN
ajlm-2681	124	41	and	and	CCONJ
ajlm-2681	124	42	that	that	PRON
ajlm-2681	124	43	of	of	ADP
ajlm-2681	124	44	tekkesin	tekkesin	NOUN
ajlm-2681	124	45	may	may	AUX
ajlm-2681	124	46	be	be	AUX
ajlm-2681	124	47	attributed	attribute	VERB
ajlm-2681	124	48	to	to	ADP
ajlm-2681	124	49	the	the	DET
ajlm-2681	124	50	underlying	underlie	VERB
ajlm-2681	124	51	disease	disease	NOUN
ajlm-2681	124	52	in	in	ADP
ajlm-2681	124	53	our	our	PRON
ajlm-2681	124	54	studies	study	NOUN
ajlm-2681	124	55	.	.	PUNCT
ajlm-2681	125	1	tekkesin	tekkesin	PROPN
ajlm-2681	126	1	et	et	PROPN
ajlm-2681	126	2	al	al	PROPN
ajlm-2681	126	3	.	.	PROPN
ajlm-2681	126	4	had	have	VERB
ajlm-2681	126	5	a	a	DET
ajlm-2681	126	6	patient	patient	ADJ
ajlm-2681	126	7	population	population	NOUN
ajlm-2681	126	8	who	who	PRON
ajlm-2681	126	9	underwent	undergo	VERB
ajlm-2681	126	10	surgical	surgical	ADJ
ajlm-2681	126	11	orthopaedic	orthopaedic	ADJ
ajlm-2681	126	12	intervention	intervention	NOUN
ajlm-2681	126	13	,	,	PUNCT
ajlm-2681	126	14	which	which	PRON
ajlm-2681	126	15	,	,	PUNCT
ajlm-2681	126	16	as	as	SCONJ
ajlm-2681	126	17	postulated	postulate	VERB
ajlm-2681	126	18	by	by	ADP
ajlm-2681	126	19	bunescu	bunescu	PROPN
ajlm-2681	126	20	et	et	PROPN
ajlm-2681	126	21	al.23	al.23	PROPN
ajlm-2681	126	22	in	in	ADP
ajlm-2681	126	23	london	london	PROPN
ajlm-2681	126	24	,	,	PUNCT
ajlm-2681	126	25	2002	2002	NUM
ajlm-2681	126	26	,	,	PUNCT
ajlm-2681	126	27	releases	release	VERB
ajlm-2681	126	28	granular	granular	ADJ
ajlm-2681	126	29	factor	factor	NOUN
ajlm-2681	126	30	from	from	ADP
ajlm-2681	126	31	platelets	platelet	NOUN
ajlm-2681	126	32	,	,	PUNCT
ajlm-2681	126	33	which	which	PRON
ajlm-2681	126	34	has	have	VERB
ajlm-2681	126	35	an	an	DET
ajlm-2681	126	36	impact	impact	NOUN
ajlm-2681	126	37	on	on	ADP
ajlm-2681	126	38	reaction	reaction	NOUN
ajlm-2681	126	39	time	time	NOUN
ajlm-2681	126	40	.	.	PUNCT
ajlm-2681	127	1	granular	granular	ADJ
ajlm-2681	127	2	factors	factor	NOUN
ajlm-2681	127	3	are	be	AUX
ajlm-2681	127	4	released	release	VERB
ajlm-2681	127	5	during	during	ADP
ajlm-2681	127	6	surgery	surgery	NOUN
ajlm-2681	127	7	but	but	CCONJ
ajlm-2681	127	8	then	then	ADV
ajlm-2681	127	9	end	end	VERB
ajlm-2681	127	10	at	at	ADP
ajlm-2681	127	11	or	or	CCONJ
ajlm-2681	127	12	shortly	shortly	ADV
ajlm-2681	127	13	after	after	ADP
ajlm-2681	127	14	completion	completion	NOUN
ajlm-2681	127	15	of	of	ADP
ajlm-2681	127	16	surgical	surgical	ADJ
ajlm-2681	127	17	procedures	procedure	NOUN
ajlm-2681	127	18	.	.	PUNCT
ajlm-2681	128	1	this	this	PRON
ajlm-2681	128	2	may	may	AUX
ajlm-2681	128	3	be	be	AUX
ajlm-2681	128	4	one	one	NUM
ajlm-2681	128	5	of	of	ADP
ajlm-2681	128	6	the	the	DET
ajlm-2681	128	7	mechanisms	mechanism	NOUN
ajlm-2681	128	8	of	of	ADP
ajlm-2681	128	9	rapid	rapid	ADJ
ajlm-2681	128	10	r	r	NOUN
ajlm-2681	128	11	-	-	PUNCT
ajlm-2681	128	12	time	time	NOUN
ajlm-2681	128	13	normalisation	normalisation	NOUN
ajlm-2681	128	14	in	in	ADP
ajlm-2681	128	15	the	the	DET
ajlm-2681	128	16	study	study	NOUN
ajlm-2681	128	17	done	do	VERB
ajlm-2681	128	18	by	by	ADP
ajlm-2681	128	19	tekkesin	tekkesin	NOUN
ajlm-2681	128	20	et	et	PROPN
ajlm-2681	128	21	al	al	PROPN
ajlm-2681	128	22	.	.	PROPN
ajlm-2681	128	23	,18	,18	PUNCT
ajlm-2681	128	24	as	as	SCONJ
ajlm-2681	128	25	opposed	oppose	VERB
ajlm-2681	128	26	to	to	ADP
ajlm-2681	128	27	ongoing	ongoing	ADJ
ajlm-2681	128	28	pro	pro	ADJ
ajlm-2681	128	29	-	-	ADJ
ajlm-2681	128	30	coagulopathic	coagulopathic	ADJ
ajlm-2681	128	31	processes	process	NOUN
ajlm-2681	128	32	in	in	ADP
ajlm-2681	128	33	covid-19	covid-19	PROPN
ajlm-2681	128	34	.	.	PUNCT
ajlm-2681	129	1	klein	klein	PROPN
ajlm-2681	129	2	et	et	PROPN
ajlm-2681	129	3	al.17	al.17	PROPN
ajlm-2681	129	4	(	(	PUNCT
ajlm-2681	129	5	united	united	PROPN
ajlm-2681	129	6	states	states	PROPN
ajlm-2681	129	7	,	,	PUNCT
ajlm-2681	129	8	2000	2000	NUM
ajlm-2681	129	9	)	)	PUNCT
ajlm-2681	129	10	found	find	VERB
ajlm-2681	129	11	a	a	DET
ajlm-2681	129	12	significant	significant	ADJ
ajlm-2681	129	13	correlation	correlation	NOUN
ajlm-2681	129	14	between	between	ADP
ajlm-2681	129	15	r	r	NOUN
ajlm-2681	129	16	-	-	PUNCT
ajlm-2681	129	17	time	time	NOUN
ajlm-2681	129	18	and	and	CCONJ
ajlm-2681	129	19	anti	anti	ADJ
ajlm-2681	129	20	-	-	ADJ
ajlm-2681	129	21	xa	xa	PROPN
ajlm-2681	129	22	levels	level	NOUN
ajlm-2681	129	23	in	in	ADP
ajlm-2681	129	24	a	a	DET
ajlm-2681	129	25	population	population	NOUN
ajlm-2681	129	26	of	of	ADP
ajlm-2681	129	27	24	24	NUM
ajlm-2681	129	28	patients	patient	NOUN
ajlm-2681	129	29	undergoing	undergo	VERB
ajlm-2681	129	30	orthopaedic	orthopaedic	ADJ
ajlm-2681	129	31	surgery	surgery	NOUN
ajlm-2681	129	32	.	.	PUNCT
ajlm-2681	130	1	contrary	contrary	ADJ
ajlm-2681	130	2	to	to	PART
ajlm-2681	130	3	tekkesin	tekkesin	VERB
ajlm-2681	130	4	et	et	PROPN
ajlm-2681	130	5	al	al	PROPN
ajlm-2681	130	6	.	.	PROPN
ajlm-2681	130	7	,	,	PUNCT
ajlm-2681	130	8	the	the	DET
ajlm-2681	130	9	significance	significance	NOUN
ajlm-2681	130	10	was	be	AUX
ajlm-2681	130	11	maintained	maintain	VERB
ajlm-2681	130	12	at	at	ADP
ajlm-2681	130	13	both	both	CCONJ
ajlm-2681	130	14	peak	peak	NOUN
ajlm-2681	130	15	and	and	CCONJ
ajlm-2681	130	16	trough	trough	NOUN
ajlm-2681	130	17	levels	level	NOUN
ajlm-2681	130	18	,	,	PUNCT
ajlm-2681	130	19	questioning	question	VERB
ajlm-2681	130	20	the	the	DET
ajlm-2681	130	21	platelet	platelet	NOUN
ajlm-2681	130	22	granular	granular	ADJ
ajlm-2681	130	23	factor	factor	NOUN
ajlm-2681	130	24	theory.17	theory.17	PROPN
ajlm-2681	130	25	white	white	PROPN
ajlm-2681	130	26	et	et	PROPN
ajlm-2681	130	27	al	al	PROPN
ajlm-2681	130	28	.	.	PUNCT
ajlm-2681	131	1	(	(	PUNCT
ajlm-2681	131	2	australia	australia	PROPN
ajlm-2681	131	3	,	,	PUNCT
ajlm-2681	131	4	2011	2011	NUM
ajlm-2681	131	5	)	)	PUNCT
ajlm-2681	131	6	found	find	VERB
ajlm-2681	131	7	no	no	DET
ajlm-2681	131	8	correlation	correlation	NOUN
ajlm-2681	131	9	between	between	ADP
ajlm-2681	131	10	anti	anti	ADJ
ajlm-2681	131	11	-	-	ADJ
ajlm-2681	131	12	xa	xa	PROPN
ajlm-2681	131	13	levels	level	NOUN
ajlm-2681	131	14	and	and	CCONJ
ajlm-2681	131	15	thromboelastogram	thromboelastogram	NOUN
ajlm-2681	131	16	r	r	NOUN
ajlm-2681	131	17	-	-	PUNCT
ajlm-2681	131	18	time	time	NOUN
ajlm-2681	131	19	(	(	PUNCT
ajlm-2681	131	20	p	p	NOUN
ajlm-2681	131	21	=	=	NOUN
ajlm-2681	131	22	0.38).24	0.38).24	NOUN
ajlm-2681	131	23	their	their	PRON
ajlm-2681	131	24	population	population	NOUN
ajlm-2681	131	25	of	of	ADP
ajlm-2681	131	26	50	50	NUM
ajlm-2681	131	27	patients	patient	NOUN
ajlm-2681	131	28	were	be	AUX
ajlm-2681	131	29	admitted	admit	VERB
ajlm-2681	131	30	to	to	ADP
ajlm-2681	131	31	a	a	DET
ajlm-2681	131	32	coronary	coronary	ADJ
ajlm-2681	131	33	care	care	NOUN
ajlm-2681	131	34	unit	unit	NOUN
ajlm-2681	131	35	and	and	CCONJ
ajlm-2681	131	36	received	receive	VERB
ajlm-2681	131	37	therapeutic	therapeutic	ADJ
ajlm-2681	131	38	dosed	dose	VERB
ajlm-2681	131	39	enoxaparin	enoxaparin	NOUN
ajlm-2681	131	40	(	(	PUNCT
ajlm-2681	131	41	1	1	NUM
ajlm-2681	131	42	mg	mg	NUM
ajlm-2681	131	43	/	/	SYM
ajlm-2681	131	44	kg	kg	PROPN
ajlm-2681	131	45	twice	twice	ADV
ajlm-2681	131	46	daily	daily	ADV
ajlm-2681	131	47	)	)	PUNCT
ajlm-2681	131	48	;	;	PUNCT
ajlm-2681	131	49	anti	anti	ADJ
ajlm-2681	131	50	-	-	ADJ
ajlm-2681	131	51	xa	xa	PROPN
ajlm-2681	131	52	levels	level	NOUN
ajlm-2681	131	53	and	and	CCONJ
ajlm-2681	131	54	thromboelastograms	thromboelastogram	NOUN
ajlm-2681	131	55	were	be	AUX
ajlm-2681	131	56	taken	take	VERB
ajlm-2681	131	57	after	after	ADP
ajlm-2681	131	58	48	48	NUM
ajlm-2681	131	59	h	h	NOUN
ajlm-2681	131	60	post	post	NOUN
ajlm-2681	131	61	first	first	ADV
ajlm-2681	131	62	dose	dose	PROPN
ajlm-2681	131	63	of	of	ADP
ajlm-2681	131	64	anticoagulation	anticoagulation	NOUN
ajlm-2681	131	65	.	.	PUNCT
ajlm-2681	132	1	of	of	ADP
ajlm-2681	132	2	note	note	NOUN
ajlm-2681	132	3	,	,	PUNCT
ajlm-2681	132	4	the	the	DET
ajlm-2681	132	5	non	non	ADJ
ajlm-2681	132	6	-	-	ADJ
ajlm-2681	132	7	significant	significant	ADJ
ajlm-2681	132	8	correlation	correlation	NOUN
ajlm-2681	132	9	between	between	ADP
ajlm-2681	132	10	anti	anti	ADJ
ajlm-2681	132	11	-	-	ADJ
ajlm-2681	132	12	xa	xa	ADJ
ajlm-2681	132	13	levels	level	NOUN
ajlm-2681	132	14	and	and	CCONJ
ajlm-2681	132	15	r	r	NOUN
ajlm-2681	132	16	-	-	PUNCT
ajlm-2681	132	17	times	time	NOUN
ajlm-2681	132	18	may	may	AUX
ajlm-2681	132	19	be	be	AUX
ajlm-2681	132	20	attributed	attribute	VERB
ajlm-2681	132	21	to	to	ADP
ajlm-2681	132	22	sampling	sample	VERB
ajlm-2681	132	23	errors	error	NOUN
ajlm-2681	132	24	(	(	PUNCT
ajlm-2681	132	25	mean	mean	VERB
ajlm-2681	132	26	time	time	NOUN
ajlm-2681	132	27	from	from	ADP
ajlm-2681	132	28	dosing	dose	VERB
ajlm-2681	132	29	of	of	ADP
ajlm-2681	132	30	enoxaparin	enoxaparin	NOUN
ajlm-2681	132	31	to	to	ADP
ajlm-2681	132	32	thromboelastogram	thromboelastogram	PROPN
ajlm-2681	132	33	measurement	measurement	PROPN
ajlm-2681	132	34	was	be	AUX
ajlm-2681	132	35	4.17	4.17	NUM
ajlm-2681	132	36	h	h	NOUN
ajlm-2681	132	37	±	±	NUM
ajlm-2681	132	38	0.5	0.5	NUM
ajlm-2681	132	39	h	h	NOUN
ajlm-2681	132	40	)	)	PUNCT
ajlm-2681	132	41	,	,	PUNCT
ajlm-2681	132	42	as	as	SCONJ
ajlm-2681	132	43	this	this	DET
ajlm-2681	132	44	study	study	NOUN
ajlm-2681	132	45	failed	fail	VERB
ajlm-2681	132	46	to	to	PART
ajlm-2681	132	47	find	find	VERB
ajlm-2681	132	48	a	a	DET
ajlm-2681	132	49	correlation	correlation	NOUN
ajlm-2681	132	50	between	between	ADP
ajlm-2681	132	51	enoxaparin	enoxaparin	NOUN
ajlm-2681	132	52	dose	dose	NOUN
ajlm-2681	132	53	and	and	CCONJ
ajlm-2681	132	54	anti	anti	PROPN
ajlm-2681	132	55	-	-	ADJ
ajlm-2681	132	56	xa	xa	PROPN
ajlm-2681	132	57	levels	level	NOUN
ajlm-2681	132	58	.	.	PUNCT
ajlm-2681	133	1	despite	despite	SCONJ
ajlm-2681	133	2	all	all	DET
ajlm-2681	133	3	patients	patient	NOUN
ajlm-2681	133	4	receiving	receive	VERB
ajlm-2681	133	5	therapeutic	therapeutic	ADJ
ajlm-2681	133	6	dosed	dose	VERB
ajlm-2681	133	7	enoxaparin	enoxaparin	NOUN
ajlm-2681	133	8	,	,	PUNCT
ajlm-2681	133	9	a	a	DET
ajlm-2681	133	10	cutoff	cutoff	NOUN
ajlm-2681	133	11	of	of	ADP
ajlm-2681	133	12	100	100	NUM
ajlm-2681	133	13	mg	mg	NUM
ajlm-2681	133	14	/	/	SYM
ajlm-2681	133	15	dose	dose	NOUN
ajlm-2681	133	16	was	be	AUX
ajlm-2681	133	17	implemented	implement	VERB
ajlm-2681	133	18	in	in	ADP
ajlm-2681	133	19	patients	patient	NOUN
ajlm-2681	133	20	weighing	weigh	VERB
ajlm-2681	133	21	more	more	ADJ
ajlm-2681	133	22	than	than	ADP
ajlm-2681	133	23	100	100	NUM
ajlm-2681	133	24	kg	kg	NOUN
ajlm-2681	133	25	in	in	ADP
ajlm-2681	133	26	this	this	DET
ajlm-2681	133	27	study	study	NOUN
ajlm-2681	133	28	.	.	PUNCT
ajlm-2681	134	1	white	white	PROPN
ajlm-2681	134	2	et	et	PROPN
ajlm-2681	134	3	al	al	PROPN
ajlm-2681	134	4	.	.	PROPN
ajlm-2681	134	5	had	have	AUX
ajlm-2681	134	6	not	not	PART
ajlm-2681	134	7	factored	factor	VERB
ajlm-2681	134	8	in	in	ADP
ajlm-2681	134	9	the	the	DET
ajlm-2681	134	10	decline	decline	NOUN
ajlm-2681	134	11	in	in	ADP
ajlm-2681	134	12	creatinine	creatinine	NOUN
ajlm-2681	134	13	clearance	clearance	NOUN
ajlm-2681	134	14	as	as	ADP
ajlm-2681	134	15	a	a	DET
ajlm-2681	134	16	result	result	NOUN
ajlm-2681	134	17	of	of	ADP
ajlm-2681	134	18	age	age	NOUN
ajlm-2681	134	19	,	,	PUNCT
ajlm-2681	134	20	which	which	PRON
ajlm-2681	134	21	would	would	AUX
ajlm-2681	134	22	impact	impact	VERB
ajlm-2681	134	23	on	on	ADP
ajlm-2681	134	24	enoxaparin	enoxaparin	PROPN
ajlm-2681	134	25	clearance.24	clearance.24	PROPN
ajlm-2681	134	26	buckley	buckley	PROPN
ajlm-2681	134	27	et	et	PROPN
ajlm-2681	134	28	al	al	PROPN
ajlm-2681	134	29	.	.	PROPN
ajlm-2681	134	30	found	find	VERB
ajlm-2681	134	31	a	a	DET
ajlm-2681	134	32	weak	weak	ADJ
ajlm-2681	134	33	but	but	CCONJ
ajlm-2681	134	34	significant	significant	ADJ
ajlm-2681	134	35	correlation	correlation	NOUN
ajlm-2681	134	36	between	between	ADP
ajlm-2681	134	37	thromboelastogram	thromboelastogram	NOUN
ajlm-2681	134	38	r	r	NOUN
ajlm-2681	134	39	-	-	PUNCT
ajlm-2681	134	40	time	time	NOUN
ajlm-2681	134	41	and	and	CCONJ
ajlm-2681	134	42	anti	anti	ADJ
ajlm-2681	134	43	-	-	NOUN
ajlm-2681	134	44	xa	xa	ADJ
ajlm-2681	134	45	level;22	level;22	NOUN
ajlm-2681	134	46	however	however	ADV
ajlm-2681	134	47	,	,	PUNCT
ajlm-2681	134	48	the	the	DET
ajlm-2681	134	49	differences	difference	NOUN
ajlm-2681	134	50	in	in	ADP
ajlm-2681	134	51	this	this	DET
ajlm-2681	134	52	study	study	NOUN
ajlm-2681	134	53	compared	compare	VERB
ajlm-2681	134	54	to	to	ADP
ajlm-2681	134	55	ours	ours	PRON
ajlm-2681	134	56	may	may	AUX
ajlm-2681	134	57	be	be	AUX
ajlm-2681	134	58	because	because	SCONJ
ajlm-2681	134	59	of	of	ADP
ajlm-2681	134	60	the	the	DET
ajlm-2681	134	61	nature	nature	NOUN
ajlm-2681	134	62	of	of	ADP
ajlm-2681	134	63	enoxaparin	enoxaparin	PROPN
ajlm-2681	134	64	administration	administration	NOUN
ajlm-2681	134	65	(	(	PUNCT
ajlm-2681	134	66	continuous	continuous	ADJ
ajlm-2681	134	67	infusion	infusion	NOUN
ajlm-2681	134	68	vs	vs	ADP
ajlm-2681	134	69	daily	daily	ADJ
ajlm-2681	134	70	and	and	CCONJ
ajlm-2681	134	71	twice	twice	ADV
ajlm-2681	134	72	-	-	PUNCT
ajlm-2681	134	73	daily	daily	ADJ
ajlm-2681	134	74	dosing	dosing	NOUN
ajlm-2681	134	75	)	)	PUNCT
ajlm-2681	134	76	.	.	PUNCT
ajlm-2681	135	1	artang	artang	PROPN
ajlm-2681	135	2	et	et	PROPN
ajlm-2681	135	3	al	al	PROPN
ajlm-2681	135	4	.	.	PUNCT
ajlm-2681	136	1	(	(	PUNCT
ajlm-2681	136	2	denmark	denmark	NOUN
ajlm-2681	136	3	,	,	PUNCT
ajlm-2681	136	4	2009	2009	NUM
ajlm-2681	136	5	)	)	PUNCT
ajlm-2681	136	6	conducted	conduct	VERB
ajlm-2681	136	7	a	a	DET
ajlm-2681	136	8	study	study	NOUN
ajlm-2681	136	9	using	use	VERB
ajlm-2681	136	10	seven	seven	NUM
ajlm-2681	136	11	healthy	healthy	ADJ
ajlm-2681	136	12	male	male	ADJ
ajlm-2681	136	13	volunteers	volunteer	NOUN
ajlm-2681	136	14	who	who	PRON
ajlm-2681	136	15	were	be	AUX
ajlm-2681	136	16	injected	inject	VERB
ajlm-2681	136	17	subcutaneously	subcutaneously	ADV
ajlm-2681	136	18	with	with	ADP
ajlm-2681	136	19	dalteparin	dalteparin	NOUN
ajlm-2681	136	20	(	(	PUNCT
ajlm-2681	136	21	lmwh	lmwh	NOUN
ajlm-2681	136	22	)	)	PUNCT
ajlm-2681	136	23	120	120	NUM
ajlm-2681	136	24	iu	iu	PROPN
ajlm-2681	136	25	/	/	SYM
ajlm-2681	136	26	kg.25	kg.25	NOUN
ajlm-2681	136	27	reaction	reaction	NOUN
ajlm-2681	136	28	time	time	NOUN
ajlm-2681	136	29	was	be	AUX
ajlm-2681	136	30	then	then	ADV
ajlm-2681	136	31	compared	compare	VERB
ajlm-2681	136	32	to	to	ADP
ajlm-2681	136	33	anti	anti	ADJ
ajlm-2681	136	34	-	-	ADJ
ajlm-2681	136	35	xa	xa	PROPN
ajlm-2681	136	36	levels	level	NOUN
ajlm-2681	136	37	at	at	ADP
ajlm-2681	136	38	baseline	baseline	NOUN
ajlm-2681	136	39	,	,	PUNCT
ajlm-2681	136	40	then	then	ADV
ajlm-2681	136	41	at	at	ADP
ajlm-2681	136	42	2	2	NUM
ajlm-2681	136	43	,	,	PUNCT
ajlm-2681	136	44	4	4	NUM
ajlm-2681	136	45	,	,	PUNCT
ajlm-2681	136	46	5	5	NUM
ajlm-2681	136	47	and	and	CCONJ
ajlm-2681	136	48	24	24	NUM
ajlm-2681	136	49	h	h	NOUN
ajlm-2681	136	50	post	post	PROPN
ajlm-2681	136	51	dalteparin	dalteparin	PROPN
ajlm-2681	136	52	administration	administration	PROPN
ajlm-2681	136	53	.	.	PUNCT
ajlm-2681	137	1	at	at	ADP
ajlm-2681	137	2	24	24	NUM
ajlm-2681	137	3	h	h	NOUN
ajlm-2681	137	4	,	,	PUNCT
ajlm-2681	137	5	a	a	DET
ajlm-2681	137	6	strong	strong	ADJ
ajlm-2681	137	7	correlation	correlation	NOUN
ajlm-2681	137	8	of	of	ADP
ajlm-2681	137	9	r	r	NOUN
ajlm-2681	137	10	=	=	PUNCT
ajlm-2681	137	11	0.82	0.82	NUM
ajlm-2681	137	12	was	be	AUX
ajlm-2681	137	13	found	find	VERB
ajlm-2681	137	14	.	.	PUNCT
ajlm-2681	138	1	however	however	ADV
ajlm-2681	138	2	,	,	PUNCT
ajlm-2681	138	3	multiple	multiple	ADJ
ajlm-2681	138	4	differences	difference	NOUN
ajlm-2681	138	5	are	be	AUX
ajlm-2681	138	6	found	find	VERB
ajlm-2681	138	7	in	in	ADP
ajlm-2681	138	8	this	this	DET
ajlm-2681	138	9	study	study	NOUN
ajlm-2681	138	10	when	when	SCONJ
ajlm-2681	138	11	compared	compare	VERB
ajlm-2681	138	12	to	to	ADP
ajlm-2681	138	13	ours	ours	PRON
ajlm-2681	138	14	;	;	PUNCT
ajlm-2681	138	15	most	most	ADV
ajlm-2681	138	16	importantly	importantly	ADV
ajlm-2681	138	17	,	,	PUNCT
ajlm-2681	138	18	the	the	DET
ajlm-2681	138	19	lmwh	lmwh	NOUN
ajlm-2681	138	20	used	use	VERB
ajlm-2681	138	21	was	be	AUX
ajlm-2681	138	22	not	not	PART
ajlm-2681	138	23	enoxaparin	enoxaparin	ADJ
ajlm-2681	138	24	but	but	CCONJ
ajlm-2681	138	25	rather	rather	ADV
ajlm-2681	138	26	dalteparin	dalteparin	NOUN
ajlm-2681	138	27	.	.	PUNCT
ajlm-2681	139	1	alongside	alongside	ADP
ajlm-2681	139	2	this	this	PRON
ajlm-2681	139	3	,	,	PUNCT
ajlm-2681	139	4	the	the	DET
ajlm-2681	139	5	study	study	NOUN
ajlm-2681	139	6	consisted	consist	VERB
ajlm-2681	139	7	of	of	ADP
ajlm-2681	139	8	seven	seven	NUM
ajlm-2681	139	9	male	male	ADJ
ajlm-2681	139	10	participants	participant	NOUN
ajlm-2681	139	11	who	who	PRON
ajlm-2681	139	12	were	be	AUX
ajlm-2681	139	13	all	all	ADV
ajlm-2681	139	14	healthy	healthy	ADJ
ajlm-2681	139	15	and	and	CCONJ
ajlm-2681	139	16	did	do	AUX
ajlm-2681	139	17	not	not	PART
ajlm-2681	139	18	suffer	suffer	VERB
ajlm-2681	139	19	from	from	ADP
ajlm-2681	139	20	the	the	DET
ajlm-2681	139	21	same	same	ADJ
ajlm-2681	139	22	disease	disease	NOUN
ajlm-2681	139	23	process	process	NOUN
ajlm-2681	139	24	as	as	ADP
ajlm-2681	139	25	our	our	PRON
ajlm-2681	139	26	population	population	NOUN
ajlm-2681	139	27	(	(	PUNCT
ajlm-2681	139	28	covid-19	covid-19	PROPN
ajlm-2681	139	29	)	)	PUNCT
ajlm-2681	139	30	.	.	PUNCT
ajlm-2681	140	1	thromboelastogram	thromboelastogram	PROPN
ajlm-2681	140	2	kinetics	kinetics	PROPN
ajlm-2681	140	3	time	time	NOUN
ajlm-2681	140	4	and	and	CCONJ
ajlm-2681	140	5	alpha	alpha	NOUN
ajlm-2681	140	6	angle	angle	NOUN
ajlm-2681	140	7	we	we	PRON
ajlm-2681	140	8	found	find	VERB
ajlm-2681	140	9	a	a	DET
ajlm-2681	140	10	statistically	statistically	ADV
ajlm-2681	140	11	significant	significant	ADJ
ajlm-2681	140	12	low	low	ADJ
ajlm-2681	140	13	correlation	correlation	NOUN
ajlm-2681	140	14	between	between	ADP
ajlm-2681	140	15	anti	anti	ADJ
ajlm-2681	140	16	-	-	ADJ
ajlm-2681	140	17	xa	xa	PROPN
ajlm-2681	140	18	levels	level	NOUN
ajlm-2681	140	19	and	and	CCONJ
ajlm-2681	140	20	k	k	NOUN
ajlm-2681	140	21	-	-	PUNCT
ajlm-2681	140	22	time	time	NOUN
ajlm-2681	140	23	(	(	PUNCT
ajlm-2681	140	24	r	r	NOUN
ajlm-2681	140	25	=	=	SYM
ajlm-2681	140	26	0.35	0.35	NUM
ajlm-2681	140	27	)	)	PUNCT
ajlm-2681	140	28	,	,	PUNCT
ajlm-2681	140	29	which	which	PRON
ajlm-2681	140	30	is	be	AUX
ajlm-2681	140	31	different	different	ADJ
ajlm-2681	140	32	from	from	ADP
ajlm-2681	140	33	the	the	DET
ajlm-2681	140	34	study	study	NOUN
ajlm-2681	140	35	by	by	ADP
ajlm-2681	140	36	buckley	buckley	PROPN
ajlm-2681	140	37	et	et	PROPN
ajlm-2681	140	38	al	al	PROPN
ajlm-2681	140	39	.	.	PROPN
ajlm-2681	140	40	,22	,22	PUNCT
ajlm-2681	140	41	who	who	PRON
ajlm-2681	140	42	found	find	VERB
ajlm-2681	140	43	no	no	DET
ajlm-2681	140	44	relationship	relationship	NOUN
ajlm-2681	140	45	between	between	ADP
ajlm-2681	140	46	anti	anti	ADJ
ajlm-2681	140	47	-	-	ADJ
ajlm-2681	140	48	xa	xa	PROPN
ajlm-2681	140	49	levels	level	NOUN
ajlm-2681	140	50	and	and	CCONJ
ajlm-2681	140	51	k	k	NOUN
ajlm-2681	140	52	-	-	PUNCT
ajlm-2681	140	53	time	time	NOUN
ajlm-2681	140	54	(	(	PUNCT
ajlm-2681	140	55	r	r	NOUN
ajlm-2681	140	56	=	=	NOUN
ajlm-2681	140	57	0.08	0.08	NUM
ajlm-2681	140	58	)	)	PUNCT
ajlm-2681	140	59	.	.	PUNCT
ajlm-2681	141	1	this	this	PRON
ajlm-2681	141	2	was	be	AUX
ajlm-2681	141	3	likely	likely	ADJ
ajlm-2681	141	4	because	because	SCONJ
ajlm-2681	141	5	we	we	PRON
ajlm-2681	141	6	measured	measure	VERB
ajlm-2681	141	7	the	the	DET
ajlm-2681	141	8	k	k	NOUN
ajlm-2681	141	9	-	-	PUNCT
ajlm-2681	141	10	time	time	NOUN
ajlm-2681	141	11	at	at	ADP
ajlm-2681	141	12	peak	peak	NOUN
ajlm-2681	141	13	enoxaparin	enoxaparin	NOUN
ajlm-2681	141	14	dose	dose	NOUN
ajlm-2681	141	15	effect	effect	NOUN
ajlm-2681	141	16	(	(	PUNCT
ajlm-2681	141	17	3	3	NUM
ajlm-2681	141	18	h	h	PROPN
ajlm-2681	141	19	post	post	NOUN
ajlm-2681	141	20	dose	dose	PROPN
ajlm-2681	141	21	)	)	PUNCT
ajlm-2681	141	22	compared	compare	VERB
ajlm-2681	141	23	to	to	ADP
ajlm-2681	141	24	the	the	DET
ajlm-2681	141	25	continuous	continuous	ADJ
ajlm-2681	141	26	infusion	infusion	NOUN
ajlm-2681	141	27	,	,	PUNCT
ajlm-2681	141	28	which	which	PRON
ajlm-2681	141	29	may	may	AUX
ajlm-2681	141	30	not	not	PART
ajlm-2681	141	31	have	have	AUX
ajlm-2681	141	32	achieved	achieve	VERB
ajlm-2681	141	33	the	the	DET
ajlm-2681	141	34	optimal	optimal	ADJ
ajlm-2681	141	35	anti	anti	ADJ
ajlm-2681	141	36	-	-	ADJ
ajlm-2681	141	37	xa	xa	ADJ
ajlm-2681	141	38	level	level	NOUN
ajlm-2681	141	39	.	.	PUNCT
ajlm-2681	142	1	furthermore	furthermore	ADV
ajlm-2681	142	2	,	,	PUNCT
ajlm-2681	142	3	differences	difference	NOUN
ajlm-2681	142	4	in	in	ADP
ajlm-2681	142	5	our	our	PRON
ajlm-2681	142	6	study	study	NOUN
ajlm-2681	142	7	population	population	NOUN
ajlm-2681	142	8	,	,	PUNCT
ajlm-2681	142	9	especially	especially	ADV
ajlm-2681	142	10	regarding	regard	VERB
ajlm-2681	142	11	disease	disease	NOUN
ajlm-2681	142	12	profile	profile	NOUN
ajlm-2681	142	13	,	,	PUNCT
ajlm-2681	142	14	may	may	AUX
ajlm-2681	142	15	be	be	AUX
ajlm-2681	142	16	contributory	contributory	ADJ
ajlm-2681	142	17	as	as	ADP
ajlm-2681	142	18	previously	previously	ADV
ajlm-2681	142	19	mentioned.22	mentioned.22	NOUN
ajlm-2681	142	20	we	we	PRON
ajlm-2681	142	21	failed	fail	VERB
ajlm-2681	142	22	to	to	PART
ajlm-2681	142	23	detect	detect	VERB
ajlm-2681	142	24	a	a	DET
ajlm-2681	142	25	statistically	statistically	ADV
ajlm-2681	142	26	significant	significant	ADJ
ajlm-2681	142	27	relationship	relationship	NOUN
ajlm-2681	142	28	between	between	ADP
ajlm-2681	142	29	anti	anti	ADJ
ajlm-2681	142	30	-	-	ADJ
ajlm-2681	142	31	xa	xa	PROPN
ajlm-2681	142	32	levels	level	NOUN
ajlm-2681	142	33	and	and	CCONJ
ajlm-2681	142	34	ma	ma	PROPN
ajlm-2681	142	35	,	,	PUNCT
ajlm-2681	142	36	which	which	PRON
ajlm-2681	142	37	is	be	AUX
ajlm-2681	142	38	similar	similar	ADJ
ajlm-2681	142	39	to	to	ADP
ajlm-2681	142	40	the	the	DET
ajlm-2681	142	41	findings	finding	NOUN
ajlm-2681	142	42	of	of	ADP
ajlm-2681	142	43	buckley	buckley	PROPN
ajlm-2681	142	44	et	et	PROPN
ajlm-2681	142	45	al.22	al.22	PROPN
ajlm-2681	142	46	these	these	DET
ajlm-2681	142	47	findings	finding	NOUN
ajlm-2681	142	48	are	be	AUX
ajlm-2681	142	49	not	not	PART
ajlm-2681	142	50	surprising	surprising	ADJ
ajlm-2681	142	51	,	,	PUNCT
ajlm-2681	142	52	as	as	ADV
ajlm-2681	142	53	much	much	ADJ
ajlm-2681	142	54	as	as	ADP
ajlm-2681	142	55	80	80	NUM
ajlm-2681	142	56	%	%	NOUN
ajlm-2681	142	57	of	of	ADP
ajlm-2681	142	58	the	the	DET
ajlm-2681	142	59	ma	ma	PROPN
ajlm-2681	142	60	is	be	AUX
ajlm-2681	142	61	contributed	contribute	VERB
ajlm-2681	142	62	to	to	ADP
ajlm-2681	142	63	by	by	ADP
ajlm-2681	142	64	platelet	platelet	NOUN
ajlm-2681	142	65	activity,26	activity,26	NOUN
ajlm-2681	142	66	which	which	PRON
ajlm-2681	142	67	is	be	AUX
ajlm-2681	142	68	not	not	PART
ajlm-2681	142	69	affected	affect	VERB
ajlm-2681	142	70	by	by	ADP
ajlm-2681	142	71	enoxaparin	enoxaparin	NOUN
ajlm-2681	142	72	.	.	PUNCT
ajlm-2681	143	1	our	our	PRON
ajlm-2681	143	2	study	study	NOUN
ajlm-2681	143	3	found	find	VERB
ajlm-2681	143	4	no	no	DET
ajlm-2681	143	5	statistically	statistically	ADV
ajlm-2681	143	6	significant	significant	ADJ
ajlm-2681	143	7	correlations	correlation	NOUN
ajlm-2681	143	8	between	between	ADP
ajlm-2681	143	9	d	d	NOUN
ajlm-2681	143	10	-	-	PUNCT
ajlm-2681	143	11	dimer	dimer	NOUN
ajlm-2681	143	12	and	and	CCONJ
ajlm-2681	143	13	thromboelastogram	thromboelastogram	NOUN
ajlm-2681	143	14	parameters	parameter	NOUN
ajlm-2681	143	15	.	.	PUNCT
ajlm-2681	144	1	this	this	PRON
ajlm-2681	144	2	has	have	AUX
ajlm-2681	144	3	also	also	ADV
ajlm-2681	144	4	been	be	AUX
ajlm-2681	144	5	found	find	VERB
ajlm-2681	144	6	by	by	ADP
ajlm-2681	144	7	chandel	chandel	PROPN
ajlm-2681	144	8	et	et	PROPN
ajlm-2681	144	9	al	al	PROPN
ajlm-2681	144	10	.	.	PROPN
ajlm-2681	145	1	in	in	ADP
ajlm-2681	145	2	a	a	DET
ajlm-2681	145	3	study	study	NOUN
ajlm-2681	145	4	of	of	ADP
ajlm-2681	145	5	24	24	NUM
ajlm-2681	145	6	patients	patient	NOUN
ajlm-2681	145	7	with	with	ADP
ajlm-2681	145	8	severe	severe	ADJ
ajlm-2681	145	9	covid-19	covid-19	PROPN
ajlm-2681	145	10	pneumonia.27	pneumonia.27	PROPN
ajlm-2681	145	11	their	their	PRON
ajlm-2681	145	12	study	study	NOUN
ajlm-2681	145	13	found	find	VERB
ajlm-2681	145	14	a	a	DET
ajlm-2681	145	15	discordant	discordant	ADJ
ajlm-2681	145	16	or	or	CCONJ
ajlm-2681	145	17	unpredictable	unpredictable	ADJ
ajlm-2681	145	18	relationship	relationship	NOUN
ajlm-2681	145	19	between	between	ADP
ajlm-2681	145	20	clot	clot	NOUN
ajlm-2681	145	21	burden	burden	NOUN
ajlm-2681	145	22	and	and	CCONJ
ajlm-2681	145	23	d	d	NOUN
ajlm-2681	145	24	-	-	PUNCT
ajlm-2681	145	25	dimer	dimer	ADJ
ajlm-2681	145	26	levels	level	NOUN
ajlm-2681	145	27	.	.	PUNCT
ajlm-2681	146	1	this	this	PRON
ajlm-2681	146	2	may	may	AUX
ajlm-2681	146	3	explain	explain	VERB
ajlm-2681	146	4	the	the	DET
ajlm-2681	146	5	lack	lack	NOUN
ajlm-2681	146	6	of	of	ADP
ajlm-2681	146	7	relationship	relationship	NOUN
ajlm-2681	146	8	between	between	ADP
ajlm-2681	146	9	d	d	NOUN
ajlm-2681	146	10	-	-	PUNCT
ajlm-2681	146	11	dimer	dimer	ADJ
ajlm-2681	146	12	,	,	PUNCT
ajlm-2681	146	13	anti	anti	ADJ
ajlm-2681	146	14	-	-	ADJ
ajlm-2681	146	15	xa	xa	PROPN
ajlm-2681	146	16	levels	level	NOUN
ajlm-2681	146	17	and	and	CCONJ
ajlm-2681	146	18	thromboelastogram	thromboelastogram	NOUN
ajlm-2681	146	19	parameters.27	parameters.27	PROPN
ajlm-2681	146	20	although	although	SCONJ
ajlm-2681	146	21	we	we	PRON
ajlm-2681	146	22	found	find	VERB
ajlm-2681	146	23	a	a	DET
ajlm-2681	146	24	statistically	statistically	ADV
ajlm-2681	146	25	significant	significant	ADJ
ajlm-2681	146	26	difference	difference	NOUN
ajlm-2681	146	27	in	in	ADP
ajlm-2681	146	28	a30	a30	NOUN
ajlm-2681	146	29	percentages	percentage	NOUN
ajlm-2681	146	30	between	between	ADP
ajlm-2681	146	31	prophylactic	prophylactic	ADJ
ajlm-2681	146	32	and	and	CCONJ
ajlm-2681	146	33	therapeutic	therapeutic	ADJ
ajlm-2681	146	34	dose	dose	NOUN
ajlm-2681	146	35	enoxaparin	enoxaparin	NOUN
ajlm-2681	146	36	,	,	PUNCT
ajlm-2681	146	37	there	there	PRON
ajlm-2681	146	38	was	be	VERB
ajlm-2681	146	39	no	no	DET
ajlm-2681	146	40	clinically	clinically	ADV
ajlm-2681	146	41	significant	significant	ADJ
ajlm-2681	146	42	difference	difference	NOUN
ajlm-2681	146	43	.	.	PUNCT
ajlm-2681	147	1	this	this	DET
ajlm-2681	147	2	finding	finding	NOUN
ajlm-2681	147	3	is	be	AUX
ajlm-2681	147	4	confirmed	confirm	VERB
ajlm-2681	147	5	by	by	ADP
ajlm-2681	147	6	lloyd	lloyd	PROPN
ajlm-2681	147	7	-	-	PUNCT
ajlm-2681	147	8	donald	donald	PROPN
ajlm-2681	147	9	et	et	PROPN
ajlm-2681	147	10	al	al	PROPN
ajlm-2681	147	11	.	.	PUNCT
ajlm-2681	148	1	(	(	PUNCT
ajlm-2681	148	2	australia	australia	PROPN
ajlm-2681	148	3	,	,	PUNCT
ajlm-2681	148	4	2020	2020	NUM
ajlm-2681	148	5	)	)	PUNCT
ajlm-2681	148	6	who	who	PRON
ajlm-2681	148	7	failed	fail	VERB
ajlm-2681	148	8	to	to	PART
ajlm-2681	148	9	find	find	VERB
ajlm-2681	148	10	any	any	DET
ajlm-2681	148	11	clinically	clinically	ADV
ajlm-2681	148	12	significant	significant	ADJ
ajlm-2681	148	13	relationship	relationship	NOUN
ajlm-2681	148	14	in	in	ADP
ajlm-2681	148	15	a30.28	a30.28	NOUN
ajlm-2681	148	16	however	however	ADV
ajlm-2681	148	17	,	,	PUNCT
ajlm-2681	148	18	our	our	PRON
ajlm-2681	148	19	finding	finding	NOUN
ajlm-2681	148	20	is	be	AUX
ajlm-2681	148	21	an	an	DET
ajlm-2681	148	22	interesting	interesting	ADJ
ajlm-2681	148	23	one	one	NOUN
ajlm-2681	148	24	,	,	PUNCT
ajlm-2681	148	25	and	and	CCONJ
ajlm-2681	148	26	may	may	AUX
ajlm-2681	148	27	require	require	VERB
ajlm-2681	148	28	further	further	ADJ
ajlm-2681	148	29	investigation	investigation	NOUN
ajlm-2681	148	30	on	on	ADP
ajlm-2681	148	31	the	the	DET
ajlm-2681	148	32	effect	effect	NOUN
ajlm-2681	148	33	of	of	ADP
ajlm-2681	148	34	enoxaparin	enoxaparin	NOUN
ajlm-2681	148	35	on	on	ADP
ajlm-2681	148	36	fibrinolysis	fibrinolysis	NOUN
ajlm-2681	148	37	.	.	PUNCT
ajlm-2681	149	1	limitations	limitation	NOUN
ajlm-2681	149	2	our	our	PRON
ajlm-2681	149	3	study	study	NOUN
ajlm-2681	149	4	had	have	VERB
ajlm-2681	149	5	several	several	ADJ
ajlm-2681	149	6	limitations	limitation	NOUN
ajlm-2681	149	7	which	which	PRON
ajlm-2681	149	8	need	need	VERB
ajlm-2681	149	9	to	to	PART
ajlm-2681	149	10	be	be	AUX
ajlm-2681	149	11	considered	consider	VERB
ajlm-2681	149	12	.	.	PUNCT
ajlm-2681	150	1	firstly	firstly	ADV
ajlm-2681	150	2	,	,	PUNCT
ajlm-2681	150	3	we	we	PRON
ajlm-2681	150	4	included	include	VERB
ajlm-2681	150	5	a	a	DET
ajlm-2681	150	6	limited	limited	ADJ
ajlm-2681	150	7	sample	sample	NOUN
ajlm-2681	150	8	size	size	NOUN
ajlm-2681	150	9	,	,	PUNCT
ajlm-2681	150	10	which	which	PRON
ajlm-2681	150	11	is	be	AUX
ajlm-2681	150	12	open	open	ADJ
ajlm-2681	150	13	to	to	ADP
ajlm-2681	150	14	large	large	ADJ
ajlm-2681	150	15	variations	variation	NOUN
ajlm-2681	150	16	in	in	ADP
ajlm-2681	150	17	precision	precision	NOUN
ajlm-2681	150	18	.	.	PUNCT
ajlm-2681	151	1	secondly	secondly	ADV
ajlm-2681	151	2	,	,	PUNCT
ajlm-2681	151	3	although	although	SCONJ
ajlm-2681	151	4	we	we	PRON
ajlm-2681	151	5	had	have	VERB
ajlm-2681	151	6	two	two	NUM
ajlm-2681	151	7	dosing	dosing	ADJ
ajlm-2681	151	8	strategies	strategy	NOUN
ajlm-2681	151	9	of	of	ADP
ajlm-2681	151	10	enoxaparin	enoxaparin	NOUN
ajlm-2681	151	11	,	,	PUNCT
ajlm-2681	151	12	the	the	DET
ajlm-2681	151	13	exact	exact	NOUN
ajlm-2681	151	14	dose	dose	NOUN
ajlm-2681	151	15	in	in	ADP
ajlm-2681	151	16	the	the	DET
ajlm-2681	151	17	therapeutic	therapeutic	ADJ
ajlm-2681	151	18	dosed	dose	VERB
ajlm-2681	151	19	group	group	NOUN
ajlm-2681	151	20	was	be	AUX
ajlm-2681	151	21	not	not	PART
ajlm-2681	151	22	considered	consider	VERB
ajlm-2681	151	23	for	for	ADP
ajlm-2681	151	24	the	the	DET
ajlm-2681	151	25	analysis	analysis	NOUN
ajlm-2681	151	26	.	.	PUNCT
ajlm-2681	152	1	the	the	DET
ajlm-2681	152	2	data	datum	NOUN
ajlm-2681	152	3	are	be	AUX
ajlm-2681	152	4	also	also	ADV
ajlm-2681	152	5	limited	limit	VERB
ajlm-2681	152	6	by	by	ADP
ajlm-2681	152	7	use	use	NOUN
ajlm-2681	152	8	of	of	ADP
ajlm-2681	152	9	a	a	DET
ajlm-2681	152	10	single	single	ADJ
ajlm-2681	152	11	lmwh	lmwh	NOUN
ajlm-2681	152	12	medication	medication	NOUN
ajlm-2681	152	13	(	(	PUNCT
ajlm-2681	152	14	enoxaparin	enoxaparin	NOUN
ajlm-2681	152	15	)	)	PUNCT
ajlm-2681	152	16	and	and	CCONJ
ajlm-2681	152	17	are	be	AUX
ajlm-2681	152	18	likely	likely	ADJ
ajlm-2681	152	19	not	not	PART
ajlm-2681	152	20	to	to	PART
ajlm-2681	152	21	apply	apply	VERB
ajlm-2681	152	22	exactly	exactly	ADV
ajlm-2681	152	23	to	to	ADP
ajlm-2681	152	24	other	other	ADJ
ajlm-2681	152	25	anticoagulants	anticoagulant	NOUN
ajlm-2681	152	26	.	.	PUNCT
ajlm-2681	153	1	the	the	DET
ajlm-2681	153	2	nature	nature	NOUN
ajlm-2681	153	3	of	of	ADP
ajlm-2681	153	4	a	a	DET
ajlm-2681	153	5	single	single	ADJ
ajlm-2681	153	6	centre	centre	NOUN
ajlm-2681	153	7	study	study	NOUN
ajlm-2681	153	8	limits	limit	VERB
ajlm-2681	153	9	the	the	DET
ajlm-2681	153	10	generalisability	generalisability	NOUN
ajlm-2681	153	11	of	of	ADP
ajlm-2681	153	12	the	the	DET
ajlm-2681	153	13	findings	finding	NOUN
ajlm-2681	153	14	.	.	PUNCT
ajlm-2681	154	1	however	however	ADV
ajlm-2681	154	2	,	,	PUNCT
ajlm-2681	154	3	given	give	VERB
ajlm-2681	154	4	the	the	DET
ajlm-2681	154	5	limited	limit	VERB
ajlm-2681	154	6	published	publish	VERB
ajlm-2681	154	7	data	datum	NOUN
ajlm-2681	154	8	available	available	ADJ
ajlm-2681	154	9	,	,	PUNCT
ajlm-2681	154	10	our	our	PRON
ajlm-2681	154	11	study	study	NOUN
ajlm-2681	154	12	findings	finding	NOUN
ajlm-2681	154	13	are	be	AUX
ajlm-2681	154	14	not	not	PART
ajlm-2681	154	15	insignificant	insignificant	ADJ
ajlm-2681	154	16	,	,	PUNCT
ajlm-2681	154	17	given	give	VERB
ajlm-2681	154	18	that	that	SCONJ
ajlm-2681	154	19	they	they	PRON
ajlm-2681	154	20	contribute	contribute	VERB
ajlm-2681	154	21	the	the	DET
ajlm-2681	154	22	second	second	ADV
ajlm-2681	154	23	largest	large	ADJ
ajlm-2681	154	24	published	publish	VERB
ajlm-2681	154	25	sample	sample	NOUN
ajlm-2681	154	26	sized	sized	ADJ
ajlm-2681	154	27	study	study	NOUN
ajlm-2681	154	28	.	.	PUNCT
ajlm-2681	155	1	conclusion	conclusion	NOUN
ajlm-2681	155	2	we	we	PRON
ajlm-2681	155	3	have	have	AUX
ajlm-2681	155	4	demonstrated	demonstrate	VERB
ajlm-2681	155	5	that	that	SCONJ
ajlm-2681	155	6	the	the	DET
ajlm-2681	155	7	tci	tci	NOUN
ajlm-2681	155	8	(	(	PUNCT
ajlm-2681	155	9	comprising	comprise	VERB
ajlm-2681	155	10	r	r	NOUN
ajlm-2681	155	11	-	-	PUNCT
ajlm-2681	155	12	time	time	NOUN
ajlm-2681	155	13	,	,	PUNCT
ajlm-2681	155	14	k	k	NOUN
ajlm-2681	155	15	-	-	NOUN
ajlm-2681	155	16	time	time	NOUN
ajlm-2681	155	17	,	,	PUNCT
ajlm-2681	155	18	and	and	CCONJ
ajlm-2681	155	19	alpha	alpha	NOUN
ajlm-2681	155	20	angle	angle	NOUN
ajlm-2681	155	21	)	)	PUNCT
ajlm-2681	155	22	is	be	AUX
ajlm-2681	155	23	statistically	statistically	ADV
ajlm-2681	155	24	significantly	significantly	ADV
ajlm-2681	155	25	correlated	correlate	VERB
ajlm-2681	155	26	with	with	ADP
ajlm-2681	155	27	anti	anti	ADJ
ajlm-2681	155	28	-	-	ADJ
ajlm-2681	155	29	xa	xa	ADJ
ajlm-2681	155	30	levels	level	NOUN
ajlm-2681	155	31	in	in	ADP
ajlm-2681	155	32	this	this	DET
ajlm-2681	155	33	study	study	NOUN
ajlm-2681	155	34	sample	sample	NOUN
ajlm-2681	155	35	receiving	receive	VERB
ajlm-2681	155	36	lmwh	lmwh	NOUN
ajlm-2681	155	37	.	.	PUNCT
ajlm-2681	156	1	in	in	ADP
ajlm-2681	156	2	particular	particular	ADJ
ajlm-2681	156	3	,	,	PUNCT
ajlm-2681	156	4	tci	tci	PROPN
ajlm-2681	156	5	values	value	NOUN
ajlm-2681	156	6	appear	appear	VERB
ajlm-2681	156	7	to	to	PART
ajlm-2681	156	8	increase	increase	VERB
ajlm-2681	156	9	as	as	SCONJ
ajlm-2681	156	10	anti	anti	ADJ
ajlm-2681	156	11	-	-	ADJ
ajlm-2681	156	12	xa	xa	ADJ
ajlm-2681	156	13	levels	level	NOUN
ajlm-2681	156	14	increase	increase	VERB
ajlm-2681	156	15	.	.	PUNCT
ajlm-2681	157	1	it	it	PRON
ajlm-2681	157	2	would	would	AUX
ajlm-2681	157	3	be	be	AUX
ajlm-2681	157	4	useful	useful	ADJ
ajlm-2681	157	5	to	to	PART
ajlm-2681	157	6	see	see	VERB
ajlm-2681	157	7	if	if	SCONJ
ajlm-2681	157	8	this	this	DET
ajlm-2681	157	9	finding	finding	NOUN
ajlm-2681	157	10	is	be	AUX
ajlm-2681	157	11	replicated	replicate	VERB
ajlm-2681	157	12	in	in	ADP
ajlm-2681	157	13	other	other	ADJ
ajlm-2681	157	14	studies	study	NOUN
ajlm-2681	157	15	and	and	CCONJ
ajlm-2681	157	16	,	,	PUNCT
ajlm-2681	157	17	if	if	SCONJ
ajlm-2681	157	18	so	so	ADV
ajlm-2681	157	19	,	,	PUNCT
ajlm-2681	157	20	why	why	SCONJ
ajlm-2681	157	21	.	.	PUNCT
ajlm-2681	158	1	our	our	PRON
ajlm-2681	158	2	findings	finding	NOUN
ajlm-2681	158	3	should	should	AUX
ajlm-2681	158	4	be	be	AUX
ajlm-2681	158	5	interpreted	interpret	VERB
ajlm-2681	158	6	with	with	ADP
ajlm-2681	158	7	reserve	reserve	NOUN
ajlm-2681	158	8	and	and	CCONJ
ajlm-2681	158	9	do	do	AUX
ajlm-2681	158	10	not	not	PART
ajlm-2681	158	11	mean	mean	VERB
ajlm-2681	158	12	that	that	SCONJ
ajlm-2681	158	13	tci	tci	PROPN
ajlm-2681	158	14	can	can	AUX
ajlm-2681	158	15	replace	replace	VERB
ajlm-2681	158	16	anti	anti	ADJ
ajlm-2681	158	17	-	-	ADJ
ajlm-2681	158	18	xa	xa	ADJ
ajlm-2681	158	19	testing	testing	NOUN
ajlm-2681	158	20	.	.	PUNCT
ajlm-2681	159	1	anti	anti	ADJ
ajlm-2681	159	2	-	-	PROPN
ajlm-2681	159	3	xa	xa	PROPN
ajlm-2681	159	4	levels	level	NOUN
ajlm-2681	159	5	were	be	AUX
ajlm-2681	159	6	associated	associate	VERB
ajlm-2681	159	7	with	with	ADP
ajlm-2681	159	8	the	the	DET
ajlm-2681	159	9	dose	dose	NOUN
ajlm-2681	159	10	of	of	ADP
ajlm-2681	159	11	lmwh	lmwh	NOUN
ajlm-2681	159	12	(	(	PUNCT
ajlm-2681	159	13	as	as	SCONJ
ajlm-2681	159	14	expected	expect	VERB
ajlm-2681	159	15	)	)	PUNCT
ajlm-2681	159	16	,	,	PUNCT
ajlm-2681	159	17	with	with	ADP
ajlm-2681	159	18	lysis	lysis	NOUN
ajlm-2681	159	19	time	time	NOUN
ajlm-2681	159	20	at	at	ADP
ajlm-2681	159	21	30	30	NUM
ajlm-2681	159	22	min	min	NOUN
ajlm-2681	159	23	being	be	AUX
ajlm-2681	159	24	the	the	DET
ajlm-2681	159	25	thromboelastogram	thromboelastogram	NOUN
ajlm-2681	159	26	parameter	parameter	NOUN
ajlm-2681	159	27	associated	associate	VERB
ajlm-2681	159	28	with	with	ADP
ajlm-2681	159	29	lmwh	lmwh	PROPN
ajlm-2681	159	30	dose	dose	NOUN
ajlm-2681	159	31	(	(	PUNCT
ajlm-2681	159	32	an	an	DET
ajlm-2681	159	33	interesting	interesting	ADJ
ajlm-2681	159	34	finding	finding	NOUN
ajlm-2681	159	35	worth	worth	ADJ
ajlm-2681	159	36	further	further	ADJ
ajlm-2681	159	37	investigation	investigation	NOUN
ajlm-2681	159	38	regarding	regard	VERB
ajlm-2681	159	39	the	the	DET
ajlm-2681	159	40	relationship	relationship	NOUN
ajlm-2681	159	41	between	between	ADP
ajlm-2681	159	42	lmwh	lmwh	NOUN
ajlm-2681	159	43	and	and	CCONJ
ajlm-2681	159	44	fibrinolysis	fibrinolysis	NOUN
ajlm-2681	159	45	)	)	PUNCT
ajlm-2681	159	46	.	.	PUNCT
ajlm-2681	160	1	the	the	DET
ajlm-2681	160	2	possibility	possibility	NOUN
ajlm-2681	160	3	should	should	AUX
ajlm-2681	160	4	also	also	ADV
ajlm-2681	160	5	be	be	AUX
ajlm-2681	160	6	considered	consider	VERB
ajlm-2681	160	7	that	that	SCONJ
ajlm-2681	160	8	the	the	DET
ajlm-2681	160	9	high	high	ADJ
ajlm-2681	160	10	tci	tci	PROPN
ajlm-2681	160	11	values	value	NOUN
ajlm-2681	160	12	obtained	obtain	VERB
ajlm-2681	160	13	in	in	ADP
ajlm-2681	160	14	patients	patient	NOUN
ajlm-2681	160	15	with	with	ADP
ajlm-2681	160	16	higher	high	ADJ
ajlm-2681	160	17	anti	anti	ADJ
ajlm-2681	160	18	-	-	ADJ
ajlm-2681	160	19	xa	xa	ADJ
ajlm-2681	160	20	levels	level	NOUN
ajlm-2681	160	21	are	be	AUX
ajlm-2681	160	22	merely	merely	ADV
ajlm-2681	160	23	a	a	DET
ajlm-2681	160	24	reflection	reflection	NOUN
ajlm-2681	160	25	of	of	ADP
ajlm-2681	160	26	the	the	DET
ajlm-2681	160	27	hypercoagulability	hypercoagulability	NOUN
ajlm-2681	160	28	present	present	ADJ
ajlm-2681	160	29	in	in	ADP
ajlm-2681	160	30	these	these	DET
ajlm-2681	160	31	patients	patient	NOUN
ajlm-2681	160	32	(	(	PUNCT
ajlm-2681	160	33	who	who	PRON
ajlm-2681	160	34	are	be	AUX
ajlm-2681	160	35	correctly	correctly	ADV
ajlm-2681	160	36	,	,	PUNCT
ajlm-2681	160	37	it	it	PRON
ajlm-2681	160	38	would	would	AUX
ajlm-2681	160	39	seem	seem	VERB
ajlm-2681	160	40	,	,	PUNCT
ajlm-2681	160	41	treated	treat	VERB
ajlm-2681	160	42	with	with	ADP
ajlm-2681	160	43	higher	high	ADJ
ajlm-2681	160	44	doses	dose	NOUN
ajlm-2681	160	45	of	of	ADP
ajlm-2681	160	46	enoxaparin	enoxaparin	NOUN
ajlm-2681	160	47	)	)	PUNCT
ajlm-2681	160	48	,	,	PUNCT
ajlm-2681	160	49	and	and	CCONJ
ajlm-2681	160	50	that	that	SCONJ
ajlm-2681	160	51	these	these	DET
ajlm-2681	160	52	high	high	ADJ
ajlm-2681	160	53	tci	tci	NOUN
ajlm-2681	160	54	values	value	NOUN
ajlm-2681	160	55	have	have	VERB
ajlm-2681	160	56	no	no	DET
ajlm-2681	160	57	direct	direct	ADJ
ajlm-2681	160	58	relationship	relationship	NOUN
ajlm-2681	160	59	with	with	ADP
ajlm-2681	160	60	the	the	DET
ajlm-2681	160	61	measured	measured	ADJ
ajlm-2681	160	62	anti	anti	ADJ
ajlm-2681	160	63	-	-	ADJ
ajlm-2681	160	64	xa	xa	ADJ
ajlm-2681	160	65	levels	level	NOUN
ajlm-2681	160	66	at	at	ADV
ajlm-2681	160	67	all	all	ADV
ajlm-2681	160	68	,	,	PUNCT
ajlm-2681	160	69	but	but	CCONJ
ajlm-2681	160	70	rather	rather	ADV
ajlm-2681	160	71	with	with	ADP
ajlm-2681	160	72	the	the	DET
ajlm-2681	160	73	particular	particular	ADJ
ajlm-2681	160	74	patient	patient	NOUN
ajlm-2681	160	75	group	group	NOUN
ajlm-2681	160	76	receiving	receive	VERB
ajlm-2681	160	77	higher	high	ADJ
ajlm-2681	160	78	enoxaparin	enoxaparin	NOUN
ajlm-2681	160	79	doses	dose	NOUN
ajlm-2681	160	80	.	.	PUNCT
ajlm-2681	161	1	this	this	DET
ajlm-2681	161	2	study	study	NOUN
ajlm-2681	161	3	serves	serve	VERB
ajlm-2681	161	4	as	as	ADP
ajlm-2681	161	5	a	a	DET
ajlm-2681	161	6	basis	basis	NOUN
ajlm-2681	161	7	for	for	ADP
ajlm-2681	161	8	future	future	ADJ
ajlm-2681	161	9	research	research	NOUN
ajlm-2681	161	10	with	with	ADP
ajlm-2681	161	11	larger	large	ADJ
ajlm-2681	161	12	sample	sample	NOUN
ajlm-2681	161	13	sizes	size	NOUN
ajlm-2681	161	14	,	,	PUNCT
ajlm-2681	161	15	including	include	VERB
ajlm-2681	161	16	patients	patient	NOUN
ajlm-2681	161	17	with	with	ADP
ajlm-2681	161	18	varying	vary	VERB
ajlm-2681	161	19	disease	disease	NOUN
ajlm-2681	161	20	profiles	profile	NOUN
ajlm-2681	161	21	and	and	CCONJ
ajlm-2681	161	22	severity	severity	NOUN
ajlm-2681	161	23	of	of	ADP
ajlm-2681	161	24	illness	illness	NOUN
ajlm-2681	161	25	.	.	PUNCT
ajlm-2681	162	1	further	further	ADJ
ajlm-2681	162	2	studies	study	NOUN
ajlm-2681	162	3	should	should	AUX
ajlm-2681	162	4	focus	focus	VERB
ajlm-2681	162	5	on	on	ADP
ajlm-2681	162	6	threshold	threshold	NOUN
ajlm-2681	162	7	values	value	NOUN
ajlm-2681	162	8	for	for	ADP
ajlm-2681	162	9	r	r	NOUN
ajlm-2681	162	10	-	-	PUNCT
ajlm-2681	162	11	time	time	NOUN
ajlm-2681	162	12	and	and	CCONJ
ajlm-2681	162	13	other	other	ADJ
ajlm-2681	162	14	thromboelastogram	thromboelastogram	NOUN
ajlm-2681	162	15	indices	index	NOUN
ajlm-2681	162	16	that	that	PRON
ajlm-2681	162	17	indicate	indicate	VERB
ajlm-2681	162	18	specific	specific	ADJ
ajlm-2681	162	19	anticoagulation	anticoagulation	NOUN
ajlm-2681	162	20	targets	target	NOUN
ajlm-2681	162	21	.	.	PUNCT
ajlm-2681	163	1	acknowledgements	acknowledgement	NOUN
ajlm-2681	163	2	this	this	DET
ajlm-2681	163	3	article	article	NOUN
ajlm-2681	163	4	is	be	AUX
ajlm-2681	163	5	partially	partially	ADV
ajlm-2681	163	6	based	base	VERB
ajlm-2681	163	7	on	on	ADP
ajlm-2681	163	8	the	the	DET
ajlm-2681	163	9	b.p	b.p	PROPN
ajlm-2681	163	10	’s	’s	PART
ajlm-2681	163	11	thesis	thesis	NOUN
ajlm-2681	163	12	entitled	entitle	VERB
ajlm-2681	163	13	‘	'	PUNCT
ajlm-2681	163	14	thromboelastography	thromboelastography	NOUN
ajlm-2681	163	15	in	in	ADP
ajlm-2681	163	16	covid-19	covid-19	PROPN
ajlm-2681	163	17	patients	patient	NOUN
ajlm-2681	163	18	:	:	PUNCT
ajlm-2681	163	19	an	an	DET
ajlm-2681	163	20	observational	observational	ADJ
ajlm-2681	163	21	study	study	NOUN
ajlm-2681	163	22	in	in	ADP
ajlm-2681	163	23	the	the	DET
ajlm-2681	163	24	south	south	ADJ
ajlm-2681	163	25	african	african	ADJ
ajlm-2681	163	26	context	context	NOUN
ajlm-2681	163	27	’	'	PUNCT
ajlm-2681	163	28	towards	towards	ADP
ajlm-2681	163	29	the	the	DET
ajlm-2681	163	30	degree	degree	NOUN
ajlm-2681	163	31	of	of	ADP
ajlm-2681	163	32	masters	master	NOUN
ajlm-2681	163	33	in	in	ADP
ajlm-2681	163	34	medicine	medicine	NOUN
ajlm-2681	163	35	in	in	ADP
ajlm-2681	163	36	the	the	DET
ajlm-2681	163	37	department	department	NOUN
ajlm-2681	163	38	of	of	ADP
ajlm-2681	163	39	internal	internal	ADJ
ajlm-2681	163	40	medicine	medicine	NOUN
ajlm-2681	163	41	,	,	PUNCT
ajlm-2681	163	42	university	university	NOUN
ajlm-2681	163	43	of	of	ADP
ajlm-2681	163	44	the	the	DET
ajlm-2681	163	45	witwatersrand	witwatersrand	NOUN
ajlm-2681	163	46	,	,	PUNCT
ajlm-2681	163	47	south	south	PROPN
ajlm-2681	163	48	africa	africa	PROPN
ajlm-2681	163	49	on	on	ADP
ajlm-2681	163	50	20	20	NUM
ajlm-2681	163	51	december	december	PROPN
ajlm-2681	163	52	2024	2024	NUM
ajlm-2681	163	53	,	,	PUNCT
ajlm-2681	163	54	with	with	ADP
ajlm-2681	163	55	supervisors	supervisor	NOUN
ajlm-2681	163	56	dr	dr	PROPN
ajlm-2681	163	57	s.a	s.a	PROPN
ajlm-2681	163	58	.	.	PROPN
ajlm-2681	163	59	van	van	PROPN
ajlm-2681	163	60	blydenstein	blydenstein	PROPN
ajlm-2681	163	61	and	and	CCONJ
ajlm-2681	163	62	professor	professor	NOUN
ajlm-2681	163	63	s.	s.	PROPN
ajlm-2681	163	64	omar	omar	PROPN
ajlm-2681	163	65	.	.	PUNCT
ajlm-2681	164	1	competing	compete	VERB
ajlm-2681	164	2	interests	interest	NOUN
ajlm-2681	164	3	the	the	DET
ajlm-2681	164	4	authors	author	NOUN
ajlm-2681	164	5	declare	declare	VERB
ajlm-2681	164	6	that	that	SCONJ
ajlm-2681	164	7	they	they	PRON
ajlm-2681	164	8	have	have	VERB
ajlm-2681	164	9	no	no	DET
ajlm-2681	164	10	financial	financial	ADJ
ajlm-2681	164	11	or	or	CCONJ
ajlm-2681	164	12	personal	personal	ADJ
ajlm-2681	164	13	relationships	relationship	NOUN
ajlm-2681	164	14	that	that	PRON
ajlm-2681	164	15	may	may	AUX
ajlm-2681	164	16	have	have	AUX
ajlm-2681	164	17	inappropriately	inappropriately	ADV
ajlm-2681	164	18	influenced	influence	VERB
ajlm-2681	164	19	them	they	PRON
ajlm-2681	164	20	in	in	ADP
ajlm-2681	164	21	writing	write	VERB
ajlm-2681	164	22	this	this	DET
ajlm-2681	164	23	article	article	NOUN
ajlm-2681	164	24	.	.	PUNCT
ajlm-2681	165	1	teg	teg	PROPN
ajlm-2681	165	2	®	®	NOUN
ajlm-2681	165	3	6s	6s	NUM
ajlm-2681	165	4	cartridges	cartridge	NOUN
ajlm-2681	165	5	were	be	AUX
ajlm-2681	165	6	provided	provide	VERB
ajlm-2681	165	7	by	by	ADP
ajlm-2681	165	8	qiagen	qiagen	PROPN
ajlm-2681	165	9	.	.	PUNCT
ajlm-2681	166	1	qiagen	qiagen	PROPN
ajlm-2681	166	2	had	have	VERB
ajlm-2681	166	3	no	no	DET
ajlm-2681	166	4	role	role	NOUN
ajlm-2681	166	5	in	in	ADP
ajlm-2681	166	6	the	the	DET
ajlm-2681	166	7	study	study	NOUN
ajlm-2681	166	8	design	design	NOUN
ajlm-2681	166	9	,	,	PUNCT
ajlm-2681	166	10	the	the	DET
ajlm-2681	166	11	collection	collection	NOUN
ajlm-2681	166	12	,	,	PUNCT
ajlm-2681	166	13	analysis	analysis	NOUN
ajlm-2681	166	14	,	,	PUNCT
ajlm-2681	166	15	and	and	CCONJ
ajlm-2681	166	16	interpretation	interpretation	NOUN
ajlm-2681	166	17	of	of	ADP
ajlm-2681	166	18	data	datum	NOUN
ajlm-2681	166	19	,	,	PUNCT
ajlm-2681	166	20	in	in	ADP
ajlm-2681	166	21	writing	writing	NOUN
ajlm-2681	166	22	of	of	ADP
ajlm-2681	166	23	the	the	DET
ajlm-2681	166	24	report	report	NOUN
ajlm-2681	166	25	,	,	PUNCT
ajlm-2681	166	26	or	or	CCONJ
ajlm-2681	166	27	in	in	ADP
ajlm-2681	166	28	the	the	DET
ajlm-2681	166	29	decision	decision	NOUN
ajlm-2681	166	30	to	to	PART
ajlm-2681	166	31	submit	submit	VERB
ajlm-2681	166	32	the	the	DET
ajlm-2681	166	33	article	article	NOUN
ajlm-2681	166	34	for	for	ADP
ajlm-2681	166	35	publication	publication	NOUN
ajlm-2681	166	36	.	.	PUNCT
ajlm-2681	167	1	authors	author	NOUN
ajlm-2681	167	2	’	'	PUNCT
ajlm-2681	167	3	contributions	contribution	NOUN
ajlm-2681	167	4	b.p	b.p	PROPN
ajlm-2681	167	5	.	.	PROPN
ajlm-2681	167	6	,	,	PUNCT
ajlm-2681	167	7	s.a.v.b	s.a.v.b	PROPN
ajlm-2681	167	8	.	.	PROPN
ajlm-2681	167	9	,	,	PUNCT
ajlm-2681	167	10	and	and	CCONJ
ajlm-2681	167	11	s.o	s.o	PROPN
ajlm-2681	167	12	.	.	PROPN
ajlm-2681	167	13	contributed	contribute	VERB
ajlm-2681	167	14	to	to	PART
ajlm-2681	167	15	study	study	VERB
ajlm-2681	167	16	conception	conception	NOUN
ajlm-2681	167	17	and	and	CCONJ
ajlm-2681	167	18	design	design	NOUN
ajlm-2681	167	19	.	.	PUNCT
ajlm-2681	168	1	s.o	s.o	PROPN
ajlm-2681	168	2	.	.	PROPN
ajlm-2681	168	3	and	and	CCONJ
ajlm-2681	168	4	b.p	b.p	PROPN
ajlm-2681	168	5	.	.	PROPN
ajlm-2681	168	6	contributed	contribute	VERB
ajlm-2681	168	7	to	to	ADP
ajlm-2681	168	8	analysis	analysis	NOUN
ajlm-2681	168	9	and	and	CCONJ
ajlm-2681	168	10	interpretation	interpretation	NOUN
ajlm-2681	168	11	of	of	ADP
ajlm-2681	168	12	results	result	NOUN
ajlm-2681	168	13	.	.	PUNCT
ajlm-2681	169	1	b.p	b.p	PROPN
ajlm-2681	169	2	.	.	PROPN
ajlm-2681	169	3	and	and	CCONJ
ajlm-2681	169	4	s.a.v.b	s.a.v.b	PROPN
ajlm-2681	169	5	.	.	PROPN
ajlm-2681	169	6	were	be	AUX
ajlm-2681	169	7	responsible	responsible	ADJ
ajlm-2681	169	8	for	for	ADP
ajlm-2681	169	9	the	the	DET
ajlm-2681	169	10	preparation	preparation	NOUN
ajlm-2681	169	11	of	of	ADP
ajlm-2681	169	12	the	the	DET
ajlm-2681	169	13	draft	draft	NOUN
ajlm-2681	169	14	manuscript	manuscript	NOUN
ajlm-2681	169	15	.	.	PUNCT
ajlm-2681	170	1	b.p	b.p	PROPN
ajlm-2681	170	2	.	.	PROPN
ajlm-2681	170	3	,	,	PUNCT
ajlm-2681	170	4	s.a.v.b	s.a.v.b	PROPN
ajlm-2681	170	5	.	.	PROPN
ajlm-2681	170	6	,	,	PUNCT
ajlm-2681	170	7	and	and	CCONJ
ajlm-2681	170	8	s.o	s.o	PROPN
ajlm-2681	170	9	.	.	PROPN
ajlm-2681	170	10	reviewed	review	VERB
ajlm-2681	170	11	the	the	DET
ajlm-2681	170	12	results	result	NOUN
ajlm-2681	170	13	and	and	CCONJ
ajlm-2681	170	14	approved	approve	VERB
ajlm-2681	170	15	the	the	DET
ajlm-2681	170	16	final	final	ADJ
ajlm-2681	170	17	version	version	NOUN
ajlm-2681	170	18	of	of	ADP
ajlm-2681	170	19	the	the	DET
ajlm-2681	170	20	article	article	NOUN
ajlm-2681	170	21	.	.	PUNCT
ajlm-2681	171	1	sources	source	NOUN
ajlm-2681	171	2	of	of	ADP
ajlm-2681	171	3	support	support	NOUN
ajlm-2681	171	4	teg	teg	PROPN
ajlm-2681	171	5	®	®	NOUN
ajlm-2681	171	6	6s	6s	NUM
ajlm-2681	171	7	cartridges	cartridge	NOUN
ajlm-2681	171	8	were	be	AUX
ajlm-2681	171	9	provided	provide	VERB
ajlm-2681	171	10	by	by	ADP
ajlm-2681	171	11	qiagen	qiagen	PROPN
ajlm-2681	171	12	.	.	PUNCT
ajlm-2681	172	1	data	datum	NOUN
ajlm-2681	172	2	availability	availability	NOUN
ajlm-2681	172	3	the	the	DET
ajlm-2681	172	4	data	datum	NOUN
ajlm-2681	172	5	that	that	PRON
ajlm-2681	172	6	support	support	VERB
ajlm-2681	172	7	the	the	DET
ajlm-2681	172	8	findings	finding	NOUN
ajlm-2681	172	9	of	of	ADP
ajlm-2681	172	10	this	this	DET
ajlm-2681	172	11	study	study	NOUN
ajlm-2681	172	12	are	be	AUX
ajlm-2681	172	13	not	not	PART
ajlm-2681	172	14	openly	openly	ADV
ajlm-2681	172	15	available	available	ADJ
ajlm-2681	172	16	because	because	SCONJ
ajlm-2681	172	17	of	of	ADP
ajlm-2681	172	18	reasons	reason	NOUN
ajlm-2681	172	19	of	of	ADP
ajlm-2681	172	20	sensitivity	sensitivity	NOUN
ajlm-2681	172	21	(	(	PUNCT
ajlm-2681	172	22	human	human	ADJ
ajlm-2681	172	23	data	data	PROPN
ajlm-2681	172	24	)	)	PUNCT
ajlm-2681	172	25	and	and	CCONJ
ajlm-2681	172	26	are	be	AUX
ajlm-2681	172	27	available	available	ADJ
ajlm-2681	172	28	from	from	ADP
ajlm-2681	172	29	the	the	DET
ajlm-2681	172	30	corresponding	corresponding	ADJ
ajlm-2681	172	31	author	author	NOUN
ajlm-2681	172	32	,	,	PUNCT
ajlm-2681	172	33	b.p	b.p	PROPN
ajlm-2681	172	34	.	.	PROPN
ajlm-2681	172	35	,	,	PUNCT
ajlm-2681	172	36	upon	upon	SCONJ
ajlm-2681	172	37	reasonable	reasonable	ADJ
ajlm-2681	172	38	request	request	NOUN
ajlm-2681	172	39	.	.	PUNCT
ajlm-2681	173	1	disclaimer	disclaimer	VERB
ajlm-2681	173	2	the	the	DET
ajlm-2681	173	3	views	view	NOUN
ajlm-2681	173	4	and	and	CCONJ
ajlm-2681	173	5	opinions	opinion	NOUN
ajlm-2681	173	6	expressed	express	VERB
ajlm-2681	173	7	in	in	ADP
ajlm-2681	173	8	this	this	DET
ajlm-2681	173	9	article	article	NOUN
ajlm-2681	173	10	are	be	AUX
ajlm-2681	173	11	those	those	PRON
ajlm-2681	173	12	of	of	ADP
ajlm-2681	173	13	the	the	DET
ajlm-2681	173	14	authors	author	NOUN
ajlm-2681	173	15	and	and	CCONJ
ajlm-2681	173	16	are	be	AUX
ajlm-2681	173	17	the	the	DET
ajlm-2681	173	18	product	product	NOUN
ajlm-2681	173	19	of	of	ADP
ajlm-2681	173	20	professional	professional	ADJ
ajlm-2681	173	21	research	research	NOUN
ajlm-2681	173	22	.	.	PUNCT
ajlm-2681	174	1	the	the	DET
ajlm-2681	174	2	article	article	NOUN
ajlm-2681	174	3	does	do	AUX
ajlm-2681	174	4	not	not	PART
ajlm-2681	174	5	necessarily	necessarily	ADV
ajlm-2681	174	6	reflect	reflect	VERB
ajlm-2681	174	7	the	the	DET
ajlm-2681	174	8	official	official	ADJ
ajlm-2681	174	9	policy	policy	NOUN
ajlm-2681	174	10	or	or	CCONJ
ajlm-2681	174	11	position	position	NOUN
ajlm-2681	174	12	of	of	ADP
ajlm-2681	174	13	any	any	DET
ajlm-2681	174	14	affiliated	affiliated	ADJ
ajlm-2681	174	15	institution	institution	NOUN
ajlm-2681	174	16	,	,	PUNCT
ajlm-2681	174	17	funder	funder	NOUN
ajlm-2681	174	18	,	,	PUNCT
ajlm-2681	174	19	agency	agency	NOUN
ajlm-2681	174	20	,	,	PUNCT
ajlm-2681	174	21	or	or	CCONJ
ajlm-2681	174	22	that	that	PRON
ajlm-2681	174	23	of	of	ADP
ajlm-2681	174	24	the	the	DET
ajlm-2681	174	25	publisher	publisher	NOUN
ajlm-2681	174	26	.	.	PUNCT
ajlm-2681	175	1	the	the	DET
ajlm-2681	175	2	authors	author	NOUN
ajlm-2681	175	3	are	be	AUX
ajlm-2681	175	4	responsible	responsible	ADJ
ajlm-2681	175	5	for	for	ADP
ajlm-2681	175	6	this	this	DET
ajlm-2681	175	7	article	article	NOUN
ajlm-2681	175	8	’s	’s	PART
ajlm-2681	175	9	results	result	NOUN
ajlm-2681	175	10	,	,	PUNCT
ajlm-2681	175	11	findings	finding	NOUN
ajlm-2681	175	12	,	,	PUNCT
ajlm-2681	175	13	and	and	CCONJ
ajlm-2681	175	14	content	content	NOUN
ajlm-2681	175	15	.	.	PUNCT
ajlm-2681	176	1	references	reference	NOUN
ajlm-2681	176	2	world	world	PROPN
ajlm-2681	176	3	health	health	PROPN
ajlm-2681	176	4	organization	organization	NOUN
ajlm-2681	176	5	.	.	PUNCT
ajlm-2681	177	1	number	number	NOUN
ajlm-2681	177	2	of	of	ADP
ajlm-2681	177	3	covid-19	covid-19	PROPN
ajlm-2681	177	4	cases	case	NOUN
ajlm-2681	177	5	reported	report	VERB
ajlm-2681	177	6	to	to	ADP
ajlm-2681	177	7	who	who	PRON
ajlm-2681	177	8	(	(	PUNCT
ajlm-2681	177	9	cumulative	cumulative	ADJ
ajlm-2681	177	10	total	total	NOUN
ajlm-2681	177	11	)	)	PUNCT
ajlm-2681	177	12	.	.	PUNCT
ajlm-2681	178	1	2021	2021	NUM
ajlm-2681	179	1	[	[	X
ajlm-2681	179	2	cited	cite	VERB
ajlm-2681	179	3	2021	2021	NUM
ajlm-2681	179	4	june	june	PROPN
ajlm-2681	179	5	27	27	NUM
ajlm-2681	179	6	]	]	PUNCT
ajlm-2681	179	7	.	.	PUNCT
ajlm-2681	180	1	available	available	ADJ
ajlm-2681	180	2	from	from	ADP
ajlm-2681	180	3	:	:	PUNCT
ajlm-2681	180	4	https://data.who.int/dashboards/covid19/cases?n=c	https://data.who.int/dashboards/covid19/cases?n=c	NOUN
ajlm-2681	180	5	poor	poor	ADJ
ajlm-2681	180	6	hd	hd	NOUN
ajlm-2681	180	7	.	.	PUNCT
ajlm-2681	180	8	pulmonary	pulmonary	ADJ
ajlm-2681	180	9	thrombosis	thrombosis	NOUN
ajlm-2681	180	10	and	and	CCONJ
ajlm-2681	180	11	thromboembolism	thromboembolism	NOUN
ajlm-2681	180	12	in	in	ADP
ajlm-2681	180	13	covid-19	covid-19	PROPN
ajlm-2681	180	14	.	.	PUNCT
ajlm-2681	180	15	chest	chest	PROPN
ajlm-2681	180	16	.	.	PUNCT
ajlm-2681	181	1	2021;160(4):1471–1480	2021;160(4):1471–1480	NOUN
ajlm-2681	181	2	.	.	PUNCT
ajlm-2681	182	1	https://doi.org/10.1016/j.chest.2021.06.016	https://doi.org/10.1016/j.chest.2021.06.016	PROPN
ajlm-2681	182	2	sakr	sakr	VERB
ajlm-2681	182	3	y	y	PROPN
ajlm-2681	182	4	,	,	PUNCT
ajlm-2681	182	5	giovini	giovini	PROPN
ajlm-2681	182	6	m	m	NOUN
ajlm-2681	182	7	,	,	PUNCT
ajlm-2681	182	8	leone	leone	PROPN
ajlm-2681	182	9	m	m	PROPN
ajlm-2681	182	10	,	,	PUNCT
ajlm-2681	182	11	et	et	PROPN
ajlm-2681	182	12	al	al	PROPN
ajlm-2681	182	13	.	.	PUNCT
ajlm-2681	183	1	pulmonary	pulmonary	ADJ
ajlm-2681	183	2	embolism	embolism	NOUN
ajlm-2681	183	3	in	in	ADP
ajlm-2681	183	4	patients	patient	NOUN
ajlm-2681	183	5	with	with	ADP
ajlm-2681	183	6	coronavirus	coronavirus	NOUN
ajlm-2681	183	7	disease-2019	disease-2019	ADJ
ajlm-2681	183	8	(	(	PUNCT
ajlm-2681	183	9	covid-19	covid-19	PROPN
ajlm-2681	183	10	)	)	PUNCT
ajlm-2681	183	11	pneumonia	pneumonia	NOUN
ajlm-2681	183	12	:	:	PUNCT
ajlm-2681	183	13	a	a	DET
ajlm-2681	183	14	narrative	narrative	NOUN
ajlm-2681	183	15	review	review	NOUN
ajlm-2681	183	16	.	.	PUNCT
ajlm-2681	184	1	ann	ann	PROPN
ajlm-2681	184	2	intensive	intensive	ADJ
ajlm-2681	184	3	care	care	NOUN
ajlm-2681	184	4	.	.	PUNCT
ajlm-2681	185	1	2020;10(1):124	2020;10(1):124	PROPN
ajlm-2681	185	2	.	.	PUNCT
ajlm-2681	186	1	https://doi.org/10.1186/s13613-020-00741-0	https://doi.org/10.1186/s13613-020-00741-0	PROPN
ajlm-2681	186	2	jing	jing	PROPN
ajlm-2681	186	3	h	h	NOUN
ajlm-2681	186	4	,	,	PUNCT
ajlm-2681	186	5	wu	wu	PROPN
ajlm-2681	186	6	x	x	PROPN
ajlm-2681	186	7	,	,	PUNCT
ajlm-2681	186	8	xiang	xiang	PROPN
ajlm-2681	186	9	m	m	PROPN
ajlm-2681	186	10	,	,	PUNCT
ajlm-2681	186	11	liu	liu	PROPN
ajlm-2681	186	12	l	l	PROPN
ajlm-2681	186	13	,	,	PUNCT
ajlm-2681	186	14	novakovic	novakovic	PROPN
ajlm-2681	186	15	va	va	PROPN
ajlm-2681	186	16	,	,	PUNCT
ajlm-2681	186	17	shi	shi	PROPN
ajlm-2681	186	18	j.	j.	PROPN
ajlm-2681	186	19	pathophysiological	pathophysiological	ADJ
ajlm-2681	186	20	mechanisms	mechanism	NOUN
ajlm-2681	186	21	of	of	ADP
ajlm-2681	186	22	thrombosis	thrombosis	NOUN
ajlm-2681	186	23	in	in	ADP
ajlm-2681	186	24	acute	acute	ADJ
ajlm-2681	186	25	and	and	CCONJ
ajlm-2681	186	26	long	long	ADJ
ajlm-2681	186	27	covid-19	covid-19	PROPN
ajlm-2681	186	28	.	.	PUNCT
ajlm-2681	186	29	front	front	ADJ
ajlm-2681	186	30	immunol	immunol	NOUN
ajlm-2681	186	31	.	.	PUNCT
ajlm-2681	187	1	2022;13:992384	2022;13:992384	NUM
ajlm-2681	187	2	.	.	X
ajlm-2681	188	1	https://doi.org/10.3389/fimmu.2022.992384	https://doi.org/10.3389/fimmu.2022.992384	PROPN
ajlm-2681	188	2	schulman	schulman	PROPN
ajlm-2681	188	3	s	s	PROPN
ajlm-2681	188	4	,	,	PUNCT
ajlm-2681	188	5	sholzberg	sholzberg	PROPN
ajlm-2681	188	6	m	m	PROPN
ajlm-2681	188	7	,	,	PUNCT
ajlm-2681	188	8	spyropoulos	spyropoulos	PROPN
ajlm-2681	188	9	ac	ac	PROPN
ajlm-2681	188	10	,	,	PUNCT
ajlm-2681	188	11	zarychanski	zarychanski	PROPN
ajlm-2681	188	12	r	r	PROPN
ajlm-2681	188	13	,	,	PUNCT
ajlm-2681	188	14	resnick	resnick	PROPN
ajlm-2681	188	15	he	he	PRON
ajlm-2681	188	16	,	,	PUNCT
ajlm-2681	188	17	bradbury	bradbury	PROPN
ajlm-2681	188	18	ca	ca	PROPN
ajlm-2681	188	19	,	,	PUNCT
ajlm-2681	188	20	et	et	PROPN
ajlm-2681	188	21	al	al	PROPN
ajlm-2681	188	22	.	.	PUNCT
ajlm-2681	189	1	isth	isth	NOUN
ajlm-2681	189	2	guidelines	guideline	NOUN
ajlm-2681	189	3	for	for	ADP
ajlm-2681	189	4	antithrombotic	antithrombotic	ADJ
ajlm-2681	189	5	treatment	treatment	NOUN
ajlm-2681	189	6	in	in	ADP
ajlm-2681	189	7	covid-19	covid-19	PROPN
ajlm-2681	189	8	.	.	PUNCT
ajlm-2681	190	1	jth	jth	PROPN
ajlm-2681	190	2	.	.	PROPN
ajlm-2681	190	3	2022	2022	NUM
ajlm-2681	190	4	oct;20(10):2214–2225	oct;20(10):2214–2225	NOUN
ajlm-2681	190	5	.	.	PUNCT
ajlm-2681	191	1	dutt	dutt	PROPN
ajlm-2681	191	2	t	t	PROPN
ajlm-2681	191	3	,	,	PUNCT
ajlm-2681	191	4	simcox	simcox	PROPN
ajlm-2681	191	5	d	d	PROPN
ajlm-2681	191	6	,	,	PUNCT
ajlm-2681	191	7	downey	downey	PROPN
ajlm-2681	191	8	c	c	PROPN
ajlm-2681	191	9	,	,	PUNCT
ajlm-2681	191	10	et	et	PROPN
ajlm-2681	191	11	al	al	PROPN
ajlm-2681	191	12	.	.	PROPN
ajlm-2681	191	13	thromboprophylaxis	thromboprophylaxis	PROPN
ajlm-2681	191	14	in	in	ADP
ajlm-2681	191	15	covid-19	covid-19	PROPN
ajlm-2681	191	16	:	:	PUNCT
ajlm-2681	191	17	anti	anti	ADJ
ajlm-2681	191	18	-	-	NOUN
ajlm-2681	191	19	fxa	fxa	NOUN
ajlm-2681	191	20	–	–	PUNCT
ajlm-2681	191	21	the	the	DET
ajlm-2681	191	22	missing	missing	ADJ
ajlm-2681	191	23	factor	factor	NOUN
ajlm-2681	191	24	?	?	PUNCT
ajlm-2681	192	1	am	be	AUX
ajlm-2681	192	2	j	j	PROPN
ajlm-2681	192	3	respir	respir	NOUN
ajlm-2681	192	4	crit	crit	PROPN
ajlm-2681	192	5	care	care	NOUN
ajlm-2681	192	6	med	me	VERB
ajlm-2681	192	7	.	.	PUNCT
ajlm-2681	193	1	2020;202(3):455–457	2020;202(3):455–457	NUM
ajlm-2681	193	2	.	.	PROPN
ajlm-2681	193	3	https://doi.org/10.1164/rccm.202005-1654le	https://doi.org/10.1164/rccm.202005-1654le	VERB
ajlm-2681	193	4	middeldorp	middeldorp	PROPN
ajlm-2681	193	5	s	s	PROPN
ajlm-2681	193	6	,	,	PUNCT
ajlm-2681	193	7	coppens	coppens	PROPN
ajlm-2681	193	8	m	m	PROPN
ajlm-2681	193	9	,	,	PUNCT
ajlm-2681	193	10	van	van	PROPN
ajlm-2681	193	11	haaps	haaps	PROPN
ajlm-2681	193	12	tf	tf	PROPN
ajlm-2681	193	13	,	,	PUNCT
ajlm-2681	193	14	et	et	PROPN
ajlm-2681	193	15	al	al	PROPN
ajlm-2681	193	16	.	.	PROPN
ajlm-2681	194	1	incidence	incidence	NOUN
ajlm-2681	194	2	of	of	ADP
ajlm-2681	194	3	venous	venous	ADJ
ajlm-2681	194	4	thromboembolism	thromboembolism	NOUN
ajlm-2681	194	5	in	in	ADP
ajlm-2681	194	6	hospitalized	hospitalize	VERB
ajlm-2681	194	7	patients	patient	NOUN
ajlm-2681	194	8	with	with	ADP
ajlm-2681	194	9	covid-19	covid-19	PROPN
ajlm-2681	194	10	.	.	PUNCT
ajlm-2681	195	1	j	j	PROPN
ajlm-2681	195	2	thromb	thromb	PROPN
ajlm-2681	195	3	haemost	haemost	VERB
ajlm-2681	195	4	.	.	PUNCT
ajlm-2681	196	1	2020;18(8):1995–2002	2020;18(8):1995–2002	NUM
ajlm-2681	196	2	.	.	PUNCT
ajlm-2681	197	1	https://doi.org/10.1111/jth.14888	https://doi.org/10.1111/jth.14888	NOUN
ajlm-2681	197	2	helms	helms	PROPN
ajlm-2681	197	3	j	j	PROPN
ajlm-2681	197	4	,	,	PUNCT
ajlm-2681	197	5	tacquard	tacquard	PROPN
ajlm-2681	197	6	c	c	NOUN
ajlm-2681	197	7	,	,	PUNCT
ajlm-2681	197	8	severac	severac	NOUN
ajlm-2681	197	9	f	f	NOUN
ajlm-2681	197	10	,	,	PUNCT
ajlm-2681	197	11	et	et	PROPN
ajlm-2681	197	12	al	al	PROPN
ajlm-2681	197	13	.	.	PROPN
ajlm-2681	197	14	high	high	ADJ
ajlm-2681	197	15	risk	risk	NOUN
ajlm-2681	197	16	of	of	ADP
ajlm-2681	197	17	thrombosis	thrombosis	NOUN
ajlm-2681	197	18	in	in	ADP
ajlm-2681	197	19	patients	patient	NOUN
ajlm-2681	197	20	with	with	ADP
ajlm-2681	197	21	severe	severe	ADJ
ajlm-2681	197	22	sars	sar	NOUN
ajlm-2681	197	23	-	-	PUNCT
ajlm-2681	197	24	cov-2	cov-2	PART
ajlm-2681	197	25	infection	infection	NOUN
ajlm-2681	197	26	:	:	PUNCT
ajlm-2681	197	27	a	a	DET
ajlm-2681	197	28	multicenter	multicenter	ADJ
ajlm-2681	197	29	prospective	prospective	ADJ
ajlm-2681	197	30	cohort	cohort	NOUN
ajlm-2681	197	31	study	study	NOUN
ajlm-2681	197	32	.	.	PUNCT
ajlm-2681	198	1	intensive	intensive	ADJ
ajlm-2681	198	2	care	care	NOUN
ajlm-2681	198	3	med	me	VERB
ajlm-2681	198	4	.	.	PUNCT
ajlm-2681	199	1	2020;46(6):1089–1098	2020;46(6):1089–1098	NOUN
ajlm-2681	199	2	.	.	PUNCT
ajlm-2681	200	1	https://doi.org/10.1007/s00134-020-06062-x	https://doi.org/10.1007/s00134-020-06062-x	PROPN
ajlm-2681	200	2	klok	klok	PROPN
ajlm-2681	200	3	fa	fa	PROPN
ajlm-2681	200	4	,	,	PUNCT
ajlm-2681	200	5	kruip	kruip	PROPN
ajlm-2681	200	6	mjha	mjha	PROPN
ajlm-2681	200	7	,	,	PUNCT
ajlm-2681	200	8	van	van	PROPN
ajlm-2681	200	9	der	der	PROPN
ajlm-2681	200	10	meer	meer	PROPN
ajlm-2681	200	11	njm	njm	PROPN
ajlm-2681	200	12	,	,	PUNCT
ajlm-2681	200	13	et	et	PROPN
ajlm-2681	200	14	al	al	PROPN
ajlm-2681	200	15	.	.	PUNCT
ajlm-2681	200	16	confirmation	confirmation	NOUN
ajlm-2681	200	17	of	of	ADP
ajlm-2681	200	18	the	the	DET
ajlm-2681	200	19	high	high	ADJ
ajlm-2681	200	20	cumulative	cumulative	ADJ
ajlm-2681	200	21	incidence	incidence	NOUN
ajlm-2681	200	22	of	of	ADP
ajlm-2681	200	23	thrombotic	thrombotic	ADJ
ajlm-2681	200	24	complications	complication	NOUN
ajlm-2681	200	25	in	in	ADP
ajlm-2681	200	26	critically	critically	ADV
ajlm-2681	200	27	ill	ill	ADJ
ajlm-2681	200	28	icu	icu	PROPN
ajlm-2681	200	29	patients	patient	NOUN
ajlm-2681	200	30	with	with	ADP
ajlm-2681	200	31	covid-19	covid-19	PROPN
ajlm-2681	200	32	:	:	PUNCT
ajlm-2681	200	33	an	an	DET
ajlm-2681	200	34	updated	update	VERB
ajlm-2681	200	35	analysis	analysis	NOUN
ajlm-2681	200	36	.	.	PUNCT
ajlm-2681	201	1	thromb	thromb	NOUN
ajlm-2681	201	2	res	re	NOUN
ajlm-2681	201	3	.	.	PUNCT
ajlm-2681	202	1	2020;191:148–150	2020;191:148–150	NUM
ajlm-2681	202	2	.	.	PUNCT
ajlm-2681	203	1	https://doi.org/10.1016/j.thromres.2020.04.041	https://doi.org/10.1016/j.thromres.2020.04.041	PROPN
ajlm-2681	203	2	trunfio	trunfio	PROPN
ajlm-2681	203	3	m	m	NOUN
ajlm-2681	203	4	,	,	PUNCT
ajlm-2681	203	5	salvador	salvador	PROPN
ajlm-2681	203	6	e	e	NOUN
ajlm-2681	203	7	,	,	PUNCT
ajlm-2681	203	8	cabodi	cabodi	PROPN
ajlm-2681	203	9	d	d	NOUN
ajlm-2681	203	10	,	,	PUNCT
ajlm-2681	203	11	et	et	PROPN
ajlm-2681	203	12	al	al	PROPN
ajlm-2681	203	13	.	.	PUNCT
ajlm-2681	204	1	anti	anti	PROPN
ajlm-2681	204	2	-	-	PROPN
ajlm-2681	204	3	xa	xa	ADJ
ajlm-2681	204	4	monitoring	monitoring	NOUN
ajlm-2681	204	5	improves	improve	VERB
ajlm-2681	204	6	low	low	ADJ
ajlm-2681	204	7	-	-	PUNCT
ajlm-2681	204	8	molecular	molecular	ADJ
ajlm-2681	204	9	-	-	PUNCT
ajlm-2681	204	10	weight	weight	NOUN
ajlm-2681	204	11	heparin	heparin	ADJ
ajlm-2681	204	12	effectiveness	effectiveness	NOUN
ajlm-2681	204	13	in	in	ADP
ajlm-2681	204	14	patients	patient	NOUN
ajlm-2681	204	15	with	with	ADP
ajlm-2681	204	16	sars	sar	NOUN
ajlm-2681	204	17	-	-	PUNCT
ajlm-2681	204	18	cov-2	cov-2	PART
ajlm-2681	204	19	infection	infection	NOUN
ajlm-2681	204	20	.	.	PUNCT
ajlm-2681	205	1	thromb	thromb	NOUN
ajlm-2681	205	2	res	re	NOUN
ajlm-2681	205	3	.	.	PUNCT
ajlm-2681	206	1	2020;196:432–434	2020;196:432–434	NUM
ajlm-2681	206	2	.	.	PUNCT
ajlm-2681	207	1	https://doi.org/10.1016/j.thromres.2020.09.039	https://doi.org/10.1016/j.thromres.2020.09.039	NOUN
ajlm-2681	207	2	thomas	thomas	PROPN
ajlm-2681	207	3	o	o	PROPN
ajlm-2681	207	4	,	,	PUNCT
ajlm-2681	207	5	lybeck	lybeck	NOUN
ajlm-2681	207	6	e	e	NOUN
ajlm-2681	207	7	,	,	PUNCT
ajlm-2681	207	8	strandberg	strandberg	PROPN
ajlm-2681	207	9	k	k	PROPN
ajlm-2681	207	10	,	,	PUNCT
ajlm-2681	207	11	tynngård	tynngård	NOUN
ajlm-2681	207	12	n	n	CCONJ
ajlm-2681	207	13	,	,	PUNCT
ajlm-2681	207	14	schött	schött	NOUN
ajlm-2681	207	15	u.	u.	NOUN
ajlm-2681	207	16	monitoring	monitor	VERB
ajlm-2681	207	17	low	low	ADJ
ajlm-2681	207	18	molecular	molecular	ADJ
ajlm-2681	207	19	weight	weight	NOUN
ajlm-2681	207	20	heparins	heparin	NOUN
ajlm-2681	207	21	at	at	ADP
ajlm-2681	207	22	therapeutic	therapeutic	ADJ
ajlm-2681	207	23	levels	level	NOUN
ajlm-2681	207	24	:	:	PUNCT
ajlm-2681	207	25	dose	dose	NOUN
ajlm-2681	207	26	-	-	PUNCT
ajlm-2681	207	27	responses	response	NOUN
ajlm-2681	207	28	of	of	ADP
ajlm-2681	207	29	,	,	PUNCT
ajlm-2681	207	30	and	and	CCONJ
ajlm-2681	207	31	correlations	correlation	NOUN
ajlm-2681	207	32	and	and	CCONJ
ajlm-2681	207	33	differences	difference	NOUN
ajlm-2681	207	34	between	between	ADP
ajlm-2681	207	35	aptt	aptt	ADJ
ajlm-2681	207	36	,	,	PUNCT
ajlm-2681	207	37	anti	anti	ADJ
ajlm-2681	207	38	-	-	NOUN
ajlm-2681	207	39	factor	factor	ADJ
ajlm-2681	207	40	xa	xa	PROPN
ajlm-2681	207	41	and	and	CCONJ
ajlm-2681	207	42	thrombin	thrombin	NOUN
ajlm-2681	207	43	generation	generation	NOUN
ajlm-2681	207	44	assays	assay	NOUN
ajlm-2681	207	45	.	.	PUNCT
ajlm-2681	208	1	plos	plos	PROPN
ajlm-2681	208	2	one	one	NUM
ajlm-2681	208	3	.	.	PUNCT
ajlm-2681	209	1	2015;10(1):e0116835	2015;10(1):e0116835	NUM
ajlm-2681	209	2	.	.	PUNCT
ajlm-2681	210	1	https://doi.org/10.1371/journal.pone.0116835	https://doi.org/10.1371/journal.pone.0116835	PROPN
ajlm-2681	210	2	jones	jones	PROPN
ajlm-2681	210	3	a	a	X
ajlm-2681	210	4	,	,	PUNCT
ajlm-2681	210	5	barnard	barnard	PROPN
ajlm-2681	210	6	s	s	PROPN
ajlm-2681	210	7	,	,	PUNCT
ajlm-2681	210	8	monis	monis	PROPN
ajlm-2681	210	9	g.	g.	PROPN
ajlm-2681	210	10	anti	anti	PROPN
ajlm-2681	210	11	-	-	NOUN
ajlm-2681	210	12	factor	factor	ADJ
ajlm-2681	210	13	xa	xa	NOUN
ajlm-2681	210	14	for	for	ADP
ajlm-2681	210	15	monitoring	monitoring	NOUN
ajlm-2681	210	16	of	of	ADP
ajlm-2681	210	17	unfractionated	unfractionate	VERB
ajlm-2681	210	18	heparin	heparin	ADJ
ajlm-2681	210	19	therapy	therapy	NOUN
ajlm-2681	210	20	[	[	X
ajlm-2681	210	21	homepage	homepage	NOUN
ajlm-2681	210	22	on	on	ADP
ajlm-2681	210	23	the	the	DET
ajlm-2681	210	24	internet	internet	NOUN
ajlm-2681	210	25	]	]	PUNCT
ajlm-2681	210	26	.	.	PUNCT
ajlm-2681	211	1	uc	uc	PROPN
ajlm-2681	211	2	davis	davis	PROPN
ajlm-2681	211	3	health	health	PROPN
ajlm-2681	211	4	–	–	PUNCT
ajlm-2681	211	5	pathology	pathology	NOUN
ajlm-2681	211	6	and	and	CCONJ
ajlm-2681	211	7	laboratory	laboratory	NOUN
ajlm-2681	211	8	medicine	medicine	NOUN
ajlm-2681	211	9	.	.	PUNCT
ajlm-2681	212	1	uc	uc	PROPN
ajlm-2681	212	2	davis	davis	PROPN
ajlm-2681	212	3	health	health	PROPN
ajlm-2681	212	4	.	.	PUNCT
ajlm-2681	213	1	2017	2017	NUM
ajlm-2681	214	1	[	[	X
ajlm-2681	214	2	cited	cite	VERB
ajlm-2681	214	3	2021	2021	NUM
ajlm-2681	214	4	oct	oct	NOUN
ajlm-2681	214	5	03	03	NUM
ajlm-2681	214	6	]	]	PUNCT
ajlm-2681	214	7	.	.	PUNCT
ajlm-2681	215	1	available	available	ADJ
ajlm-2681	215	2	from	from	ADP
ajlm-2681	215	3	:	:	PUNCT
ajlm-2681	215	4	https://health.ucdavis.edu/blog/lab-best-practice/anti-factor-xa-for-monitoring-of-unfractionated-heparin-therapy/2017/10	https://health.ucdavis.edu/blog/lab-best-practice/anti-factor-xa-for-monitoring-of-unfractionated-heparin-therapy/2017/10	PROPN
ajlm-2681	215	5	shaydakov	shaydakov	VERB
ajlm-2681	215	6	me	i	PRON
ajlm-2681	215	7	,	,	PUNCT
ajlm-2681	215	8	sigmon	sigmon	NOUN
ajlm-2681	215	9	df	df	PROPN
ajlm-2681	215	10	,	,	PUNCT
ajlm-2681	215	11	blebea	blebea	PROPN
ajlm-2681	215	12	j.	j.	PROPN
ajlm-2681	215	13	thromboelastography	thromboelastography	PROPN
ajlm-2681	216	1	[	[	X
ajlm-2681	216	2	homepage	homepage	NOUN
ajlm-2681	216	3	on	on	ADP
ajlm-2681	216	4	the	the	DET
ajlm-2681	216	5	internet	internet	NOUN
ajlm-2681	216	6	]	]	PUNCT
ajlm-2681	216	7	.	.	PUNCT
ajlm-2681	217	1	ncbi	ncbi	NOUN
ajlm-2681	217	2	.	.	PUNCT
ajlm-2681	218	1	2021	2021	NUM
ajlm-2681	219	1	[	[	X
ajlm-2681	219	2	cited	cite	VERB
ajlm-2681	219	3	2021	2021	NUM
ajlm-2681	219	4	oct	oct	NOUN
ajlm-2681	219	5	03	03	NUM
ajlm-2681	219	6	]	]	PUNCT
ajlm-2681	219	7	.	.	PUNCT
ajlm-2681	220	1	available	available	ADJ
ajlm-2681	220	2	from	from	ADP
ajlm-2681	220	3	:	:	PUNCT
ajlm-2681	220	4	http://www.ncbi.nlm.nih.gov/books/nbk537061/	http://www.ncbi.nlm.nih.gov/books/nbk537061/	PROPN
ajlm-2681	220	5	jackson	jackson	PROPN
ajlm-2681	220	6	gnb	gnb	PROPN
ajlm-2681	220	7	,	,	PUNCT
ajlm-2681	220	8	ashpole	ashpole	NOUN
ajlm-2681	220	9	kj	kj	PROPN
ajlm-2681	220	10	,	,	PUNCT
ajlm-2681	220	11	yentis	yentis	PROPN
ajlm-2681	220	12	sm	sm	PROPN
ajlm-2681	220	13	.	.	PUNCT
ajlm-2681	221	1	the	the	DET
ajlm-2681	221	2	teg	teg	PROPN
ajlm-2681	221	3	®	®	NOUN
ajlm-2681	221	4	vs	vs	ADP
ajlm-2681	221	5	the	the	DET
ajlm-2681	221	6	rotem	rotem	PROPN
ajlm-2681	221	7	®	®	PROPN
ajlm-2681	221	8	thromboelastography	thromboelastography	PROPN
ajlm-2681	221	9	/	/	SYM
ajlm-2681	221	10	thromboelastometry	thromboelastometry	NOUN
ajlm-2681	221	11	systems	system	NOUN
ajlm-2681	221	12	.	.	PUNCT
ajlm-2681	222	1	anaesthesia	anaesthesia	NOUN
ajlm-2681	222	2	.	.	PUNCT
ajlm-2681	223	1	2009;64(2):212–215	2009;64(2):212–215	X
ajlm-2681	223	2	.	.	PUNCT
ajlm-2681	223	3	https://doi.org/10.1111/j.1365-2044.2008.05752.x	https://doi.org/10.1111/j.1365-2044.2008.05752.x	PROPN
ajlm-2681	223	4	collett	collett	PROPN
ajlm-2681	223	5	lw	lw	PROPN
ajlm-2681	223	6	,	,	PUNCT
ajlm-2681	223	7	gluck	gluck	PROPN
ajlm-2681	223	8	s	s	PROPN
ajlm-2681	223	9	,	,	PUNCT
ajlm-2681	223	10	strickland	strickland	PROPN
ajlm-2681	223	11	rm	rm	PROPN
ajlm-2681	223	12	,	,	PUNCT
ajlm-2681	223	13	reddi	reddi	NOUN
ajlm-2681	223	14	bj	bj	NOUN
ajlm-2681	223	15	.	.	PUNCT
ajlm-2681	224	1	evaluation	evaluation	NOUN
ajlm-2681	224	2	of	of	ADP
ajlm-2681	224	3	coagulation	coagulation	NOUN
ajlm-2681	224	4	status	status	NOUN
ajlm-2681	224	5	using	use	VERB
ajlm-2681	224	6	viscoelastic	viscoelastic	ADJ
ajlm-2681	224	7	testing	testing	NOUN
ajlm-2681	224	8	in	in	ADP
ajlm-2681	224	9	intensive	intensive	ADJ
ajlm-2681	224	10	care	care	NOUN
ajlm-2681	224	11	patients	patient	NOUN
ajlm-2681	224	12	with	with	ADP
ajlm-2681	224	13	coronavirus	coronavirus	NOUN
ajlm-2681	224	14	disease	disease	NOUN
ajlm-2681	224	15	2019	2019	NUM
ajlm-2681	224	16	(	(	PUNCT
ajlm-2681	224	17	covid-19	covid-19	PROPN
ajlm-2681	224	18	):	):	PUNCT
ajlm-2681	224	19	an	an	DET
ajlm-2681	224	20	observational	observational	ADJ
ajlm-2681	224	21	point	point	NOUN
ajlm-2681	224	22	prevalence	prevalence	NOUN
ajlm-2681	224	23	cohort	cohort	NOUN
ajlm-2681	224	24	study	study	NOUN
ajlm-2681	224	25	.	.	PUNCT
ajlm-2681	225	1	aust	aust	PROPN
ajlm-2681	225	2	crit	crit	PROPN
ajlm-2681	225	3	care	care	PROPN
ajlm-2681	225	4	.	.	PUNCT
ajlm-2681	226	1	2021;34(2):155–159	2021;34(2):155–159	NUM
ajlm-2681	226	2	.	.	PUNCT
ajlm-2681	226	3	https://doi.org/10.1016/j.aucc.2020.07.003	https://doi.org/10.1016/j.aucc.2020.07.003	ADJ
ajlm-2681	226	4	kazi	kazi	PROPN
ajlm-2681	226	5	s	s	PROPN
ajlm-2681	226	6	,	,	PUNCT
ajlm-2681	226	7	noureldin	noureldin	VERB
ajlm-2681	226	8	a	a	PRON
ajlm-2681	226	9	,	,	PUNCT
ajlm-2681	226	10	deng	deng	PROPN
ajlm-2681	226	11	y	y	PROPN
ajlm-2681	226	12	,	,	PUNCT
ajlm-2681	226	13	othman	othman	PROPN
ajlm-2681	226	14	m.	m.	PROPN
ajlm-2681	226	15	teg	teg	PROPN
ajlm-2681	226	16	/	/	SYM
ajlm-2681	226	17	rotem	rotem	PROPN
ajlm-2681	226	18	:	:	PUNCT
ajlm-2681	226	19	a	a	DET
ajlm-2681	226	20	tool	tool	NOUN
ajlm-2681	226	21	to	to	PART
ajlm-2681	226	22	aid	aid	VERB
ajlm-2681	226	23	in	in	ADP
ajlm-2681	226	24	the	the	DET
ajlm-2681	226	25	diagnosis	diagnosis	NOUN
ajlm-2681	226	26	and	and	CCONJ
ajlm-2681	226	27	management	management	NOUN
ajlm-2681	226	28	of	of	ADP
ajlm-2681	226	29	covid	covid	PROPN
ajlm-2681	226	30	19	19	NUM
ajlm-2681	226	31	coagulopathies	coagulopathie	NOUN
ajlm-2681	226	32	–	–	PUNCT
ajlm-2681	226	33	a	a	DET
ajlm-2681	226	34	systematic	systematic	ADJ
ajlm-2681	226	35	review	review	NOUN
ajlm-2681	226	36	[	[	X
ajlm-2681	226	37	homepage	homepage	NOUN
ajlm-2681	226	38	on	on	ADP
ajlm-2681	226	39	the	the	DET
ajlm-2681	226	40	internet	internet	NOUN
ajlm-2681	226	41	]	]	PUNCT
ajlm-2681	226	42	.	.	PUNCT
ajlm-2681	227	1	isth	isth	NOUN
ajlm-2681	227	2	.	.	PUNCT
ajlm-2681	227	3	2021	2021	NUM
ajlm-2681	228	1	[	[	X
ajlm-2681	228	2	cited	cite	VERB
ajlm-2681	228	3	2021	2021	NUM
ajlm-2681	228	4	oct	oct	NOUN
ajlm-2681	228	5	03];pb0199	03];pb0199	PROPN
ajlm-2681	228	6	.	.	PUNCT
ajlm-2681	229	1	available	available	ADJ
ajlm-2681	229	2	from	from	ADP
ajlm-2681	229	3	:	:	PUNCT
ajlm-2681	229	4	https://abstracts.isth.org/abstract/teg-rotem-a-tool-to-aid-in-the-diagnosis-and-management-of-covid-19-coagulopathies-a-systematic-review/	https://abstracts.isth.org/abstract/teg-rotem-a-tool-to-aid-in-the-diagnosis-and-management-of-covid-19-coagulopathies-a-systematic-review/	PROPN
ajlm-2681	229	5	klein	klein	PROPN
ajlm-2681	229	6	sm	sm	PROPN
ajlm-2681	229	7	,	,	PUNCT
ajlm-2681	229	8	slaughter	slaughter	VERB
ajlm-2681	229	9	tf	tf	PROPN
ajlm-2681	229	10	,	,	PUNCT
ajlm-2681	229	11	vail	vail	PROPN
ajlm-2681	229	12	pt	pt	PROPN
ajlm-2681	229	13	,	,	PUNCT
ajlm-2681	229	14	et	et	PROPN
ajlm-2681	229	15	al	al	PROPN
ajlm-2681	229	16	.	.	PROPN
ajlm-2681	229	17	thromboelastography	thromboelastography	NOUN
ajlm-2681	229	18	as	as	ADP
ajlm-2681	229	19	a	a	DET
ajlm-2681	229	20	perioperative	perioperative	ADJ
ajlm-2681	229	21	measure	measure	NOUN
ajlm-2681	229	22	of	of	ADP
ajlm-2681	229	23	anticoagulation	anticoagulation	NOUN
ajlm-2681	229	24	resulting	result	VERB
ajlm-2681	229	25	from	from	ADP
ajlm-2681	229	26	low	low	ADJ
ajlm-2681	229	27	molecular	molecular	ADJ
ajlm-2681	229	28	weight	weight	NOUN
ajlm-2681	229	29	heparin	heparin	NOUN
ajlm-2681	229	30	:	:	PUNCT
ajlm-2681	229	31	a	a	DET
ajlm-2681	229	32	comparison	comparison	NOUN
ajlm-2681	229	33	with	with	ADP
ajlm-2681	229	34	anti	anti	ADJ
ajlm-2681	229	35	-	-	ADJ
ajlm-2681	229	36	xa	xa	ADJ
ajlm-2681	229	37	concentrations	concentration	NOUN
ajlm-2681	229	38	.	.	PUNCT
ajlm-2681	230	1	anesth	anesth	PROPN
ajlm-2681	230	2	analg	analg	PROPN
ajlm-2681	230	3	.	.	PUNCT
ajlm-2681	231	1	2000;91(5):1091–1095	2000;91(5):1091–1095	PROPN
ajlm-2681	231	2	.	.	PUNCT
ajlm-2681	232	1	https://doi.org/10.1097/00000539-200011000-00009	https://doi.org/10.1097/00000539-200011000-00009	PROPN
ajlm-2681	232	2	tekkesin	tekkesin	PROPN
ajlm-2681	232	3	n	n	PROPN
ajlm-2681	232	4	,	,	PUNCT
ajlm-2681	232	5	tekkesin	tekkesin	NOUN
ajlm-2681	232	6	m	m	PROPN
ajlm-2681	232	7	,	,	PUNCT
ajlm-2681	232	8	kaso	kaso	PROPN
ajlm-2681	232	9	g.	g.	PROPN
ajlm-2681	232	10	thromboelastography	thromboelastography	PROPN
ajlm-2681	232	11	for	for	ADP
ajlm-2681	232	12	the	the	DET
ajlm-2681	232	13	monitoring	monitoring	NOUN
ajlm-2681	232	14	of	of	ADP
ajlm-2681	232	15	the	the	DET
ajlm-2681	232	16	antithrombotic	antithrombotic	ADJ
ajlm-2681	232	17	effect	effect	NOUN
ajlm-2681	232	18	of	of	ADP
ajlm-2681	232	19	low	low	ADJ
ajlm-2681	232	20	-	-	PUNCT
ajlm-2681	232	21	molecular	molecular	ADJ
ajlm-2681	232	22	-	-	PUNCT
ajlm-2681	232	23	weight	weight	NOUN
ajlm-2681	232	24	heparin	heparin	NOUN
ajlm-2681	232	25	after	after	ADP
ajlm-2681	232	26	major	major	ADJ
ajlm-2681	232	27	orthopedic	orthopedic	ADJ
ajlm-2681	232	28	surgery	surgery	NOUN
ajlm-2681	232	29	.	.	PUNCT
ajlm-2681	233	1	anatol	anatol	PROPN
ajlm-2681	233	2	j	j	PROPN
ajlm-2681	233	3	cardiol	cardiol	NOUN
ajlm-2681	233	4	.	.	PUNCT
ajlm-2681	234	1	2015;15(11):932–937	2015;15(11):932–937	NUM
ajlm-2681	234	2	.	.	PUNCT
ajlm-2681	235	1	https://doi.org/10.5152/akd.2014.5723	https://doi.org/10.5152/akd.2014.5723	PROPN
ajlm-2681	235	2	harris	harris	PROPN
ajlm-2681	235	3	pa	pa	PROPN
ajlm-2681	235	4	,	,	PUNCT
ajlm-2681	235	5	taylor	taylor	PROPN
ajlm-2681	235	6	r	r	PROPN
ajlm-2681	235	7	,	,	PUNCT
ajlm-2681	235	8	minor	minor	ADJ
ajlm-2681	235	9	bl	bl	PROPN
ajlm-2681	235	10	,	,	PUNCT
ajlm-2681	235	11	elliott	elliott	PROPN
ajlm-2681	235	12	v	v	PROPN
ajlm-2681	235	13	,	,	PUNCT
ajlm-2681	235	14	fernandez	fernandez	PROPN
ajlm-2681	235	15	m	m	PROPN
ajlm-2681	235	16	,	,	PUNCT
ajlm-2681	235	17	o’neal	o’neal	PROPN
ajlm-2681	235	18	l	l	PROPN
ajlm-2681	235	19	,	,	PUNCT
ajlm-2681	235	20	et	et	PROPN
ajlm-2681	235	21	al	al	PROPN
ajlm-2681	235	22	.	.	PUNCT
ajlm-2681	236	1	the	the	DET
ajlm-2681	236	2	redcap	redcap	NOUN
ajlm-2681	236	3	consortium	consortium	NOUN
ajlm-2681	236	4	:	:	PUNCT
ajlm-2681	236	5	building	build	VERB
ajlm-2681	236	6	an	an	DET
ajlm-2681	236	7	international	international	ADJ
ajlm-2681	236	8	community	community	NOUN
ajlm-2681	236	9	of	of	ADP
ajlm-2681	236	10	software	software	NOUN
ajlm-2681	236	11	platform	platform	NOUN
ajlm-2681	236	12	partners	partner	NOUN
ajlm-2681	236	13	.	.	PUNCT
ajlm-2681	237	1	j	j	PROPN
ajlm-2681	237	2	biomed	biome	VERB
ajlm-2681	237	3	inform	inform	NOUN
ajlm-2681	237	4	.	.	PUNCT
ajlm-2681	238	1	2019	2019	NUM
ajlm-2681	238	2	jul;95:103208	jul;95:103208	NOUN
ajlm-2681	238	3	.	.	PUNCT
ajlm-2681	239	1	whitton	whitton	PROPN
ajlm-2681	239	2	tp	tp	PROPN
ajlm-2681	239	3	,	,	PUNCT
ajlm-2681	239	4	healy	healy	PROPN
ajlm-2681	239	5	wj	wj	PROPN
ajlm-2681	239	6	.	.	PUNCT
ajlm-2681	240	1	review	review	PROPN
ajlm-2681	240	2	of	of	ADP
ajlm-2681	240	3	thromboelastography	thromboelastography	NOUN
ajlm-2681	240	4	(	(	PUNCT
ajlm-2681	240	5	teg	teg	NOUN
ajlm-2681	240	6	):	):	PUNCT
ajlm-2681	240	7	medical	medical	ADJ
ajlm-2681	240	8	and	and	CCONJ
ajlm-2681	240	9	surgical	surgical	ADJ
ajlm-2681	240	10	applications	application	NOUN
ajlm-2681	240	11	.	.	PUNCT
ajlm-2681	241	1	ther	ther	INTJ
ajlm-2681	241	2	adv	adv	PROPN
ajlm-2681	241	3	pulm	pulm	NOUN
ajlm-2681	241	4	crit	crit	PROPN
ajlm-2681	241	5	care	care	NOUN
ajlm-2681	241	6	med	me	VERB
ajlm-2681	241	7	.	.	PUNCT
ajlm-2681	242	1	2023;18:29768675231208426	2023;18:29768675231208426	NUM
ajlm-2681	242	2	.	.	PUNCT
ajlm-2681	242	3	https://doi.org/10.1177/29768675231208426	https://doi.org/10.1177/29768675231208426	X
ajlm-2681	242	4	shaydakov	shaydakov	VERB
ajlm-2681	242	5	me	i	PRON
ajlm-2681	242	6	,	,	PUNCT
ajlm-2681	242	7	sigmon	sigmon	NOUN
ajlm-2681	242	8	df	df	PROPN
ajlm-2681	242	9	,	,	PUNCT
ajlm-2681	242	10	blebea	blebea	PROPN
ajlm-2681	242	11	j.	j.	PROPN
ajlm-2681	242	12	thromboelastography	thromboelastography	PROPN
ajlm-2681	243	1	[	[	X
ajlm-2681	243	2	homepage	homepage	NOUN
ajlm-2681	243	3	on	on	ADP
ajlm-2681	243	4	the	the	DET
ajlm-2681	243	5	internet	internet	NOUN
ajlm-2681	243	6	]	]	PUNCT
ajlm-2681	243	7	.	.	PUNCT
ajlm-2681	244	1	treasure	treasure	NOUN
ajlm-2681	244	2	island	island	NOUN
ajlm-2681	244	3	:	:	PUNCT
ajlm-2681	244	4	statpearls	statpearls	PROPN
ajlm-2681	244	5	publishing	publishing	NOUN
ajlm-2681	244	6	;	;	PUNCT
ajlm-2681	244	7	2025	2025	NUM
ajlm-2681	244	8	[	[	PUNCT
ajlm-2681	244	9	cited	cite	VERB
ajlm-2681	244	10	2025	2025	NUM
ajlm-2681	244	11	jan	jan	PROPN
ajlm-2681	244	12	21	21	NUM
ajlm-2681	244	13	]	]	PUNCT
ajlm-2681	244	14	.	.	PUNCT
ajlm-2681	245	1	available	available	ADJ
ajlm-2681	245	2	from	from	ADP
ajlm-2681	245	3	:	:	PUNCT
ajlm-2681	245	4	http://www.ncbi.nlm.nih.gov/books/nbk537061/	http://www.ncbi.nlm.nih.gov/books/nbk537061/	PROPN
ajlm-2681	245	5	buckley	buckley	PROPN
ajlm-2681	245	6	ms	ms	PROPN
ajlm-2681	245	7	,	,	PUNCT
ajlm-2681	245	8	benanti	benanti	PROPN
ajlm-2681	245	9	ge	ge	PROPN
ajlm-2681	245	10	,	,	PUNCT
ajlm-2681	245	11	gilbert	gilbert	PROPN
ajlm-2681	245	12	b	b	PROPN
ajlm-2681	245	13	,	,	PUNCT
ajlm-2681	245	14	meckel	meckel	PROPN
ajlm-2681	245	15	j	j	PROPN
ajlm-2681	245	16	,	,	PUNCT
ajlm-2681	245	17	dzierba	dzierba	PROPN
ajlm-2681	245	18	al	al	PROPN
ajlm-2681	245	19	,	,	PUNCT
ajlm-2681	245	20	maclaren	maclaren	PROPN
ajlm-2681	245	21	r.	r.	PROPN
ajlm-2681	245	22	correlation	correlation	NOUN
ajlm-2681	245	23	between	between	ADP
ajlm-2681	245	24	heparin	heparin	ADJ
ajlm-2681	245	25	anti	anti	ADJ
ajlm-2681	245	26	-	-	ADJ
ajlm-2681	245	27	xa	xa	ADJ
ajlm-2681	245	28	activity	activity	NOUN
ajlm-2681	245	29	and	and	CCONJ
ajlm-2681	245	30	thromboelastography	thromboelastography	NOUN
ajlm-2681	245	31	in	in	ADP
ajlm-2681	245	32	adult	adult	NOUN
ajlm-2681	245	33	critically	critically	ADV
ajlm-2681	245	34	ill	ill	ADJ
ajlm-2681	245	35	covid-19	covid-19	PROPN
ajlm-2681	245	36	patients	patient	NOUN
ajlm-2681	245	37	.	.	PUNCT
ajlm-2681	246	1	pharmacotherapy	pharmacotherapy	NOUN
ajlm-2681	246	2	.	.	PUNCT
ajlm-2681	247	1	2023;43(8):795–803	2023;43(8):795–803	X
ajlm-2681	247	2	.	.	PUNCT
ajlm-2681	247	3	https://doi.org/10.1002/phar.2829	https://doi.org/10.1002/phar.2829	PROPN
ajlm-2681	248	1	bunescu	bunescu	PROPN
ajlm-2681	248	2	a	a	PROPN
ajlm-2681	248	3	,	,	PUNCT
ajlm-2681	248	4	widman	widman	PROPN
ajlm-2681	248	5	j	j	PROPN
ajlm-2681	248	6	,	,	PUNCT
ajlm-2681	248	7	lenkei	lenkei	ADJ
ajlm-2681	248	8	r	r	NOUN
ajlm-2681	248	9	,	,	PUNCT
ajlm-2681	248	10	menyes	menyes	PROPN
ajlm-2681	248	11	p	p	NOUN
ajlm-2681	248	12	,	,	PUNCT
ajlm-2681	248	13	levin	levin	PROPN
ajlm-2681	248	14	k	k	PROPN
ajlm-2681	248	15	,	,	PUNCT
ajlm-2681	248	16	egberg	egberg	PROPN
ajlm-2681	248	17	n.	n.	PROPN
ajlm-2681	248	18	increases	increase	VERB
ajlm-2681	248	19	in	in	ADP
ajlm-2681	248	20	circulating	circulate	VERB
ajlm-2681	248	21	levels	level	NOUN
ajlm-2681	248	22	of	of	ADP
ajlm-2681	248	23	monocyte	monocyte	NOUN
ajlm-2681	248	24	-	-	PUNCT
ajlm-2681	248	25	platelet	platelet	NOUN
ajlm-2681	248	26	and	and	CCONJ
ajlm-2681	248	27	neutrophil	neutrophil	ADJ
ajlm-2681	248	28	-	-	PUNCT
ajlm-2681	248	29	platelet	platelet	NOUN
ajlm-2681	248	30	complexes	complex	NOUN
ajlm-2681	248	31	following	follow	VERB
ajlm-2681	248	32	hip	hip	NOUN
ajlm-2681	248	33	arthroplasty	arthroplasty	NOUN
ajlm-2681	248	34	.	.	PUNCT
ajlm-2681	249	1	clin	clin	PROPN
ajlm-2681	249	2	sci	sci	PROPN
ajlm-2681	249	3	(	(	PUNCT
ajlm-2681	249	4	lond	lond	PROPN
ajlm-2681	249	5	)	)	PUNCT
ajlm-2681	249	6	.	.	PUNCT
ajlm-2681	250	1	2002;102(3):279–286	2002;102(3):279–286	NUM
ajlm-2681	250	2	.	.	PUNCT
ajlm-2681	251	1	https://doi.org/10.1042/cs1020279	https://doi.org/10.1042/cs1020279	PROPN
ajlm-2681	251	2	white	white	PROPN
ajlm-2681	251	3	h	h	PROPN
ajlm-2681	251	4	,	,	PUNCT
ajlm-2681	251	5	sosnowski	sosnowski	PROPN
ajlm-2681	251	6	k	k	NOUN
ajlm-2681	251	7	,	,	PUNCT
ajlm-2681	251	8	bird	bird	NOUN
ajlm-2681	251	9	r	r	PROPN
ajlm-2681	251	10	,	,	PUNCT
ajlm-2681	251	11	jones	jones	PROPN
ajlm-2681	251	12	m	m	PROPN
ajlm-2681	251	13	,	,	PUNCT
ajlm-2681	251	14	solano	solano	PROPN
ajlm-2681	251	15	c.	c.	PROPN
ajlm-2681	251	16	the	the	DET
ajlm-2681	251	17	utility	utility	NOUN
ajlm-2681	251	18	of	of	ADP
ajlm-2681	251	19	thromboelastography	thromboelastography	NOUN
ajlm-2681	251	20	in	in	ADP
ajlm-2681	251	21	monitoring	monitor	VERB
ajlm-2681	251	22	low	low	ADJ
ajlm-2681	251	23	molecular	molecular	ADJ
ajlm-2681	251	24	weight	weight	NOUN
ajlm-2681	251	25	heparin	heparin	NOUN
ajlm-2681	251	26	therapy	therapy	NOUN
ajlm-2681	251	27	in	in	ADP
ajlm-2681	251	28	the	the	DET
ajlm-2681	251	29	coronary	coronary	ADJ
ajlm-2681	251	30	care	care	NOUN
ajlm-2681	251	31	unit	unit	NOUN
ajlm-2681	251	32	.	.	PUNCT
ajlm-2681	252	1	blood	blood	NOUN
ajlm-2681	252	2	coagul	coagul	NOUN
ajlm-2681	252	3	fibrinolysis	fibrinolysis	NOUN
ajlm-2681	252	4	.	.	PUNCT
ajlm-2681	253	1	2012;23(4):304–310	2012;23(4):304–310	X
ajlm-2681	253	2	.	.	PUNCT
ajlm-2681	254	1	https://doi.org/10.1097/mbc.0b013e32835274c0	https://doi.org/10.1097/mbc.0b013e32835274c0	NUM
ajlm-2681	254	2	artang	artang	PROPN
ajlm-2681	254	3	r	r	PROPN
ajlm-2681	254	4	,	,	PUNCT
ajlm-2681	254	5	frandsen	frandsen	PROPN
ajlm-2681	254	6	nj	nj	PROPN
ajlm-2681	254	7	,	,	PUNCT
ajlm-2681	254	8	nielsen	nielsen	PROPN
ajlm-2681	254	9	jd	jd	PROPN
ajlm-2681	254	10	.	.	PUNCT
ajlm-2681	254	11	application	application	NOUN
ajlm-2681	254	12	of	of	ADP
ajlm-2681	254	13	basic	basic	ADJ
ajlm-2681	254	14	and	and	CCONJ
ajlm-2681	254	15	composite	composite	ADJ
ajlm-2681	254	16	thrombelastography	thrombelastography	NOUN
ajlm-2681	254	17	parameters	parameter	NOUN
ajlm-2681	254	18	in	in	ADP
ajlm-2681	254	19	monitoring	monitoring	NOUN
ajlm-2681	254	20	of	of	ADP
ajlm-2681	254	21	the	the	DET
ajlm-2681	254	22	antithrombotic	antithrombotic	ADJ
ajlm-2681	254	23	effect	effect	NOUN
ajlm-2681	254	24	of	of	ADP
ajlm-2681	254	25	the	the	DET
ajlm-2681	254	26	low	low	ADJ
ajlm-2681	254	27	molecular	molecular	ADJ
ajlm-2681	254	28	weight	weight	NOUN
ajlm-2681	254	29	heparin	heparin	ADJ
ajlm-2681	254	30	dalteparin	dalteparin	NOUN
ajlm-2681	254	31	:	:	PUNCT
ajlm-2681	254	32	an	an	DET
ajlm-2681	254	33	in	in	ADP
ajlm-2681	254	34	vivo	vivo	NOUN
ajlm-2681	254	35	study	study	NOUN
ajlm-2681	254	36	.	.	PUNCT
ajlm-2681	255	1	thromb	thromb	PROPN
ajlm-2681	255	2	j.	j.	PROPN
ajlm-2681	255	3	2009;7:14	2009;7:14	PROPN
ajlm-2681	255	4	.	.	PUNCT
ajlm-2681	256	1	https://doi.org/10.1186/1477-9560-7-14	https://doi.org/10.1186/1477-9560-7-14	PROPN
ajlm-2681	256	2	harr	harr	PROPN
ajlm-2681	256	3	jn	jn	PROPN
ajlm-2681	256	4	,	,	PUNCT
ajlm-2681	256	5	moore	moore	PROPN
ajlm-2681	256	6	ee	ee	PROPN
ajlm-2681	256	7	,	,	PUNCT
ajlm-2681	256	8	chin	chin	PROPN
ajlm-2681	256	9	tl	tl	PROPN
ajlm-2681	256	10	,	,	PUNCT
ajlm-2681	256	11	et	et	PROPN
ajlm-2681	256	12	al	al	PROPN
ajlm-2681	256	13	.	.	PUNCT
ajlm-2681	257	1	platelets	platelet	NOUN
ajlm-2681	257	2	are	be	AUX
ajlm-2681	257	3	dominant	dominant	ADJ
ajlm-2681	257	4	contributors	contributor	NOUN
ajlm-2681	257	5	to	to	ADP
ajlm-2681	257	6	hypercoagulability	hypercoagulability	NOUN
ajlm-2681	257	7	after	after	ADP
ajlm-2681	257	8	injury	injury	NOUN
ajlm-2681	257	9	.	.	PUNCT
ajlm-2681	258	1	j	j	PROPN
ajlm-2681	258	2	trauma	trauma	PROPN
ajlm-2681	258	3	acute	acute	PROPN
ajlm-2681	258	4	care	care	NOUN
ajlm-2681	258	5	surg	surg	NOUN
ajlm-2681	258	6	.	.	PUNCT
ajlm-2681	259	1	2013;74(3):756–762	2013;74(3):756–762	X
ajlm-2681	259	2	;	;	PUNCT
ajlm-2681	259	3	discussion	discussion	NOUN
ajlm-2681	259	4	762–765	762–765	NUM
ajlm-2681	259	5	.	.	PUNCT
ajlm-2681	260	1	https://doi.org/10.1097/ta.0b013e3182826d7e	https://doi.org/10.1097/ta.0b013e3182826d7e	PROPN
ajlm-2681	260	2	chandel	chandel	VERB
ajlm-2681	260	3	a	a	PRON
ajlm-2681	260	4	,	,	PUNCT
ajlm-2681	260	5	patolia	patolia	NOUN
ajlm-2681	260	6	s	s	NOUN
ajlm-2681	260	7	,	,	PUNCT
ajlm-2681	260	8	looby	looby	PROPN
ajlm-2681	260	9	m	m	PROPN
ajlm-2681	260	10	,	,	PUNCT
ajlm-2681	260	11	bade	bade	NOUN
ajlm-2681	260	12	n	n	CCONJ
ajlm-2681	260	13	,	,	PUNCT
ajlm-2681	260	14	khangoora	khangoora	X
ajlm-2681	260	15	v	v	NOUN
ajlm-2681	260	16	,	,	PUNCT
ajlm-2681	260	17	king	king	PROPN
ajlm-2681	260	18	cs	cs	PROPN
ajlm-2681	260	19	.	.	PROPN
ajlm-2681	260	20	association	association	PROPN
ajlm-2681	260	21	of	of	ADP
ajlm-2681	260	22	d	d	NOUN
ajlm-2681	260	23	-	-	PUNCT
ajlm-2681	260	24	dimer	dimer	NOUN
ajlm-2681	260	25	and	and	CCONJ
ajlm-2681	260	26	fibrinogen	fibrinogen	NOUN
ajlm-2681	260	27	with	with	ADP
ajlm-2681	260	28	hypercoagulability	hypercoagulability	NOUN
ajlm-2681	260	29	in	in	ADP
ajlm-2681	260	30	covid-19	covid-19	PROPN
ajlm-2681	260	31	requiring	require	VERB
ajlm-2681	260	32	extracorporeal	extracorporeal	ADJ
ajlm-2681	260	33	membrane	membrane	NOUN
ajlm-2681	260	34	oxygenation	oxygenation	NOUN
ajlm-2681	260	35	.	.	PUNCT
ajlm-2681	261	1	j	j	PROPN
ajlm-2681	261	2	intensive	intensive	ADJ
ajlm-2681	261	3	care	care	NOUN
ajlm-2681	261	4	med	me	VERB
ajlm-2681	261	5	.	.	PUNCT
ajlm-2681	262	1	2021;36(6):689–695	2021;36(6):689–695	NUM
ajlm-2681	262	2	.	.	PUNCT
ajlm-2681	263	1	https://doi.org/10.1177/0885066621997039	https://doi.org/10.1177/0885066621997039	NOUN
ajlm-2681	263	2	lloyd	lloyd	PROPN
ajlm-2681	263	3	-	-	PUNCT
ajlm-2681	263	4	donald	donald	PROPN
ajlm-2681	263	5	p	p	PROPN
ajlm-2681	263	6	,	,	PUNCT
ajlm-2681	263	7	vasudevan	vasudevan	PROPN
ajlm-2681	263	8	a	a	PRON
ajlm-2681	263	9	,	,	PUNCT
ajlm-2681	263	10	angus	angus	ADJ
ajlm-2681	263	11	p.	p.	NOUN
ajlm-2681	263	12	comparison	comparison	NOUN
ajlm-2681	263	13	of	of	ADP
ajlm-2681	263	14	thromboelastography	thromboelastography	NOUN
ajlm-2681	263	15	and	and	CCONJ
ajlm-2681	263	16	conventional	conventional	ADJ
ajlm-2681	263	17	coagulation	coagulation	NOUN
ajlm-2681	263	18	tests	test	NOUN
ajlm-2681	263	19	in	in	ADP
ajlm-2681	263	20	patients	patient	NOUN
ajlm-2681	263	21	with	with	ADP
ajlm-2681	263	22	severe	severe	ADJ
ajlm-2681	263	23	liver	liver	NOUN
ajlm-2681	263	24	disease	disease	NOUN
ajlm-2681	263	25	.	.	PUNCT
ajlm-2681	264	1	clin	clin	PROPN
ajlm-2681	264	2	appl	appl	PROPN
ajlm-2681	264	3	thromb	thromb	PROPN
ajlm-2681	264	4	hemost	hemost	VERB
ajlm-2681	264	5	.	.	PUNCT
ajlm-2681	265	1	2020;26:107602962092591	2020;26:107602962092591	X
ajlm-2681	265	2	.	.	PUNCT
ajlm-2681	265	3	https://doi.org/10.1177/1076029620925915	https://doi.org/10.1177/1076029620925915	X